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ABSTRACT 
 
 
 
Naturally occurring cyclic peptides exist in the ascidians Lissoclinum Patella of the Pacific and 
Indian Oceans. The biological role of these structural interesting marine secondary metabolites 
is still unclear. The patellamides are able to bind a variety of transition metal ions. Some of the 
copper(II) complexes of cyclic pseudo-peptides are known to form carbonato-bridged 
complexes when exposed to CO2. 1 Thus, in previous studies a library of patellamide derivatives 
has been designed and prepared. The copper(II) coordination properties of these patellamide 
derivatives is widely understood. Interestingly, the corresponding dinuclear copper(II) 
complexes are able to very efficiently, catalytically hydrolyze phosphoesters and hydrate CO2. 
The natural peptides are produced by the cyanobacteria prochloron didemnid, a photosynthetic 
symbiont of L.Patella. Since the patellamides are extracted from an hydrophilic cytoplasmic 
environment, together with notably high concentrations of some transition metal ions like 
copper(II) and zinc(II). It is likely that a natural function of probably existing transition metal 
complexes in this environment is hydrolase activity. The biologic background as well as the state 
of the art regarding the copper(II) coordination chemistry is summarized in Chapter 1. 
The synthesis of the patellamide derivatives is shortly discussed.  
In Chapter 3, the electrochemistry of the copper(II) complexes is discussed. Cyclic voltammetry 
and square wave voltammetry were used to study the existence of a complexation equilibrium 
between various species in solution. From the obtained results, it is concluded that the 
copper(I/II) redox chemistry is probably not a biological relevant metabolic function at neutral 
pH. Under basic conditions, it is possible that stable copper(I) species exist. It can be proposed 
that these are carbonate or bicarbonate bridged. Moreover, under basic conditions an 
oxygenation test reaction was performed, and it was shown that a dinuclear copper(II) complex 
of an patellamide derivative is involved in an oxygenation reaction under these rather 
unphysiological conditions. A tentative mechanistic proposal is discussed, which is based on the 
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observation of a radical coupling product and insights obtained from a low temperature NMR 
experiment. 
In addition, the proposed copper(II) complexation equilibria of the ligand H4pat4 is discussed, 
and the respective EPR spectra with their simulations are in the focus of the last section of 
Chapter 3. Especially while regarding the formation of heterodinuclear copper(II)/ zinc(II) 
complexes with H4pat4 in Chapter 5 this equilibrium is requested. 
Since biological relevant hydrolysis chemistry is often based on zinc enzymes, zinc(II) complexes 
of the macrocyclic peptides were studied. Chapter 4 presents the formation of zinc(II) 
complexes, which are explored using isothermal calorimetric titrations in combination with 
NMR spectroscopy and mass spectrometry. After an overview of the biological relevance of 
zinc(II) based hydrolases, Chapter 4 presents a proposed zinc(II) complexation equilibrium. 
In Chapter 5, the formation of heterodinuclear copper(II)/zinc(II) complexes is described based 
on spectroscopic results. EPR spectroscopy, paramagnetic NMR and UV/vis spectroscopy in 
combination with mass spectrometry are used to describe two different heterodinuclear 
complexes. Furthermore, Chapter 5 descriebes the formation of a copper(II)/zinc(II) complex, 
due to a distinct cooperative effect, with a ligand that does not form stable spectroscopically 
characterizable homodinuclear zinc(II) complex. 
Phosphoester hydrolysis reactions with a model substrate of all complexes, described in the 
Chapters 3, 4 and 5, have been investigated in a kinetic assay. The pH dependent results are 
discussed in Chapter 6. Furthermore the substrate dependency of the initial rate was tested. 
All complexes disussed exhibit catalytic ativity in a pH range close to neutral. Comparison of all 
data obtained shows that the zinc(II) complexes are slightly more active than the corresponding 
homodinuclear copper(II) complexes. 
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KURZZUSAMMENFASSUNG 
 
 
 
Patellamide und Ascidiacyclamid sind natürlich vorkommende zyklische Peptide. Da sie aus 
Aszidien der Art Lissoclinum Patella (vorkommend im Pazifik und im Indischen Ozean) isoliert 
wurden bezeichnet man sie als marine Metabolite. Sie sind in der Lage verschiedene 
Übergangsmetallionen zu koordinieren. Einige der dinuklearen Kupfer(II)-Komplexe bilden in 
Gegenwart von CO2 carbonatoverbrückte Komplexe. Um die biologische Rolle der Patellamide 
in Hinblick auf eventuell existierende Kupfer(II)-Komplexe im biologischen Umfeld zu 
untersuchen, wurde eine kleine Bibliothek synthetisch leichtzugänglicher Derivate der 
Patellamide erstellt. Die Kupfer(II) Koordinationschemie dieser Derivate ist weitestgehend 
erforscht. Interessanterweise konnte vor kurzem gezeigt werden, dass die dinuklearen 
Kupfer(II)-Komplexe der Patellamid-Derivate in der Lage sind sowohl Phosphoester als auch CO2 
katalytisch zu hydrolysieren. 
Die natürlich vorkommenden zyklischen Peptide werden von den symbiotisch lebenden 
cyanobakterien der Art Prochloron Didemnid produziert. In Anbetracht der Tatsache, dass die 
natürlich vorkommenden zyklischen Peptide aus einer hydrophylen zytoplastischen Umgebung 
extrahiert wurden, zusammen mit bemerkenswerten Konzentrationen an 
Übergangsmetallionen wie Cu2+ und Zn2+ isoliert, liegt die Vermutung nahe, dass in der 
biologischen Umwelt existierende Komplexe als Hydrolasen arbeiten. 
Auf die Synthese der Patellamid-Derivate wird in Kapitel 2 kurz eingegangen.  
Die Elektrochemie der dinuklearen Kupfer(II)komplexe wird in Kapitel 3 diskutiert. 
Elektrochemische Ergebnisse wurden mittels cyclovoltammetrischer und square-wave-
voltammetrischer Experimente erlangt. Die voltammetrischen Experimente spiegeln die 
bekannte aber komplexe Gleichgewichtschemie der dinuklearen Kupfer(II)-komplexe in Lösung 
wieder, was eine exakte Zuordnung der irreversiblen Reduktionen schwierig machte. Die 
Zuordnung einzelner Potentiale beruht auf publizierten Daten anderer Systeme. So kann man 
annehmen, dass die irreversiblen und eher positiven Reduktionspotentiale zwischen 350 und 
450 mV zur Bildung unstabiler Kupfer(I)/Kupfer(II) Spezies gehören, was in Übereinstimmung 
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mit den relativ kleinen Stabilitätskonstanten zu erwarten war. Unter basischen Bedingungen 
und nach Einleitung von CO2 werden einige zusätzliche negative Reduktionspotentiale 
gefunden, welche darauf hindeuten, dass die dinuklearen Carbonato-verbrückten Komplexe 
der Patellamid-Derivate Kupfer(I) stabilisieren. 
Dieser Beobachtung folgend, wurde unter basischen Bedingungen der dinukleare 
Kupfer(II)komplex des Liganden H4pat1 einem Oxygenierungstest unterzogen. Der zeigte dass 
unter diesen recht unphysiologischen Bedingungen Kupfer-vermittelte Sauerstoffchemie 
möglich ist. Die Oxygenierungsprodukte wurden analysiert und deuten auf eine radikalischen 
Mechanismus hin. Ein vorläufiger mechanistische Vorschlag wird erläutert, der anhand eines 
tieftemperatur NMR Experiments an einem ESR-inaktiven dinuklearen Kupfer(II)-Komplex, 
erstellt wurde.  
Desweiteren, wird in Kapitel 3 das Kupfer(II) Lösungsgleichgewicht des Liganden H4pat4 
erläutert, das mit Hilfe von ESR Spektoskopie, den dazugehörigen Simulationen und Massen 
spektrommetrischen Ergebnissen aufgestellt wurde. Welches in Hinblick auf die später 
diskutierte Bildung heterodinuklearer Kupfer(II)/ Zink(II) Komplexe interresant ist. 
Da Hydrolyse Chemie in der Natur häufig von Zink(II) Enzymen betrieben wird, und Zink(II) 
ebenfall sehr konzentriert in den Aszidien gefunden wurde, wird in Kapitel 4 die Zink(II) 
koordinationschemie der Liganden H4pat1, H4pat2 und H4pat4 diskutiert. Welche mit Hilfe 
isothermaler kalorimetrischer Titrationen, NMR Spektroskopie und Massenspektrometrie 
erforscht wurde. Dieses Kapitel, das mit dem biologischen Hintergrund von Zink(II)-hydrolasen 
eingeleitet wird, endet mit einem vorgeschlagenen Lösungsgleichgewicht der verschiedenen 
dinuklearen Zink(II)komplexe. 
In Kapitel 5 wird die Bildung heterodinuklearer Kupfer(II)/ Zink(II) Komplexe diskutiert, und 
Anhand von ESR-, UV/vis- und NMR Spektroskopie verdeutlicht. Kapitel 5 liefert außerdem ein 
Beispiel eines Liganden der durch einen ausgeprägten kooperativen Effekt einen 
Kupfer(II)/Zink(II) Komplex bildet, obwohl es keinen stabilen spektroskopisch 
charakterisierbaren homodinuklearen Zink(II)komplex dieses Liganden gibt. 
Alle in dieser Dissertation beschrieben Komplexe wurden einem Phosphoesterhydrolyse Assay 
unterzogen. Die Fähigkeit, einen aktivierten Modell-Phosphoester zu hydrolysieren wurde 
sowohl in Abhängigkeit von pH Wert untersucht, als auch in einem 
substratkonzentrationsabhängigen Scan untersucht. Alle Komplexe des Liganden H4pat4 
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zeigten katalytische Aktivität in einem natürlich relevanten pH Bereich. Die Ergebnisse werden 
ausführlich verglichen und diskutiert. Der Vergleich zeigen deutlich, dass alle dinuklearen 
Zink(II) Komplexe leicht aktiver sind als die entsprechenden homodinuklearen Kupfer(II) 
Komplexe. 
 
| VII 
 
 
 
TABEL OF MOLECULES 
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ABREVIATIONS AND ACRONYMS 
Å   Ångström 
Abs   absorbance 
Ala    alanine 
AP   alkaline phosphatase 
Arg   arginine 
Asn   asparagine 
Asp   aspartate 
ADP   adenosine diphosphate 
AP   alkaline phosphatase 
ATP   adenosine triphosphate 
B   magnetic field 
BDTBPH  bis-(2,2´,4,4´-ditertbutylphenole) 
BDNPP    bis-(2,4-dinitrophenyl)phosphate 
Bn   benzyl 
Brine   saturated aqueous NaHCO3 solution  
Bu   butyl 
Boc   tertbutylcarboxycarbonyl 
Calc.   calculated 
CAPS   3-(cyclohexylamino)-1-propanesulfonic acid 
Cbz   carboxybenzyl 
CHES   2-(cyclohexylamino)ethanesulfonic acid 
CW   continuous wave 
CT   charge transfer 
CD   circular dichroism 
COMU®  (1-cyano-2-ethoxy-2-oxoethylidenaminooxo)dimethylamino-  
   morpholino-carbenium hexafluorophosphate 
CV   cyclovoltammetry 
Cys   Cysteine 
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COSY   correlation spectroscopy 
conc.   concentrated 
d   day(s) 
D   deuterium 
DART   direct analysis in real time 
DFT   density functional theory 
DMF   dimethyl formamide 
DNA   deoxyribonucleic acid 
DTPPH   2,4-ditertbutylphenole 
DTBQ   3,5-ditertbutylquinone 
DCM   dichloromethane 
DMSO   dimethylsulfoxide 
EDIPA   N,N-diisopropylethylamine 
EtOAc   ethylacetate 
EtOH   ethanol 
ESI   electron spray ionization 
EPR   electron paramagnetic resonance 
et al.   et alii 
eq.   equivalent(S) 
E.coli   escheria coli 
Et2O   diethylether 
EPR   electron paramagnetic resonance 
FAB   fast atom bombardment  
Fc/Fc+   Ferrocene/ Ferrocenium 
FDPP   pentafluorophenyl diphenylphosphinate 
g   Landéfactor 
G   gauss 
Glu   glutamin acid 
Gln   glutamine 
Gly   glycin 
h   hour(s) 
His   histidine 
  | X 
 
Hz   hertz 
HCA II   human carbonic anhydrase II 
HEPES   4-(2-hydroxyethyl)piperazin-1-ethanesulfonic acid 
HMBC   heteronuclear multiple bond correlation 
HSQC   heteronuclear single quantum correlation 
HR   high resolution 
ITC   isothermal titration calorimetry  
Ile   Ileucine 
K   Kelvin 
Leu   leucine 
LSE   least square error 
Met   methionine 
m   meta 
mV   milli volt 
M   mol/l 
MALDI   matrix assisted laser desorption/ionisation 
MES   2-(N-morpholino)ethanolicsulfonic acid 
Me   methyl 
MM   molecular mechanics 
MeOH   methanol 
MeCN   acetonitrile 
MS   mass spectrometry 
Min   min 
ml   milliliters 
mM   millimol/l 
NMR   nuclear magnetic reosance 
NOESY   nuclear overhauser effect spectroscopy 
NMM   n-methylmorpholine 
NIR   near infra red 
o   ortho 
OTf   triflate 
OAc   acetate 
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p   para 
PE   petroleum ether 
ppm   parts per million 
Phe   phenylalanine 
p.a.   pro analysi 
pdb   protein data bank 
PAP   purple acid phosphatase 
Ph   phenyl  
rt   room temperature, 25°C  
RNA   ribonucleic acid 
ROS   reactive oxygen species 
Ser   serine 
SQW   square-wave-voltammetry 
tert   tertiäry 
TLC   thin layer chromatography 
TFA   trifluoroacetic acid 
THF   tetrahydrofuran 
Thr   threonine 
TON   turnover number 
TOF   turnover frequency 
UV/vis-NIR  ultraviolet/ visible near infrared 
Val   valine 
vs.   versus 
%vol   volume percent 
%w   weigth percent 
ße   bohr magneton 
δ   chemical shift (NMR) 
ν   frequency 
ɛ   extinction coefficient 
γ   wavelength 
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1 Patellamides – Biology and Transition Metal Chemistry 
 
1.1 Cyclic Peptides from Ascidians - Marine Metabolites 
 
The ocean is inspiring and authoritative at the same time. For centuries it has lead humanity to 
great achievements and it is able to show us the limits of ambition. The ocean covers more than 
two thirds of the earth’s surface and, considering its depth, it represents the largest natural 
habitat on earth. Nevertheless, we are still at the beginning of understanding its ecosystems 
and its richness of species. The ocean has inspired humankind in various ways since the 
beginning of time. There are puzzling pictures from the early Bronze Age, in which the mysteries 
and features of the ocean are described. Artifacts like these are found at nearly all places where 
humans have ever been. The ocean is also an inspiration for science, as it harbors a vast amount 
of unknown and fascinating strategies of life; in addition, new and potentially useful molecules 
remain to be discovered in the oceanic ecosystems. 
Due to their huge differences compared to terrestrial life, organisms from the ocean were often 
assigned as sources of foreign or strange life- strategies. The biodiversity of the ocean is still to 
be estimated. From 2000 to 2010 more than 6000 potential new species were discovered, from 
these 1200 have been proved to be unique species. A global research network “the census of 
marine life” has attempted to count, map, monitor and to track all species.2 Each of these 
species has its own life strategy and a unique role in a specific ecosystem, which leads to the 
conclusion that each single species (from a bacteria to a shark) needs to produce and 
metabolize a diverse range of highly specialized substances. This is especially true for coral reefs 
P A T E L L A M I D E S  –  B I O L O G Y  A N D  T R A N S I T I O N  M E T A L  C H E M I S T R Y   
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in tropic and subtropic regions, which bear a high biodiversity and thus an even higher range 
of promising molecules. 
For various reasons, Science is interested in finding new substances and understanding their 
biological function. They may help us to understand foreign ecosystems and could thus be 
directly and indirectly useful in dealing with ecologic challenges. Furthermore, the 
pharmaceutical potential of marine products is generally promising. Also, industrial use of 
marine products is conceivable, as there are substances, which may be used as efficient and 
sustainable catalysts. 
A classical pharmaceutical drug discovery process is based on high-throughput screenings of 
rationally designed compounds or of chemical libraries. Reviewing the number of hits by marine 
natural products in such screenings suggests that it is obvious that this number competes 
advantageously with the success of notionally realized combinatorial screenings. 3 Isolated 
marine natural compounds not directly necessary for the growth and development of their 
producer are defined as secondary metabolites.4  Most of them are involved, or assumed to be 
involved, in survival or interspecies communication strategies of their producing organisms. In 
1970 though, the Interest in secondary marine natural products was enhanced with the first 
reports of their antitumor activities.5,6 In 1980 the two first peptidic secondary metabolites 
(ulicyclamide and ulithiacyclamide) were discovered and isolated from marine organisms (in 
Lissoclinum Patella) (Figure 1.1).7 
 
Figure 1.1: Structures of Ulithiacyclamide (a) and Ulicyclamide (b).7  
a) b) 
P H O S P H A T A S E - A C T I V I T Y  O F  H O M O -  A N D  H E T E R O D I N U C L E A R  T R A N S I T I O N  M E T A L  
C O M P L E X E S  O F  P A T E L L A M I D E  D E R I V A T I V E S    | 4 
 
These peptidic marine natural products are formed in three ways:- (i) RIPP: ribosomal 
production and post- translational modification; (ii) the production on a non-ribosomal 
pathway (NRP), which is performed by NRP-enzymes in cytoplasm; or (iii) a mixed process, in 
which polyketide synthases (PKS) and NRP intervene. Thus, a large structural diversity is 
posisble, which gives the hosting organism the possibility to be highly accommodative to its 
environment.4 
 
Figure 1.2: Structures: Ascidiacyclamide (a), Patellamide D (b) and Westiellamide (c).8-10  
During the 1980s Ireland and Scheuer,11 and others,12 13-15 discovered further examples of cyclic 
peptides with a similar molecular scaffold (Figure 1.2). These were the patellamides A-G and 
ascidiacyclamide, which could be isolated from the same organism, Lissoclinum Patella. Since 
it is more common in nature that cyclic peptides and/or peptides with D-amino acids (e.g. and 
other unusual substances, like ß-aminoacids, γ-amino acids or hydroxo acids) are produced 
from a non-ribosomal pathway (NRP), the fact that the patellamides and ascidiacyclamide 
(Figure 1.2a) are produced ribosomally (RIPP) indicates them to have an essential biological 
role. 16-18 
 
1.2 The Prochloron - Lissoclinum patella Symbiotic Association 
 
Cyclic peptides like the patellamides (Figure 1.2a), wetsiellamide (Figure 1.2c) and 
ulithiacyclamide (Figure 1.1a) are found in the ascidia Lissoclinum Patella (Figure 1.3a), one 
type of a family of sessile filter animals, commonly called sea squirts, that live in coral reefs in 
a) b) c) 
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the Pacific and Indian Oceans. The peptides could be isolated in large quantities, up to several 
gram per dry weight.16,17 Like most ascidians L. Patella lives in a symbiotic relationship with the 
cyanobacteria Prochloron didemnid (Figure 1.5).  
     
Figure 1.3: A colony of the didemnid Ascidiacea Lissoclinum Patella covering corals (a), a 
photograph of a cut through a colony (b).both reproduced with permission from 19 
 
Since the biological function of these natural occurring cyclic peptides is still unclear, and 
considering that the unusual cyclic peptides are produced at the ribosome of Prochloron (RIPP), 
16,17,20,21 it is important to understand this symbiosis. 
The sea squirt Lissoclinum Patella belongs to the phylum Chordata, subphylum Urochordata 
(tunicates), class Ascidiacea, order Aplousobranchia and the family Didemnidea. Lissoclinum 
Patella can be found either as solitary organisms but mostly in colonies. Colonies of L. Patella 
are green to green-blue and can reach 10 - 25 cm in diameter, 1 - 2 cm in thickness and weigh 
up to 200g.22,23 The larvae of L. Patella resemble amphibian tadpoles and have nerve cords 
which they lose during their development.24 Ascidians are tunicates because adults (single 
zooids) of this class live in colonies (usually a few thousand per colony), which are entirely 
embedded in a tunic. The tunic is a matrix of proteins and cellulose-like carbohydrates 
containing calcareous spicules, which display for the single exemplars of the invertebrate L. 
Patella a kind of exoskeleton, which maintains their body shape as well as playing a role in 
digestion and storage of metabolism products. It is possible for a colony to fuse and divide 
within a day; in addition, a single zooid has the ability to perform a coordinated movement 
within its tunic.23,25 Bladder cells, which contain mycosporine-like amino acids (MAA) like 
shinorine,26 are embedded in the tunic. MAAs from L. Patella have a strong absorption in UVa 
(320 - 400 nm) and UVb (280 - 300 nm) but they are transparent to visible light,26,27 and as a 
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result they act as ideal sunscreens for L. Patella, allowing their producing organism, e.g. its 
symbiont, to photosynthesize efficiently. Zooids of L. Patella are connected to cloacal cavities 
in the tunic (Figure 1.4), which they use to excrete filtered water and waste products, but also 
for uptake of photosynthesis products and presumably N2-fixation products. A colony of L. 
Patella adheres usually to corals, sea grass or stone substrates through a reddish biofilm, which 
contains further different cyanobacteria, optimizing the utilization of all radiated light. The 
consideration that didemnid ascidians as L. Patella are playing a major role in the ecosystem 
reef has been demonstrated from observations of ascidians smothering scleratinian corals.28 
 
Figure 1.4: Lissoclinum patella colonie: schematic cut:. Drawing of a cross-section illustrating the 
organization of zooids and symbionts in the tunic. The zooids are embedded in the tunic, where they 
suck in and filter particles out of the seawater. Waste products and filtered water are excreted into 
the surrounding peribranchial space and in the cloacal cavities. Was redrawn and modified from ref.:26 
L. Patella harbors the endosymbiotic living cyanobacterium Prochloron didemid (Figure 1.5) in 
the cloacal cavities, the cyanobacterium involved with photosynthesis and probably N2- fixation 
for its host. Prochloron didemnid is a unicellular oxygenic photosynthetic prokaryote that 
possesses besides chlorophyll A and chlorophyll B plant-like thylakoids, and it lacks 
cyanobacteria-typical phycobilins,25,29 making Prochloron resembling plants chloroplasts. 
However, molecular biology has shown that Prochloron is not an ancestor of green-plant 
chloroplasts, it is now considered that both have the same ancestors.30 Despite the fact that 
the Prochloron can be obtained by simply manually pressing a colony, it has eluded cultivation 
and is thus considered to be an obligate symbiont. Larvae of L. Patella were released together 
with Prochloron-cells, and it could be shown that their settling on new substrates is controlled 
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by light conditions, providing the best photosynthesis conditions for the symbiont 
Prochloron.18,30 
    
Figure 1.5: Green Prochloron cells (left), Reproduced with permission from ref.31  individual Prochloron cells (right). 
Reproduced with permission from ref.16 
Prochloron didemnid is an excellent example for chemical diversity in marine cyanobacteria, 
because so far it has produced the widest range of secondary marine metabolites that have 
been reported. Therefore, Prochloron uses all three of the previously described ways for the 
formation of marine natural products (RIPP, NRP and PKS).4 Thus, it may be that the symbiont 
provides a chemical defense for its host. 
Understanding the lifestyle of symbiont and host is important for natural product discovery and 
chemical ecology, and indeed, also for determining the natural role of the patellamides. As they 
are produced by the cyanobacteria Prochloron, the patellamides are classified as marine 
cyanobactins. There are also some peptidic terrestrial cyanobactins known, most of them are, 
in contrast to the patellamides, non-ribosomal products (NRP).4 Patellamides are known for 
their versatility, their resistance to proteolysis and their ability to traverse membranes30 Hence, 
the patellamides from L. Patella display antibacterial-, antiviral- and cytotoxic-activity as well as 
they are able to reverse multiple-drug resistance in human leukemia cells.13,32-41 Recently 
published phylogenetical approaches confirm the suggestion that patellamides and some other 
secondary metabolites (e.g. trunkamide), are produced from a linear prepeptide, the 
production of which is dependent on a gene cluster of seven genes called PatA-PatF.16,17 Five 
of these seven genes are necessary to build a patellamide.21 Additionally, it is known that only 
small changes such as single- point- mutations lead to a different cyclic peptide. Studies have 
shown that it is possible to influence the DNA of prochloron cells by a single point mutation, so 
that (in an E.coli culture) a new artificial cyclic peptide is produced.16 It was assumed that, in 
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this way, the ascidians may use different secondary metabolites as a kind of immune- system 
or they may be used as signal substances against predators or to entice attractors, which may 
slightly differ from reef to reef. Additionally, the research confirmed that the amount and the 
kind of patellamide produced varies from ascidian to ascidian, which indicates that the 
patellamides are needed under the different environmental conditions present.28 However, it 
is still unclear on which exact conditions the patellamide production is dependent: water 
conditions as salinity, temperature or pH could play a role, but also it is possible that nutrients, 
predators or attractors in different regions may play a role. Parallel to these studies (the 
methods of which could be described as“reversive genetics”) Jaspars et al were able to achieve 
the same result by using a method called “shotgun cloning”.17 In shotgun cloning, all DNA 
fragments are transferred solely to an E. coli culture, then produces secondary metabolites that 
are finally analyzed by a high through-put method (e.g. LC-MS). In reversive genetics, in 
contrast, one first looks for a logically required amino acid sequence, transfers this particular 
DNA fragment to an E. coli culture and lets this produce secondary metabolites, followed by 
analysis of the final products. 18 
Between 30 and 50% of the carbon required by L. Patella is produced by Prochloron and mainly 
delivered as glycolate, which is an inhibitor of photosynthesis.18,42 Studies with radio labelled 
14CO2 have shown that most of the carbon transferred (from Prochloron to L. Patella) was found 
in the lipids, the nucleic acids and the proteins of the host.42 In addition to Prochloron providing 
nearly all of the necessary carbon, it is presumed that all nitrogen required for animal survival 
and nitrogen recycling comes from the same source, and this is indicated from the unusual 
N15/N14 abundance in Prochloron cells. 42-46 Contrary to these findings, it could be shown that 
Prochloron didemnid has no nif-genes, which are the known genes for N2-fixing enzymes.47 
There are numerous symbiotic cyanobacteria known, which fulfill in addition to photosynthesis, 
a second small molecule activation for their own metabolism or for that of their host. For 
example, in a lake at Yellowstone National park (which, is regarding its high salinity, is a biotope 
with extreme highly adjusted organisms) a cyanobacterium was discovered that is undergoing 
photosynthesis during the day and nitrogen-fixation at night.48 Prochloron in ascidians can vary 
the amount of patellamides and the sequences by only small changes in the prepeptide, 21,38 In 
this way it may be, that prochloron has a similar way of dealing with different processes with 
changing environment or nutrients. The aim to understand the natural biological function of 
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these cyclic peptides may thus lead to a better understanding of reef ecology. In addition, it 
may help indirectly to discover and investigate new pharmaceutically interesting peptides. 
 
1.3 Patellamides: Biosynthesis, Conformation and Chemical Features  
 
The chemical diversity of L. Patella is displayed by the fact that there are several families of 
azole and azoline based cyclic peptides isolated from this single species.24 There are the 21-
atom macrocyclic Lissoclinamides (Figure 1.6b), the 18-atom macrocyclic Westiellamide (Figure 
1.2c) (which could also be isolated from the terrestrial cyanobacteria Westiellopsis prolifica)10,49 
and the patellins (Figure 1.6a). Another interesting peptide from L. Patella is tawicyclamide 
(Figure 1.6c) which has a proline and a thiazoline instead of two oxazolines. Furthermore 
Prepatellamide A and B (Figure 1.7) could be isolated from L. Patella. In both peptides one of 
the oxazolines is hydrolysed which suggests that they may be precursor molecules for the 
respective Patellamides.4,18 All native cyclic peptides are 18- to 24-atom macrocylic azacrowns, 
with a scaffold composed of altering N-heterocycles combined with amides. 
 
Figure 1.6: Structures of Patellin 1 (a), Lissoclinamide 1 (b), Tawicyclamide A (c).  
Studies of the chemistry of the patellamides were encouraged by their known antibacterial, 
cytotoxic and antiviral activities. 13,32-41,50 The patellamides from L. Patella are low weight cyclic 
peptides and can be described as macrocyclic azacrowns with eight possible N-donors, with the 
potential to bind metal ions within this macrocyclic cavity. .(Figure 1.6, Table 1.1). Since these 
cyclic peptides are possible ligands for transition metal ions, it is necessary to have a look at 
c) b) a) 
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their diversity, biosynthesis, the combination of amino acids, the azacrown ring size, the 
peptide conformation and the overall configurations of the patellamides. 
 
Figure 1.7: Structures of Patellamide D (a) (red: Phe, blue: Cys, green: Ile, yellow: Thr), Patellamide 
skeleton (b), Prepatellamide skeleton (c).  
The patellamides are designated as pseudo-octapeptides because, formally, their scaffold of 
alternating azoles/azolines with amides originates from the condensation of eight amino 
acids24,35,50-52 (Figure 1.7 colored patellamide D for visualization).  
Tabel 1.1: Structural variations in the patellamide scaffold.9,11,12,15,37,53-55 
Pseudo-octapeptides R1 R2 R3 R4 R5 
 A   D-Val L-Ile D-Val L-Ile H 
 B   D-Phe L-Ile D-Ala L-Leu CH3 
 C   D-Phe L-Ile D-Ala L-Val CH3 
 D   D-Phe L-Ile D-Ala L-Ile CH3 
 E   D-Phe L-Ile D-Val L-Val CH3 
 F   D-Val L-Val D-Phe L-Val H 
 G   D-Ala L-Leu D-Phe L-Ile CH3 
Ascidiacyclamide D-Val L-Ile D-Val L-Ile CH3 
  Prepatellamide A   D-Val L-Ile D-Val L-Ile H 
 Prepatellamide B  D-Phe L-Ile D-Ala L-Leu CH3 
 
The condensation of eight amino acids is the first ribosomal step of the native patellamide 
synthesis. Biosynthesis starts with the ribosomal formation of a propeptide, which is initiated 
by a gene cluster with seven genes, called Pat A-G, but only five genes are required for the 
patellamide synthesis. The resulting propeptide has at its beginning a start-cyclization sequence 
a) b) c) 
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that is a pentapeptide and at its end a stop-cyclization-sequence which is a tripeptide.56 The 
heterocycles, i. e. thiazols, thiazolines and oxazolines are produced by cyclic condensation of 
serine, threonine and cysteine and, in some cases subsequent oxidation (Figure 1.8). The 
thiazoles/thiazolines are produced prior to the commencement of oxazoline condensation. 
Both steps are post translational modifications.43,57 The biosynthesis ends with a macrocyclic 
condensation of both peptide ends. This final step is directed by the start and end sequences 
and is presumably enzyme-driven.58,59 Due to the fact that all steps occur in prochloron 
ribosomes the synthesis is classified as ribosomal production and post-translational 
modification (RIPP). 
Until now no imidazole-containing cyclic pseudo-peptide has been discovered in L. Patella. This 
may be the case because the necessary 2,3-diaminopropionic acid is not abundant in the 
ribosome.60,61 However, considering the various metabolic roles of the imidazole-groups as side 
chains of histidine containing peptides and proteins, this fact increases curiosity about the 
natural role of the patellamides even more. 
 
     L-Val    L-CYS       L-Ala      L-Thr      L-Ser 
 
Figure 1.8: Post transalational heterocyclization of a hypothetical linear propeptide. 
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The absolute configuration (R* or S*) of the amides-stereo centers is another characteristic 
feature of this peptide family. The potential for the differences in absolute configuration at Cα 
is illustrated in Figure 1.6 and Table 1.1 and shown in Figure 1.9. 
 
Figure 1.9: Visualization of Cα and Cß. 
It is known that peptides containing D-amino acids are protease resistant and less immunogenic 
than their stereoisomers with only L-amino acids.62,63 Therefore, it is understandable that 
studies were able to show that D-amino acids and D-peptides have high potential for improving 
selectivity and maintaining activity of therapeutic agents64 Investigation of the dynamics of the 
glycopeptide peptidoglycan (Figure 1.10), an essential component of the bacterial cell wall, 
showed that the substitution of one single L-alanine with D-alanine lead to a significant change 
in the biological response.65 
 
Figure 1.10: modified Peptidoglycan. 
Thus, the consequent use of D-amino acids in a ribosomally produced peptide presumably 
plays a key-role in the biological function of the patellamides. Furthermore, the fact that 
N τ  
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amino acid residues that are opposite to each other adopt the same absolute configuration 
is the mainly influencing feature for the whole peptides structure. 
Another key feature of the patellamides is their structure, both, in solid state and in solution. 
Due to the heterocycles and the amides, the structure of the macrocycles is relativly rigid.66,67 
The dihedral angle χ [Namide-Cα-Cimi-X] is an indicator for the extension of deviation from 
planarity of the complete macrocycle (χ=0, 180° indicates planarity) and is the decisive factor 
for the macrocycles final structure. It has been shown with DFT calculations (Figure 1.11) that 
χ depends on the kind of azole-system and the size of the amino acid residues.68,69 By 
comparing the small-residue cyclic peptides (Figure 1.11a) it is obvious that the thiazol 
reference system has one minimum more than the oxazole and the imidazole reference 
system, which leads to the suggestion that thiazole-containing macrocycles have a higher 
flexibility than oxazole- or imidazole-containing macrocycles.66,69 The second observation 
from the data in figure 11 is that while changing to a sterically more demanding residue 
(Figure 1.11b), the rotational activation barrier increases and so there is for all three 
reference systems just one minimum left in the less planar range from 100°- 150°. 
Investigations of the crystal structures and DFT calculations on imidazole and oxazole 
containing cyclic octapeptides confirmed, by comparing the structures of C2- and C4- 
symmetric cyclic octapeptides, that the final structure of these peptides depends on the kind 
of azole used and not on the symmetry of the system.69 
 
 
Figure 1.11: Energy profiles – DFT calculated of the oxazole- , thiazole- and imidazole- reference 
systems, respectively, in relation to the dihedral angle.66,67,70 
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The solution structures of the patellamides are determined by NMR Spectroscopy52,71,72 in 
combination with molecular mechanics, molecular dynamics and Monte Carlo9 71,72 as well as 
DFT calculations.73 A mixed NOE-NMR and circular dichroism study indicated a figure-of-eight 
structure for patellamides A and C in non-polar solvents; in contrast in polar solvents the 
pseudo-symmetric patellamide A adopts the known saddle-shaped conformation whereas 
the non-C2-symmetric patellamide C remains in an figure-of-eight conformation.74  
All structural investigations in solution indicate that there are two main types of conformation 
in solution the “saddle-shaped” (square) and the “figure-of-eight” geometry (Figure 1.12), 
which depend on the degree of symmetry as well as on the polarity of solvents used. 
Additionally the NMR studies pointed out that most patellamides adopt in general in solution 
the same conformations as they adopt in the solid state.10,13,69,71,75 Within the saddle-shaped 
conformation the thiazoles and the oxazolines occupy the corners of a rectangle. The most 
important feature of this conformation is that all nitrogens are directed towards the center 
of the macrocycle. The figure-of-eight conformation therefore is characterized by a twist 
within the two opposite amide sides. 
               
Figure 1.12: Visualisation of possible conformations; drawings of all possible conformations. 
In 1988 the X-ray structure of ascidiacyclamide (Figure 1.13b) was reported by Ishida et al.9 
In later work the same group reported the X-ray structures of Patellamide A and D.73,76 Both 
Patellamide A and D seem on the first view to have similar rectangular structures, but on 
closer inspection, the C2-symmetric asciacyclamide (as the C2 symmetric patellamide A) 
crystallized in a so called saddle-shape conformation (Figure 1.13b) whereas patellamide D, 
which is less symmetric, crystallized in a so called twisted figure-of-eight form (Figure 1.13a).  
a) b) c) 
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Figure 1.13: crystalstructures of Patellamide D (a)77 and Ascidiacyclamid (b).9,70 
Also, patellamide B and C which have a lower than C2-symmetry, were later found to 
crystallize in a twisted figure-of-eight configuration.71 The different solid state conformations 
of the patellamides are related to the type of symmetry.54  
 
1.4 Patellamides and their Metal Complexes  
 
The last sections indicate that there are a number of attempts to discover the natural role of 
the patellamides. These approaches include investigations of their synthesis,53,69,78-80 finding 
the genetic information responsible for their production16,17 and also investigations towards 
their ability to coordinate metal ions. 1,70,81-85 The fact that transition metals like copper(II), 
vanadium(III) and zinc(II) are highly concentrated in the ascidians leads, together with the 
[18]- and [24]-azacrown structure of the cyclic peptides, to the assumption that coordination 
chemistry may play a major role for the cyclic peptides found in Lissoclinum Patella.86-88 
However, investigations of the metal ion coordination by marine secondary metabolites was 
rarely considered before 1993 when a review of the field by Pattenden stimulated greater 
interest in the topic.89 
In 1996 Jaspars et al. collectecd samples of Lissoclinum Patella, which revealed, after solvent 
extraction, that the concentration of copper(II) and the concentration of zinc(II) was 
approximately four orders of magnitude higher than in the surrounding seawater. 
Interestingly, the highest concentrations were detected in the dichloromethane extract, 
a) b) 
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which indicated that the metal ions must have been complexed.88 One suggestions for the 
biological function of the patellamides, considering the high copper enrichment, was 
copper(II) complexation, transport, storage or detoxificationor.88 The high copper(II) 
concentrations found in the ascidiacea Lissoclinum patella would be toxic for most organisms 
as toxicity towards copper(II) can be observed for most organisms at a concentration in a 
range from 10-7 to 10-6 M.1,41,88,90 
The copper(II) complexes of the patellamides have been investigated extensively 1,70,81-85 In 
addition, the zinc(II), calcium(II), magnesium(II) and potassium(I) complexes have been 
investigated.41,82,91-93 94 While comparing the calcium binding ability of patellamides A, B, C and 
D with synthetic analogues, via NMR and CD spectroscopy, it was concluded that only the 
conformationally more flexible peptides exhibit a significant affinity for calcium(II) ions. 91,93 The 
calcium(II) ions were proposed to be coordinated by the amides oxygen, preferring to form 1:1 
complexes with these ligands.91,93 The crystallization of a potassium complex (Figure 1.14) with 
a twice hydrolyzed ascidiacyclamide was also reported.82 The hydrolysis of the oxazoline 
moieties led to a more flexible macrocycle and thus, it was possible for potassium to coordinate 
to two heterocyclic nitrogens and two carbonylic oxygens. Astonishingly this potassium 
complex was able to form by addition of copper(II) perchlorate a purple compound which had 
an EPR spectrum indicative of two different mononuclear copper(II) complexes.82 
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Figure 1.14: Potassium complex of Ascidiacyclamide. (carbon=grey, sulfur=yellow, nitrogen = blue, 
oxygen=red)70,82 
Comparison of the zinc(II) coordination properties of ascidiacyclamide with those of an 
synthetic analogue showed the formation of three species, depending on the nature of the 
anion and the presence or absence of base.92 Complex formation by zinc(II) triflate, perchlorate 
and chloride led to the formation of two different mononuclear species. The NMR spectrum of 
the mononuclear species indicated C2 symmetric complexes. Only the use of zinc(II) chloride 
resulted in a dinuclear species, characterized by mass spectrometry.  
Freeman and Pattenden studied the coordination preferences of patellamides A,B and E and 
showed that all three have no affinity for the coordination of calcium(II) or magnesium(II).95 
However, the patellamides investigated showed a high affinity for the coordination of zinc(II) 
ions and an even higher affinity for the coordination of copper(II) ions. Interestingly, all 
investigations showed that the patellamides bind up to two metal ions. In the case of copper(II) 
and zinc(II) the binding constants for the first metal were in the range 2 x 104 to 3 x 105 and for 
the second metal ion in the range from 20 to 230. It was also confirmed that patellamides B 
and E underwent a conformational change from figure-of-eight to a saddle-shaped 
conformation while complexing copper(II) ions.95 
While for the patellamides there is no report of the formation of sandwich-type complexes nor 
clusters, Wipf et al. reported for the smaller analogue westiellamide (Figure 1.2) the formation 
of a silver(I) complex harboring four silver(I) ions with a sandwich-like structure.96 Bertram and 
Pattenden studied the possibilities of template-synthesis and reported the discovery of a 
sandwich complex with five silver(I) ions in between two four-thiazole containing patellamide-
model peptides.97 
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Figure 1.15: Silver(I) complex of Ascidiacyclamide. (carbon=grey, nitrogen = blue, oxygen=red)70,96 
In 1988 Hawkins et al. published circular dichroism studies of the interaction of the 
patellamides with copper(II). It was shown that mono- and dinuclear complexes were 
formed.1,81 One of the most significant discoveries was that the dinuclear copper(II) complexes 
of ascidiacyclamide reacted with carbon dioxide to form a carbonato-bridged complex (Figure 
1.16). This was characterized by X-ray crystallography, as well as through magnetic 
susceptibility measurements and ion-spray mass spectrometry.1 In this complex the two 
copper(II) ions are separated by a bridging carbonate and embedded in the saddle-shaped 
ligand. Each cpper(II) ion is coordinated by two heterocyclic nitrogen atoms (Nimi), one amide 
nitrogen atom (Namid), the carbonate and a water molecule. This crystal structure lead the first 
time to the idea that potentially existing dinuclear copper(II) complexes of the patellamides in 
vivo might be involved in the fixation of CO2. 1 
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Figure 1.16: Carbonato-bridged dinuclear Copper(II) complex of ascidiacyclamide; Top view (left), 
side view (right) (carbon=grey, sulfur=yellow, nitrogen = blue, oxygen=red).1,70 
There was also an electronic paramagnetic resonance (EPR) mass spectrometry (MS) and 
circular dichroism (CD) study in 1994 investigating the copper(II) binding properties of 
patellamide D.81 The study showed the formation of two mononuclear and three dinuclear 
complexes, one of which was a carbonato-bridged complex.81 The copper(II) coordination 
depended on the choice of the copper(II) salt, on the solvent employed and on the presence of 
base. Furthermore, it was concluded that in the dinuclear carbonato-bridged copper(II) 
complex of patellamide D, the ligand had a saddle-shape conformation as it does in the same 
complex with ascidiacyclamide. In later work the results were reinterpreted with the help of 
molecular modeling which showed that the coordination of metal ions could change the 
conformation of the cyclic peptide if necessary.98 Similar results were obtained by Jaspars et al. 
while investigating the copper(II) coordination properties of patellamide A, C and 
ulithiacyclamide with circular dichroism and mass spectrometry. Patellamide C showed a higher 
affinity for copper(II) ions than patellamide A. This finding was assigned to the greater 
willingness of a conformational change from figure-of-eight to saddle-shaped by patellamide C. 
Furthermore, this result indicated a cooperative effect of the macrocycle: that is, the 
coordination of the first metal ion preorganizes the macrocycle for the coordination of the 
second metal ion.41,88 Jaspars et al. studied the metal ion selectivity of these peptides and found 
out that there was no binding of cobalt(II), nickel(II) or mecury(II) and that patellamide C (as 
well as ulithiacyclamide) had a higher selectivity for copper(II) than patellamide A, in 
comparison to zinc(II).88 The higher selectivity of copper(II) over zinc(II) could be assigned to 
the ability of copper(II) ions to induce the conformational necessary change, for the uptake of 
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a second metal ion, in patellamide C earlier than zinc(II) does. Copper(II) favours a square planar 
or a square pyramidal coordination environment, which is provided for two metal ions when 
patellamide C adopts a saddle-shaped conformation. On the contrary zinc(II) is geometrically 
highly flexible (as in Chapter 4 described; zinc(II) could easily adopt tedrahedral, octahedral or 
trigonal bipyramidal geometries). From all their studies jaspars et al. concluded that it is more 
likely that copper(II) is the biologically relevant metal for the patellamides.94 
Tabel 1.2: Published complex stabilities of the patellamides.70 
Peptide Metal ion K1 K2 method reference 
Patellamide A Cu(II) 2.00*104 7.76*102 CD  41,95 
  3.31*104 1.00*104 MS 41 
 Zn(II) 3.02*104 1.00*103 CD 41 
  2.82*103 3.89*103 MS 41 
Patellamide B Cu(II) 3.02*105 2.29*102 CD 95 
 Zn(II) 3.02*104 1.19*10 CD 95 
Patellamide C Cu(II) 6.70*104  CD 41 
  6.31*104 6.03*103 MS 41 
 Zn(II) 1.78*104 8.13*102 CD 41 
  2.40*103 2.57*103 MS 41 
Patellamide D Ca(II) 7.94*102  NMR, CD 91 
Patellamide E Cu(II) 1.51*104  CD 95 
 Zn(II) 7.94*104 2.00*10 CD 95 
Ascidiacyclamide Ca(II) 7.94*102  NMR 91 
 
The complex stabilities discussed above and in the literature are listed in Table 2. While 
interpretation of these values one has to keep in mind that different analytical methods were 
used.  
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1.5 Model Peptides and their Copper(II)-Complexes 
 
In order to model structural features of the patellamides and to investigate possible biological 
activities of probably naturally occurring patellamide-metal complexes, a range of artificial 
occurring cyclic peptides were synthesized. 69,70,83-85,99 The main focus for the design of new 
ligands was on the stereochemistry of the amino acid residues and the donor strengh of the 
azoles and azolines. A set of synthetic peptides was developed, labeled H4pat1 to H4pat5 and 
H4ascA (Figure 1.17). 
   
Figure 1.17: Synthetic pseudo octapeptides.100,101 69,99 
Even if imidazole-containing patellamides were not found in Lissoclinum patella, diamino 
propionic acid is not abundant in prochlorons ribosomes, they were chosen for this set of 
ligands. 99 Imidazoles are less hydrolytically sensitive than oxazoles, thiazoles and oxazolines.102-
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104 and offered the possibility of varying the electronic effect of the second hetero-atom by 
substitution of the residue at the nitrogen Nτ. The pKA values of the heterocyclic nitrogen donor 
of N-methylimidazole is 7.0, which is considerably higher than the pKA values of; oxazoles (pKA: 
0,8), oxazolines (pKA: 4.8) and thiazolines (pKA: 2.5).105  
All synthetic ligands have valine side chains. The ligands H4pat1 and H4pat2 have the same 
chemical composition but in contrast to H4pat2, H4pat1 adopts the native configuration 
(R*,S*,R*,S*) of the amino acid residues. The configurational change makes H4pat1 a C2 
symmetric ligand and H4pat2 a C4 symmetric ligand. The C4 symmetric ligand H4pat3 has the 
same configuration as H4pat2 but instead of four methyl-imidazoles there are four oxazoles. 
H4pat4, has a 4S* configuration, harbors two methyl imidazoles alternating with two benzyl 
imidazoles and therefore has C2 symmetry. In addition, there is the four benzyl-imidazole 
containing ligand H4pat5 with C4 symmetry. The most biomimetic ligand is H4ascA which differs 
from ascidiacyclamide only by substitution of two isoleucine- to two valine- side chains. 
Cyclic pseudo octapeptides are highly preorganized for the coordination of copper(II), and 
these artificial macrocycles show a strong cooperativity in the binding of two copper(II) ions. 
70,99,106 Various experiments and computational analyses illustrated the cooperativity of the 
binding event of two copper(II) ions, and it was possible to detect a dinuclear copper(II) 
complex via EPR-spectroscopy in at 10-fold excess of the macrocyclic ligand H4pat2.100 85 The 
equilibrium of copper(II) complexes of the artificial patellamides was experimentally explored 
in methanolic solutions because most of the artificial pseudo-peptides have only a low solubility 
in water, and also to keep all systems comparable. The equilibria can be described as follows 
(Figure 1.18): 
 
1.) All cyclic pseudo-peptides considered here prefer to coordinate two copper(II) ions. The 
 preorganization by the coordination of the first metal ion leads to a change in 
 conformation which facilitates the coordination of the second metal ion, and is thus 
 described as cooperativity. 
2.) Due to the large number of possibile mono- and dinuclear complexes (co-ligands: solvent, 
 deprotonated solvent, OH-, bridging or terminal), there is an complex equilibrium 
 between different species for all cyclic pseudo peptides (Figure 1.18). This 
 makes the spectroscopic characterization of a distinct single species difficult, 
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 compared to ligands which do form under diverse conditions selectively distinct 
 complexes. And also, crystallization of a single species has only rarely been 
 achieved.99 
3.) The copper(II) ions are always coordinated to two heterocyclic nitrogen atoms and one 
 deprotonated amide nitrogen atom. The formation of mono- and dinuclear complexes 
 with copper(II) involves two metal ion assisted deprotonation steps of the amide 
 nitrogen donors, the resulting drop in pH makes it necessary to add base for a complete 
 complexation. 
4.) Nevertheless, the equilibria of the different cyclic pseudo peptides are characteristic.  
The copper(II) complexation equilibria of all ligands are described by various spectroscopically 
monitored titration experiments (EPR, UV/vis-NIR, CD, MS), as a function of copper(II)- and 
base- (OMe-) concentration. The native configuration (R*,S*,R*,S*) of H4pat1 results in the most 
stable copper(II) complexes.106 Also, this ligand forms directly dinuclear complexes without 
evidence of any mononuclear species.. It was possible to trap the hydroxo bridged 
[Cu2H2pat1(µ-OH)]+ species and to structurally characterize it.99,101 The 4S* configured ligand 
H4pat2 forms a mononuclear copper(II) complex as well as a higher concentrated dinuclear 
copper(II) complex at low copper(II) and base ratios.85,100 With H4pat2 it was also possible to 
detect a carbonato-bridged species in contrast to H4pat1. Interestingly, H4pat2 forms a pink 
species upon addition of water to titration at a low base ratio. The ligand H4pat3, which has four 
oxazoles instead of four imidazoles shows at low copper(II) concentrations the formation of a 
2:1 ligand/copper(II) complex, a so-called outside-coordination. (Figure 1.18) UV/vis and CD 
spectroscopic monitored titration studies of the ligands H4pat4 and H4pat5 with copper(II) have 
been reported.107 Ligand H4ascA as a close analogue of ascidiacyclamide has a similar copper(II) 
coordination equilibrium as H4pat1 and H4pat2. Addition of copper(II), even without base, shows 
a d-d absorption band at 687 nm that increases rapidly with the addition of two equivalents of 
base. The fact that there is only one d-d band which does not shift upon addition of base 
suggests that both copper(II) ions have an identical coordination sphere, even if there would 
be a mononuclear species in solution, this would have the same coordination sphere. The 
corresponfding CD-spectrum shows an expected change in conformation upon addition of 
copper(II) which is visible below 400 nm. Addition of a third equivalent of base leads to a 
decreasing intensity and to a shift to higher wavelengths of the d-d absorption. Upon addition 
of a fourth equivalent of base the d-d band shifts to 660 nm. This result can be explained by 
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the formation of a dihydroxo complex and of a bridged hydroxo species at higher base ratios. 
The copper(II) coordination chemistry of H4pat4 will be in chapter 3 of this thesis. At low 
copper(II) concentrations, H4pat4 forms a single existing mononuclear copper(II) complex. 
Thermodynamic stabilities of all dinuclear copper(II) complexes with the patellamide 
derivatives were determined by isothermal titration calorimetry (Table 1.3). H4pat1 forms the 
most stable dinuclear copper(II) complex. The high thermodynamic stability of H4pat1 indicates 
that the alternating configuration promotes formation of dinuclear copper(II) complexes.  
 
Table 1.3. Copper(II) stability constants, entropies and enthalpies of complexation of the patellamide 
derivatives (standard deviations in brackets), obtained from ITC.106 
  [H2pat1Cu2]2+ [H2pat2Cu2]2+ [H2pat3Cu2]2+ [H2pat4Cu2]2+ [H2pat5Cu2]2+ 
N a) 1.90 (0.09) 1.84 (0.08) 1.99 (0.02) 2.03 (0.02) 1.89 (0.02) 
K 1.71x106 (0.71) 4.03x104 (0.55) 2.27x105 (0.14) 1.43x105 (0.08) 1.50x105 (0.09) 
∆H [kJ/mol] 46.8 (4.6) 84.52 (7.7) 62.7 (0.8) 74.8 (0.8) 73.5 (1.8) 
∆S [J/(mol K)] 278.6 371.5 313.8 349.3 344.7 
      
a)  computed CuII : (H2patn) ratio     
 
P A T E L L A M I D E S  –  B I O L O G Y  A N D  T R A N S I T I O N  M E T A L  C H E M I S T R Y   
  | 25 
 
Figure 1.18: Scheme of all possible complex structures in Pseudo octapeptide copper(II) 
equilibrium. 70   
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1.6 Hydrolase Activity by Model Complexes  
 
Since potentially existing copper(II) complexes of the patellamides assumably fullfil their 
metabolic role in a hydrophilic environment, its likely that this metabolic role is hydrolysis 
chemistry. Regarding the ubiquitious occurrence of CO2 and its various metabolic functions, it 
is obvious that nature needs various strategies to fix and to hydrolyse CO2. 
Hydrolysis of CO2 is important in context of climate change and the acidification of the oceans. 
The development of technologies that are able to fix and to hydrolyze atmospheric CO2 are 
thus important environmental questions. 108-110 The mechanistic and kinetic analysis of the 
carbonic anhydrase activity of dinuclear copper(II) complexes of patellamide derivatives has 
recently been described.111 The dinuclear copper(II) complex of the ligand H4pat1 was the most 
active [kcat=7.3 × 103 s−1 (uncatalyzed: 3.7 × 10−2 s−1)]111 and is, thus far, the most potent 
copper(II)-based model complex for the enzyme carboanhydrase.  
Phosphoester-hydrolysis is also an interesting reaction with respect to the structures of the 
dinuclear copper(II) complexes of the patellamide derivatives. Phosphoester have numerous 
biological functions as being part of the DNA, RNA, phospholipids, ADP, ATP and 
pyrophosphates. Nature needs substances and strategies to hydrolyze phosphoesters 
catalytically under various conditions, in hydrophobic pockets, in cytoplasm, at different 
temperatures and different pH values. Since there are numerous CO2 hydrolyzing systems that 
are also active in phosphoesters hydrolysis, this could also be a relevant reaction for  the 
dinuclear transition metal complexes of the patellamides. Therefore, the copper(II) complexes 
of the Ligands H4pat1 and H4pat2 have been shown to hydrolyze the model phosphoester 
BDNPP (2,2´,4,4´-bis(dinitrophenyl)phosphate).70,112 
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Figure 1.19: Graphical comparison of the catalytic effencies in CO2 hydrolysis, of the patellamide 
derivatives dinuclear copper(II) complexes, at various pKA values.107,111 
 
1.7 Aims 
 
On the continuous search for the natural role of the patellamides and ascidiacyclamide the 
coordination chemistry of specific derivatives shall be further investigated. Copper(II) is 
considered to play an important role in the natural chemistry of the patellamides. The 
copper(II) solution chemistry of a library of designed patellamide derivatives has been studied 
spectroscopically and thermodynamically. The first aim of this thesis was to study the 
electrochemical behavior of the corresponding copper(II) complexes. The electrochemical 
description of the copper(II) solution equilibria shall help to determine whether redox 
chemistry of potentially existing complexes under biological conditions is relevant.  
Zinc(II) is also highly concentrated in the ascidians88 and, in addition, it plays a key role in most 
hydrolyzing metallo enzymes. Thus, the focus of Chapters 4 and 5 lies on zinc(II) coordination 
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chemistry of the cyclic pseudo-octapeptides. Three peptides of the already existing library were 
chosen to explore their zinc(II) chemistry. 
The coordination chemistry of zinc(II) containing cyclic pseudo peptides in the present thesis 
was explored with the objective focus on catalytic hydrolysis chemistry. The challenging 
question the present thesis is whether the characterized dinuclear zinc(II) containing cyclic 
pseudo peptide complexes are able to hydrolyze phosphoesters under physiologic conditions? 
Thus, all described complexes were tested using phosphoester model assays.  
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2 Synthesis of Patellamide Derivatives 
 
The intention to describe the formation of zinc(II) complexes with patellamide derivatives 
required first the selection of appropriate ligands from an existing library (see Figure 1.17). The 
decision was made to explore the zinc(II) chemistry with the imidazole containing pseudo-
octapeptides H4pat1, H4pat2 and H4pat4 (Figure 2.1). By altering the configuration of the valine-
residues and the residues at Nτ of the imidazoles, it should be possible to determine which 
structural features are essential for the formation of the zinc(II) peptides.  
 
 
Figure 2.1: Structures of selected ligands: H4pat1 (a), H4pat2 (b) and H4pat4 (c). 
The three patallamide derivatives chosen for this study have similar donor sets (N-
methylimidazoles or N-benzylimidazols and amides) but are different in symmetry: H4pat2 is C4 
symmetric and H4pat1 and H4pat4 are C2 symmetric. In case of H4pat1, the C2 symmetry is a 
result of the alternating R*,S* configuration of the valine side chains, while in case of H4pat4, 
the C2 symmetry is the result of the alternation of N-methylimidazoles with N-benzylimidazoles. 
The conformation adopted by these artificial cyclic pseudo octapeptides depends mainly on the 
stereochemistry of the amino acid residue (Cα) between the imidazole moieties. From 
a) b) c) 
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comparison of the X-ray structures (Figure 2.2) of all three ligands it appears that all may be 
described as saddle-shaped. Comparison of NMR studies with X-ray crystallography indicated 
that in solution and in solid state these peptides adopt the same saddle-shaped 
conformation.101 
 
Figure 2.2: Crystal Structures of H4pat1 (a),101 H4pat2 (b)100,101 and H4pat4 (c)101. 
Although, all three crystal structures are assigned as saddle-shape conformed, there is a 
remarkable difference between them. The crystal structur of H4pat1 shows four imidazols that 
are oriented in a zig-zag fashion (Figure 2.2a). Contrary, in the the crystal structures of H4pat2 
and H4pat4 the imidazoles are more conical oriented.70,101 
 
2.1 Synthesis Strategy 
 
The patellamide derived cyclic pseudo octapeptides were prepared following a modular 
synthesis route.69,71,113,114 First heterocyclic building block were prepared (Figure 2.3), these 
were then formed to the final peptides in a cascade of deprotection- and coupling steps (Figure 
2.4).  
a) b) c) 
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Figure 2.3: Structures of protected monomers H4pat1 (a), H4pat2 (b) and H4pat4 (c). 
With this general approach it is possible to tune the final properties of the peptides while 
changing the type of heterocycle or the configuration of the amino acid side 
chain.66,69,85,99,105,113 In this thesis all cyclic pseudo-peptides were synthesized via a double 
dimerization to avoid the formation of trimers.100,101 
 
 
Figure 2.4: Schematic drawing of the modular synthesis route to the artificial cyclic pseudo peptides. 
First two deprotected pseudo dipeptides were coupled, and the resulting product was 
subsequently deprotected and cyclodimerized. All reactions are known in the literature and 
only slight modifications to the published procedures will be highlighted.6966,106 
 
2.2 Monomer Synthesis 
 
The preparation of all three heterocyclic building blocks 5, 6 and 21 (Figure 4.5) starts with the 
same molecule; the oxime 1, which was prepared by the reaction of methyl 3-oxobutanoate 
a) b) c) 
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with sodium nitrate in glacial acetic acid. The oxide obtained was reduced in a methanolic HCl 
solution under a hydrogen atmosphere using 10% palladium on charcoal as catalyst. The 
resulting ammonium chloride salt 2 is the starting material for all three monomeric building 
blocks. Using isobutyl chloroformate and n-methyl morpholine (NMM) as coupling agent and 
base, the ammonium chloride salt 2 was converted into peptides. Ammonium chloride salt 2 
was converted by coupling with Boc-protected R-valine into peptide 4, by coupling with Boc-
protected S-valine into peptide 3, or into peptide 18 by coupling with Cbz-protected R-valine. 
 
Figure 2.5: Scheme of monomer synthesis. 
The heterocyclic building blocks 5 and 6, the monomer subunits of H4pat1 and H4pat2, were 
prepared in a hetero-cyclization reaction (cyclo-Mannich condenzation) with methylamine and 
acetic acid. The benzyl imidazole building block 19 was obtained by hetero-cyclization with 
ammonia and trifluoroacetic acid. The formation of the benzyl imidazole building block 
required two additional steps. First the Cbz protecting group had to be substituted by a Boc 
protecting group via deprotection with palladium hydroxide and subsequent protection with 
Boc2O. A benzyl group was then attached by the addition benzyl bromide and sodium hydride 
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in DMF. All heterocyclic building blocks were obtained as crystalline white solids: the R-valine 
methyl imidazole 5 was obtained in 63.6%, the S-valine methyl imidazole 6 in 86.6% and the R-
valine benzyl imidazole 21 in 80.1% yield. 
 
2.3 Peptide Coupling and Cyclization 
 
For the preparation of the final cyclic peptides it was necessary that monomer a (Figure 2.6) 
was deprotect at one site. Deprotection of the carboxylate ester was achieved by hydrolysis 
with sodium hydroxide and Boc-deprotection by trifluoroacetic acid. The resulting deprotected 
monomers b and c were coupled using COMU as coupling agent and EDIPA as base. 
 
Figure 2.6: Schematic representation of the cyclo-peptide coupling. 
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The dipeptide building block d was first Boc-deprotected using TFA and subsequently methyl 
deprotected using NaOH. Finally, coupling to the desired cyclic pseudo-peptide e was achieved 
using COMU as coupling agent and EDIPA as base. After an extensive purification procedure by 
column chromatography and repetitive recrystallization all cyclic pseudo-octapeptides were 
obtained as crystalline white solids: yield of H4pat1 16.8%, H4pat2 8.8% and H4pat4 11.9%.The 
main influencing change in the cyclic pseudo-peptide synthesis was the use of COMU® as 
coupling reagent instead of FDPP. The uronium-type coupling reagent is less expensive, has a 
higher solubility and it is additionally easier to handle because of its stability. The herein 
reported yields are the result from the purification of only a part of the crude product after 
recrystallization and column chromatography. Nevertheless, with further time consuming 
purification steps it was possible to purify more of the crude product, which increases yields by 
approximately 2 to 3 time
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Parts of the following chapter are published in “Copper Solution Chemistry of Cyclic Pseudo-
Octapeptides”; Peter Comba, Nina Dovalil, Gebhard Haberhauer, Klaus Kowski, Nina 
Mehrkens, Zeitschrift für anorganische und allgemeine Chemie 2013, 639 (8-9), 1395-1400.  
  
3 Copper(II) Complexes of Patellamide Derivatives 
Since the biological function of the patellamides and ascidiacyclamide remains unknown and the 
donor set provided, as well as the shape of the macrocyclic peptides, appear to be suitable, 
copper(II) coordination chemistry is assumed to be of importance. Therefore, the copper(II) 
coordination chemistry of the patellamides and of their derivatives has been widely 
investigated.1,52,70,81-85,99 The biological role of potentially existing copper(II) complexes might be 
copper(II) transport and storage, oxygen activation, CO2 hydrolysis, carbonate transport, 
phosphoester hydrolysis, ß-lactam hydrolysis and glycoside hydrolysis.52,85,112,115-117 Biologically 
relevant electron transfer reactions, oxygenations and oxidations by copper proteins (tyrosinase, 
hemocyanine, plastocyanine, catechol oxidase) usually occur in a hydrophobic microenvironment 
provided by a protein.118 Considering the fact that the patellamides were isolated from ascidian 
cytoplasm together with high concentrations of copper(II) and zinc(II),88 the suggestion that 
potentially existing copper(II) complexes of the patellamides acting as small molecular systems in 
an hydrophilic environment as hydrolysis catalysts seems very likely. To combine structural 
properties and thermodynamic stabilities of the known copper(II) complexes of cyclic pseudo-
octapeptides with the electrochemical properties of the corresponding complexes, cyclo 
voltammetry (CV) measurements and square wave voltammetry (SQW) experiments were 
performed. Furthermore, knowing the reduction potentials Ered of dinuclear copper(II) complexes 
should give information about the stability of the according copper(I) species, and thus be able to 
answer the question whether there is a sufficiently stable copper(I) species which could be 
involved in biologically relevant electron transfer, oxygenation or oxidation reactions. 
Furthermore, the complexation equilibrium of the copper(II) complexes of H4pat4 were 
investigated by electron paramagnetic resonance (EPR) spectroscopy to provide important 
information about possible heterodinuclear complexes discussed in Chapter 5.  
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3.1 Electrochemical Studies  
 
Electrochemical properties of the copper(II) complexes of the ligands H4pat1-H4pat5 were 
investigated by voltammetry. Cyclic voltammetry was performed under anaerobic conditions in 
methanol (1mM complex) with ferrocene as the internal reference.119,120  
Table 3.1 (S. 42) lists all redox potentials of the copper(II) complexes of the patellamide derivatives 
H4pat1-H4pat5. Cyclic voltammetry proved to be inconclusive, since the processes studied are 
electrochemically irreversible (Figure 3.1). Based on the known structures and stabilities of the 
copper(II) complexes, chemically reversible processes were not expected. The donor set provided 
by the macrocyclic peptides consists of two heterocyclic nitrogen atoms and one amide per 
copper(II) center, and the ligand sphere is completed by two solvent molecules, hydroxide or 
methoxide (terminal or bridging) and is thus not expected to stabilize copper(I).121-124 
Electrochemistry reveals in all cases that the copper(II) complexes of the cyclic pseudo-peptides 
do exist in equilibria. Thus, there is a number of different species in solution (Chapter 1, Figure 
1.18) that can be electrochemically reduced. Moreover, the dinuclear copper(II) complexes with 
K values around 105 are only moderately stable.106,107 Therefore, it is not unexpected that 
complicated voltammograms are obtained as shown (Figure 3.1). These voltammograms are 
depending on the concentration of all species involved (ligand, copper(II), base),119 and exclude a 
simple assignment of the observed processes. 
The cyclic voltammograms of solutions of H4pat4 with two equivalents of copper(II), that have been 
taken upon addition of various equivalents of base, show a number of irreversible reduction waves 
(Figure 3.1). Since the cyclo voltammograms did not change significantly with multiple scans, it 
can be supposed that no decomposition occurs. The first CV (Figure 3.1 a) is of a solution with 0.5 
equivalents of base, with a ligand-copper(II) ratio of 1:2. The irreversible reduction at -370 mV 
belongs to solvated copper(II) ions (in methanol solvated copper(II) triflate shows an intense and 
irreversible reduction potential at -430 mV, which shifts to -350 mV upon addition of base). 
However, the signal assigned to free solvated copper(II) disappears upon further addition of base. 
The reduction potential of the solvated copper(II) is already disappeared at a ligand/copper(II)/ 
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base ratio of 1:1:2. Moreover, irreversible reduction potentials at 363 and 773 mV appear and 
grow in intensity with increasing addition of base. The assignment of these positive reduction 
potentials is this way not possible, because of various different reasons. First, according to mass 
spectrometry (Section 3.3) there are different mono- and dinuclear species in solution. Second, 
even if there would be a single hydroxo coligated dinuclear copper(II) complex in solution (which 
is according to MS the main component), it wold be hard to assigne the potentials. One one hand 
it is not clear wether the hydroxo coligand is bridging or terminal, and on the other hand for both 
kinds of species are some options possible. A hydroxo-bridged species for example could have 
one, two or three reduction potentials.121 Moreover, it is possible that both copper(II) ions are 
reduced at the same potential. Thus, a dinuclear copper(II) complex with a terminal hydroxid could 
have one or two reduction potentials. 
 
Figure 3.1: CV traces for selected copper(II) complexation-steps of H4pat4 (1mM in methanol with 0.1M 
(tBu)4NPF6 and vs. Fc/Fc+, 100 mV/s, Ag/AgNO3 0.01M, 25°C) 
Redox potentials of dinuclear hydroxo-bridged copper(II) complexes which are comparable to the 
copper(II) complexes of cyclic pseudo-octapeptides have been studied by Krebs et al.125,126. Casella 
et al. studied the differences between terminal or bridging coordinated hydroxides and water 
molecules at dinuclear copper(II) complexes and stated, that hydroxo-bridged dinuclear copper(II) 
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complexes have a poor ability to bind the electro-generated copper(I), and therefore, the 
processes have higher potentials.127 
To simplify the analysis, square wave voltammetry (SQW) measurements were undertaken in 0.1 
mM methanolic solution. Data reported in table 3.1 (s. 42) are those of the more sensitive SQW 
experiments. The higher-resolution of the square wave voltammetric titration (Figure 3.2) shows 
a very negative potential (-1242 mV) after flushing with CO2 for five minutes. This leads to the 
assumption that the formation of carbonato-bridged species stabilizes coordinated copper(I). 
 
Figure 3.2: SQW traces for selected copper(II) complexation-steps of H4pat4 (0.1mM in methanol with 
0.1M (tBu)4NPF6 and vs. Fc/Fc+, 25°C). 
The redox potential of a carbonato-bridged dinuclear copper(II) complex was determined to           
be -620 mV vs Ag/Ag+.128  Thus, the negative potentials at -302, -750, -1086 and -1242 mV obtained 
upon flushing with CO2 can presumably be assigned to different species with coordinated 
carbonate or bicarbonate.After flushing with CO2 the complex solutions of all ligands show a 
characteristic voltammogram (Appendix). All ligand-copper(II) solutions have the formation of a 
quite negative reduction potentials (-714 to -1289 mV) in common, which could presumably be 
assigned to the reduction of dinuclear copper(II) carbonato or bicarbonato species 
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Based on literature derived data of mono and dinuclear copper(II) complexes,121,126,127,129 and the 
square wave voltammograms of the copper(II) complexes of all five ligands H4pat1-H4pat5 (see 
Figure 3.2 and Appendix) reduction potentials around 350 -450 mV are tentatively assigned to the 
reduction of one of the central copper(II) ions to result in an unstable copper(II)-copper(I)-
complex. These rather positive reduction potentials are in agreement with the only moderate 
stability constants and the complex equilibria in solution. 
Considering the expected instability of the reduced systems and the positive reduction potentials 
in agreement with the only moderate complex stabilities, it is unlikely that copper(II)/(I) based 
oxygen activation may be of importance in neutral aqueous solution. 
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Table 3.1. Redox potentials of the copper(II) complexes of the patellamide derivates. 
Ligand CuII Base                                                                      reduction potentials [mV] vs. Fc/FC+   
      0.1M TBA-PF6 in MeOH 
H4Pat4 2eq          -214 354 746  1162 
 2eq  2eq       -750  382 784 1062 1218 
 2eq  3eq       -754  368 798 1054 1214 
 2eq  4eq      -778  350 764 1070 1210 
CO2     -1938 -1758 -1242 -1086 -750 -302     1054 1171 
      -1938 -1758 -1242 -1086 -750 -258 363(13) 773(20) 1060(7) 1195(24) 
H4Pat2 2eq            770 1186 1294 
 2eq  2eq         486 775 1178 1305 
 2eq  3eq         494 772 1187 1301 
 2eq  4eq        506 783 1178 1295 
CO2        -1289  -714      1178   
          -1289   -714   495(8) 777(5) 1181(4) 1299(4) 
H4Pat1 2eq              1239 
 2eq  2eq    -1402  -1102   466 794  1259 
 2eq  3eq   -1387  -1101   394 819  1259 
 2eq  4eq  -1378  -1094   411 836  1270 
CO2     -1762   -1168   -766  352 828   1254 
      -1762 -1389 -1168 -1099 -766   405(41) 819(16)   1256(10) 
H4Pat3 2eq           390 810 1038 1294 
 2eq  2eq         383 865 1042 1298 
 2eq  3eq        402 782 1117 1286 
 2eq  4eq   -1216    391 771 1107 1287 
CO2     -1806  -1202  -726 -354       1290 
      -1806   -1207   -726 -354 392(7) 807(36) 1076(36) 1291(5) 
H4Pat5 2eq             1154  
 2eq  2eq         291 794 1163  
 2eq  3eq        378 781 1152  
 2eq  4eq       439 776 1138  
CO2     -1709   -880 -728 -239     1154  
      -1709     -880 -728 -239 369(61) 784(8) 1152(8)   
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3.2 Oxygenation Properties of [Cu2(H4pat1)(OH)]+ 
 
Although, the electrochemical results indicate that in a hydrophilic environment at 
physiological pH no stable copper(I) species can be formed, under basic conditions and after 
flushing with CO2, low reduction potentials are visible. Considering the possibility that a 
naturally existing dinuclear copper(II) complex of a patellamide derivative may act as a cofactor 
in a protein, i.e. in a hydrophobic microenvironment, copper-based redox chemistry seems 
possible. Furthermore, this scenario may involve amino acid side chains of the protein acting 
as a base. Thus, it appears to be worth to check, whether a dinuclear copper(II) complex of a 
patellamide derivative could act as oxygenase or oxidase. 
There are biologically relevant oxygenation, oxidation and electron transfer reactions which 
have dinuclear copper centers in the active sides of the appropriate enzyme.118,130 For instance, 
the copper type-3 proteins tyrosinase, catechol oxidase and hemocyanine are important 
copper-type-3 proteins. While catecholase catalyzes the oxidation from catechol to quinone, 
tyrosinase catalyzes the oxygenation from the phenol derivative tyrosine to the corresponding 
quinone.131,132 Hemocyanine is the oxygen transporting protein of mollusks. Even if 
hemocyanine does not oxygenate phenols or oxidize catechols it was spectroscopically shown 
that oxygen binds in a side-on fashion between the two copper centers in µ-ƞ2:ƞ2-geometry, 
which is comparable to the oxy-forms of tyrosinase and catecholoxidase.133 All three proteins 
are structurally related and contain a dinuclear copper(II) center in their "resting state" ( the 
met-form, Figure 3.3). The met-form is hydroxo-bridged and features a copper(II)-copper(II) 
distance from 2.9 Å to 3.5 Å. The metal site is antiferromagnetically coupled and thus EPR 
silent.118,131,134 The literature-described mechanism of tyrosinase is illustrated in Figure 
3.5.135,136 The monophenolase cycle (creolase cycle) shown in blue can be described as a 
hydroxylation reaction and is the rate determining step.137 The second part of the catalystic 
cycle, the diphenolase cycle (catecholase cycle), displays a two-electron transfer process with 
a subsequent proton transfer.135,136 
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Figure 3.3: Schematic drawing of the tyrosinase catalysis.135,136 
Koval et al. published in 2006 a carbonato-bridged dinuclear copper(II) complex of a 
macrocyclic ligand with a copper(II)-copper(II) distance of 4.5 Å, that showed catecholase 
activity. 128 The reduction potential of this species was detected at -620mV (vs. Ag/Ag+) (-707 
mV vs. Fc/Fc+)120 which is comparable to the reduction potentials detected for all ligands at -
714 to -766 mV (Tabel 3.1).128 The copper(II)-copper(II) distance in the previously published 
crystal structure of [Cu2[H2pat1)(OH)(H2O)2]+ is about 3.6 Å.85 Thus, a similar reactivity is 
imagineable, the ability to oxygenate or oxidize a distinct model substrate. It is also possible 
that a bridging or terminal co-ligand may act as a radical and generate Copper(I).128,129,138,139 In 
2010 Kaizer and Speier reported a dinuclear hydroxyl-bridged Copper(II) complex that was able 
to act as catechol oxidase mimic, via the radical semiquinone.140 
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The chosen oxygenation assay is well established.137,141,142 The model substrate 2,4-
ditertbutylphenole (DTBPH) (Figure 3.7a) was dissolved under anaerobic and basic conditions 
in methanol. The previously prepared catalyst solution (anaerobic conditions, to avoid the 
formation of carbonato species) was added before the reaction was started by flushing with 
air. The formation of the product was monitored via UV/Vis-NIR spectroscopy (Figure 3.6). 
 
Figure 3.4: Time dependent change in the UV/Vis spectrum, of the oxygenation solution.  
The formed 3,5-ditertbutylquinone (Figure 3.7b) has an absorption maximum at 407 nm (ɛ= 
1830 L*mol-1*cm-1),137 and it was possible to calculate the turnover number (equation 1, Figure 
3.7 a), which shows the number of catalytic cycles a catylyst performs till it gets inactive. 
Furthermore, it is possible to calculate the turnover frequency (equation 2, Figure 3.7 b), which 
displays the efficiency of the catalyst. 
𝑇𝑂𝑁 =
[𝑝𝑟𝑜𝑑𝑢𝑐𝑡]
[catalyst]
  (1) 
𝑇𝑂𝐹 =
𝑇𝑂𝑁
𝑡𝑖𝑚𝑒
   (2) 
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The second observed absorption maximum at 421 nm belongs presumably to the formation of 
the corresponding semiquinone. The formation of semiquinone is characteristic for catalytic 
model systems with a radical intermediate.137 
        
Figure 3.5: Plot of the TON (a) and of the TOF (b) of the generation of DTBQ. 
The turnover number of this reaction is 3 after 2 hours, which indicates that the reaction is 
better described as a stoichiometric reaction rather than as catalytic. From the plot of the 
turnover frequency (Figure 3.7 b) it is obvious that the catalyst is deactivated within one hour. 
An interesting observation is that the reaction can be interrupted by flushing the solution with 
CO2 (Figure 3.8). When changing back from CO2 to O2 the reaction proceeds again. The behavior 
of CO2 as inhibitor leads to the assumption that both molecules be of co-ligands and CO2, i.e. 
CO2 may displace O2.  
 
Figure 3.6: Plot of the change in absorbance at 407 nm by time, interrupted by CO2. 
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To obtain more information about the reaction, the oxygenation products were characterized. 
The desired products were isolated by quenching the reaction with 6 M HCl, and extracting 
oxygenation products with dichloromethane. To identify the oxygenation products, the 
resulting brownish precipitate was investigated with mass spectrometry (Figure 3.9) and NMR 
spectroscopy (Figure 3.10). 
 
 
 
Figure 3.7: HR -ESI mass spectra of a) DTBPH, b) DTBQ+Cl- and c) BDTBPH; observed (top) calculated 
(bottom). 
The mass spectra of the oxygenation products show as highest mass the oxygenation 
substrate DTBPH (Figure 3.7 a), the quinone DTPQ (Figure 3.7 b) and the coupling product 
3,3,5,5-bis(ditertbutylphenole) BDTBPH (Figure 3.7 c). 
a) b) c) 
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Figure 3.8: aromatic region of the 1H NMR of the oxygenation products at 25°C in CDCl3. 
Due to the coupling product BDPBPH a radical pathway seems likely. However, in contrast to 
the mass spectrum, the 1H-NMR spectrum of the oxygenation products (Figure 3.10) shows the 
unreacted oxygenation substrate DTBPH and the quinone product in a ratio of 11:1. Also, the 
1H-NMR spectrum does not exhibit the coupling product BDTBPH. There is the possibility that 
BDTBPH evolved during the mass spectrometric analysis from a semiquinone intermediate 
which is paramagnetic and thus NMR silent. 
To obtain further mechanistic information mass spectra from the original oxygenation solution 
were also measured (Figure in appendix). Further an EPR spectrum of the concentrated 
reaction solution was measured (Figure 3.11). The EPR experiment at 113 K shows a spectrum 
that is typical for a dinuclear copper(II) complex. However, due to the fact that there is a 
copper(II) complex EPR signal detectable, there is definitely no dinuclear met-form-like 
copper(II) center in solution, which indicates that the oxygenation starts from a different type 
of species.  
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Figure 3.9: EPR spectrum of the frozen oxygenation solution at 113K (~.0.3 mM in MeOH, ν = 
9.439058 GHz) 
The mass spectrum of the oxygenation solution shows an intense signal for the complex 
[Cu2(H2pat1)(OH)]+. All other signals are far less intense except for those of the substrate and 
of the base ((nBu)4N+).  
In order to identify a putative dinuclear copper(II) dioxygen species, paramagnetic NMR 
measurements were performed. Koval et al published in 2005 a temperature-dependent 1H-
NMR experiment of an antiferromagnetically coupled dinuclear copper(II) complex.143 The 
signal of the µ-OH co-ligand of their sample shifts with decreasing temperature (from rt 
decreasing to -40°C) from -50 ppm to -30 ppm.  
A sample of [Cu2(H2pat1)(OH)]+ that was originally prepared for an nmr experiment was stored 
under air for some weeks. The paramagnetic 1H NMR spectrum did not change with time but 
the sample was EPR silent after the long storage time. Interestingly, while freezing in liquid 
nitrogen the sample color changed from green to blue. This observation might be explained 
with the formation of an antiferromagnetically coupled dinuclear copper(II) complex, that was 
formed while freezing. In order to monitor the change from the paramagnetic dinuclear 
copper(II) complex to the antiferromagnetically coupled species (virtually diamagnetic) a low 
temperature 1H-NMR experiment was performed (Figure 3.10). The number of signals 
increases as well as broad signals become narrower and better resolved with decreasing 
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temperatures. This indicates that the sample loses its paramagnetism with decreasing 
temperatures which might be due to coordination of coordination of a bridging hydroxid which 
was terminal coordinated at room temperature. Furthermore, at -80°C there is a broad doublet 
visible at -1ppm with an integral of one compared to the valine-H´s which might belong to a 
bridging hydroxo-species. Nevertheless, this interpretation is tentative and needs further 
experimental support. 
 
Figure 3.10: 1H NMR spectra of the blue EPR-silent copper(II) complex of H4pat1 at various 
temperatures: a) 25°C, b) at -40°C and c) at -80°C. 
A suggested preliminary proposal of the oxygenation mechanism is given by Figure 3.13. 
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  Figure 3.11: Sceme of the proposed mechanism.
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Assuming the deprotonated substrate as an electron donor, it may coordinates to one of the 
copper(II) centers and reduce the first copper(II) while forming a phenyl radical. The stabilized 
radical intermediate might undergo a recombination and form the coupling product BDTBPH, or 
react with dioxygen. The peroxo phenyl radical might coordinate to and reduce the second 
copper(II). Both copper(I) centers may react with O2 and form a dicopper(II) peroxophenyl 
complex, that rebuilds the starting form under the release of DTBQ.  
For a complete more throuout mechanistic understanding of the reaction additional experiments 
are necessary, e.g. 18O2 labeling, low temperature UV/Vis-NIR spectroscopy, Raman spectroscopy 
and variations in the reaction such as a change of substrate and study the reaction stoichiometry 
might also be helpful, as well as support by quantum chemical calculations. Recently, Solomon, 
Tolman and Cramer et al. published a macrocyclic hydroxo-bridged dinuclear copper(II) complex, 
which was oxidized to a copper(II)-copper(III) species and further to a copper(III)-copper(III) species 
that was able to act as an oxidation catalyst.144. They have been able to measure an EPR spectrum 
of the mixed valent species which looks pseudo-mononuclear. Thus, it smight also be tested 
whether in our system a copper(III) species may play an important role. 
 
3.3 Copper(II) Coodination Chemistry of H4pat4 
 
The coordination chemistry of the ligand H4pat4 was investigated previously by UV/Vis-NIR and CD 
spectroscopy107 but not by EPR spectroscopy. EPR gives crucial information about the relative 
orientation of the two copper(II) centers and their distance.  
Copper(II) has a d9 electron configuration with a S = 1/2 ground state. The magnetic energy levels 
(described by the magnetic quantum number ms) split when a magnetic field is applied (Zeeman 
phenomenom). The energy difference between the two levels ms=-1/2 and ms=1/2 can be 
described by hν= gßeB . The magnetic tensor g reflects the ligand field and the coordination 
environment around the copper(II) ions. Furthermore, the interaction of the unpaired electron 
with the nucleus results in a hyperfine structure of the spectrum obtained. The hyperfine coupling 
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(AHF) originates from the nuclear spin (copper(II) I = 3/2) and leads to four allowed transitions. Well 
resolved spectra of mononuclear copper(II) complexes may have additionally coupling, especially 
the so-called superhyperfine coupling (ASHF), which results from the interaction of the unpaired 
electron with the nuclei of donor atoms. All interactions are described with the spin Hamiltonian 
given in equation 3.145 
𝐻 = ∑ (ß𝑒𝐵𝑖𝑔𝑖𝑆𝑖 + 𝑆𝑖𝐴𝐻𝐹𝑖(𝐶𝑢) 𝐼𝑖𝑖=𝑥,𝑦,𝑧 (𝐶𝑢) − 𝑔𝑛ß𝑛𝐵𝑖𝐼𝑖) + ∑ (𝑆𝑖𝐴𝑖(𝑁) 𝐼𝑖(𝑁)𝑖=1 − 𝑔𝑛ß𝑛𝐵𝑖𝐼𝑖(𝑁))  (3) 
 
Figure 3.12: Traces of selected EPR spectra (X-Band, 140k, 1 mM in MeOH) at distinct ligand: copper(II) 
: OMe- ratios; a)1:05:0.5 and ν = 9.445927 GHz, b) 1:2:2 and ν = 9.440451 GHz and c) 1:2:4. ν = 9.452096 
GHz. 
In order to study the copper(II) complexation equilibrium with ligand H4pat4, EPR spectra of frozen 
methanolic solutions (140 K) were taken at different ligand/copper(II)/base ratios (Figure 3.12). 
Surprisingly, at low copper(II) and low base concentrations (below one equivalent) it is possible to 
detect a mononuclear species (Figure 3.12 a). Comparing the detected EPR spectra with the 
copper(II) complexation equilibria of the other patellamide derivatives,85 which show at low 
copper(II) and low base ratios solvated copper(II) in addition to mononuclear and dinuclear 
copper(II) species or only dinuclear species, the spectra in figure 3.12 indicate that the in the 
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cooperative effect is less pronounced for H4pat4. When the copper(II) ratio exceeds 0.5 equivalents 
the formation of dinuclear species is also detectable. 
 
Figure 3.13: EPR spectra of [Cu(H3pat4)(OH]; first derivative a) second derivative b) and simulated second 
derivative of [Cu(H3pat4)(OH]. (X-Band, 140K, 1 mM in MeOH, ν = 9.445927 GHz) 
The spectrum of the mononuclear complex and its simulation performed with the program 
Xsophe145 are displayed in figure 3.13, and the EPR parameters obtained are given in table 3.2. The 
well resolved spectrum (Figure 3.13 a) exhibits superhyperfine coupling constants (second 
derivative; Figure 3.13 b). The superhyperfine coupling which is more precisely displayed in the 
second derivative (Figure 3.13 b) was simulated assuming that the copper(II) is coordinated to two 
different types of nitrogen atoms (one amide and two imidazoles).  
Table 3.2. Simulated EPR parameter. 
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A
z  [10-4cm-1] 159.0 Az(Nam) 13.1 
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The simulation of the dinuclear copper(II) complex (Figure 3.12 b) was performed using the 
program MoSophe.146 The simulation with MoSophe includes the relative orientation and the 
distance of both copper(II) ions (Figure 3.14).146 
 
Figure 3.14: schematic representation of the Euler angles ρ, τ and χ used for EPR simulations with the 
program MoSophe.146 
At a ligand / copper(II) / base ratio of 1:2:2, H4pat4 shows an EPR spectrum of a single dinuclear 
copper(II) complex (Figure 3.15 b black spectrum). It´s stoichiometry [Cu2(H2pat4)(OH)]+ emerges 
from mass spectrometry (Figure 3.15). The formally forbidden ΔmS = 1 transition, which is typical 
for dinuclear copper(II) complexes, is also detected (Figure 3.15 a black spectrum) but had a poor 
resolution. The simulated spin hamiltonian parameters are given in table 3.3 and are comparable 
to the parameters of the respective species by other patellamides derivatives85. The 
copper(II)····copper(II) distance of 5.16 Å is too long for a bridging hydroxide. 99 Thus the hydroxide 
is believed to coordinated terminally at one copper(II) ion. It is convincible that a bidentate co-
ligand such as bicarbonate or phosphate might coordinate in a bridging fashion at this metal-metal 
distance. 
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Figure 3.16: EPR spectra of [Cu2(H2pat4)(OH]+; a) ΔmS = 1 region and b) ΔmS=1/2 region; measured 
(black) and simulated (blue). (X-Band, 140K, 1 mM in MeOH, ν = 9.440451 GHz) 
Table 3.3. Simulated EPR parameter. 
 Cu
a
 Cu
b
  R [Å] 5.210 
g
x
 2.035 2.055    
g
y
 2.150 2.155  χ [°] 17 
g
z
 2.286 2.215    
A
x  [10-4cm-1] 125 25  τ [°] 47 
A
y  [10-4cm-1] 65 110    
A
z  [10-4cm-1] 212 120  ρ [°] 17 
 
The EPR spectrum of a ligand / copper(II) / base ratio of 1:2:4 (Figure 3.14 c) is interpreted as 
containing a mixture of more than one species. It appears to be a mixture of spectrum a) and b). 
However, subtraction of neither spectrum a) nor subtraction of spectrum b) leads to satisfactory 
results that could be simulated.  
High-resolution mass spectra of all methanolic solutions were measured. Figure 3.17 shows two 
selected mass spectra with a distinct pattern for dinuclear copper(II) complexes. It is possible to 
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2
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2
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4
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+
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detected more masses belonging to mononuclear and dinuclear complexes (solvent, H2O, OH-, 
MeO-). 
 
Figure 3.17: Selected recorded mass spectra (top) and calculated (bottom) isotopic pattern for a) 
[Cu(H3pat4)]+ and b) [Cu2(H2pat1)(OH)]+ in methanol.  
 
Considering the findings described in this study by EPR spectroscopy, mass spectrometry and 
electrochemistry (Figure 3.1 and Figure 3.2) and the findings of published ITC, UV/Vis and CD-based 
studys107 the proposed complexation equilibria are displayed in figure 3.18. 
H4pat4 forms at low copper(II) and low base concentrations, in contrast to the other ligands a 
distinct mononuclear species. Starting with 0.75 equivalents of both copper(II) and base, the 
formation of a dinuclear species is detecable. At a copper(II) and base concentration of two 
equivalents, only one dinuclear copper(II) species with is detectable (Figure 3.16). The addition of 
higher base ratios leads to formation of further species.  
b) a) 
C O P P E R ( I I )  C O M P L E X E S  O F  P A T E L L A M I D E  D E R I V A T I V E S  | 61 
 
  
Figure 3.18: Proposed copper(II) complexation equilibrium of H4pat4. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parts of the following chapter are to be published in a manuscript entitled: “Dinuclear Zinc(II) and 
Copper(II)/Zinc(II) complexes of artificial Patellamides as Phosphatase models”; Peter Comba, 
Annika Eisenschmidt, Lawrence R. Gahan, Graeme R. Hanson, Nina Mehrkens, Michael Westphal, 
manuscript in preparation, 2015   
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4 Zinc(II) Coordination Chemistry 
4.1 Zinc(II) Hydrolases 
 
4.1.1 Zinc(II) enzymes – a general introduction 
 
In biological coordination chemistry there is no other metal known which has as many biological 
roles as zinc.147 Nevertheless, zinc(II) is often ironically described as “boring”. The d10 electronic 
configuration leads to the absence of ligand field stabilization energy with the consequence of a 
high geometric flexibility. It exchanges its ligands rapidly and prefers both hard and soft donors.147-
149 In 2007 Heinrich Vahrenkamp described the chemistry of zinc(II) and it´s lack of properties in 
the following way: “in essence, the non-properties of zinc(II) are the basis of its success: no redox 
chemistry, no ligand field effects, no typical coordination numbers or geometries, no stability or 
inertness of its complexes, no typical hard or soft characteristics. For generations of chemists zinc(II) 
was the boring element.”147 150 However, this unspectacular reputation is completely undeserved. 
Zinc(II) is the second most abundant inorganic transition metal in human bodies, and it is 
indispensable to all forms of life.147 Nature uses it in structural functions as well as in catalytic 
processes.150 Zinc(II) occurs in all enzyme classes; in 2007 it was reported that the number of 
known enzymes that contain zinc(II) in their active center exceeded 1000.151 There are about 5000 
further proteins known in which zinc(II) plays a role.152 The role of zinc(II) ions and proteins is, in 
the majority of cases, a structural one, comparable to the role of hydrogen bonds.147 A well-known 
example of this structural role is zinc(II)-finger proteins. Zinc(II) is necessary for effective growth 
and development due to its various functional roles.147 Zinc(II) can be 6, 5 or 4 coordinate, 
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depending on the ligands, solvent and possible co-ligands. In proteins in which zinc(II) plays a 
structural role, it is usually tetrahedrally coordinated by cysteine and histidine side chains (N2S2 
motif).149  
If the native role of zinc(II) is not structural it is mostly acting as a hydrolytic agent. Examples of 
zinc(II) containing hydrolyzing enzymes include alcohol hydrolases, phosphoesterases, carbonic 
anhydrases, carboxypeptidases, and metallo-ß-lactamases (Table 2.1).149 In hydrolyzing enzymes, 
the zinc(II) ion is tetrahedrally coordinated, usually coordinated by three amino acid side chains 
and one site occupied by a water molecule. The amino acid side chains are mainly provided by 
histidine and cysteine, the carboxylates of glutamine and asparagine can also be involved.149 When 
it comes to dinuclear or even trinuclear hydrolyzing zinc(II) enzymes, such as alkaline phosphatase, 
nuclease P1 or phospholipase C, it is often observed that the zinc(II) center is pentacoordinated in 
a trigonal bipyramidal geometry.149 Glutamate and aspartate are especially known to bind in a 
bridging manner between two zinc(II) centers, mainly besides a bridging hydroxide.153-155 For the 
whole group of zinc(II) enzymes the pKA value of a coordinated and activated OH2 molecule is the 
main influencing factor for the activity. Zinc(II) acts as a Lewis acid and lowers the pKA value of the 
coordinated water molecule, causing the nucleophilic OH- group to be available at physiological 
pH.156,157, 158 The Lewis acidic zinc(II) is thus neither involved in reactions with high energetic 
changes nor does it have colorful chemistry but it rather exhibits an ubiquitous hydrolysis 
chemistry.147,149,159,160  
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Tabel 4.1: Examples of zinc(II) based hydrolases. 
enzyme 
active side 
metal center 
Metabolic functions 
Zinc(II) 
coordination motif 
ref. 
purpel acid 
phosphatase 
(PAP) 
Fe(III)-Zn(II)* 
bone resorption 
iron transport 
generation of ROS 
His, Asn, His 
161, 162, 
163 
carbonic 
anhydrase (CA) 
Zn(II) 
hydration of CO2 
respiration, pH control 
fluid secretion 
His, His, His 
164, 149, 
165, 166. 
Metallo-ß-
lactamase 
Fe(II)-Zn(II)*2 
transduction of neuronal 
signals 
His, His, His 167 
carboxypeptidase Zn(II)-Zn(II) 
protein decomposition 
amino acid synthesis 
His, His, Glu 149 
alkaline 
phosphatase (AP) 
Zn(II)-Zn(II)-
(Mg(II)) 
bone mineralisation 
Asp, His, His 
 Ser,His, Asp 
168 
nuclease P1 Zn(II)-Zn(II)-Zn(II) 
hydrolysis of single strain 
DNA and RNA 
His, His, µ-Asp 
His, His, Asp 
His, Trp, µ-Asp 
169 
*PAPs are also known with Fe(III)-Fe(II) and Fe(III)-Mn(II) 
*2Metallo-ß-lactamases are also known with Mn(II)-Mn(II)  
 
Possibly the most abundant zinc(II) based hydrolyzing enzyme is carbonic anhydrase, a 
mononuclear zinc(II) enzyme. Carbonic anhydrase is one of the most effective enzymes known, it 
accelerates the uncatalyzed hydration of CO2 approximately 108-fold.170 Human carbonic 
anhydrase II (HCA II) is predominantly found in red blood cells where it catalyzes the hydration of 
respirated CO2 to HCO3-. The first crystal structure of HCA II was published in 1988 with 2.0 Å 
resolution.171 Figure 4.1 shows the crystal structure of the engineered wild type variant of HCA II, 
which has an additional disulfide bond, that shall provide a higher stability for industrial reaction 
conditions.164 
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Figure 4.1: The X-ray structure of the disulfide-containing human carbonic anhydrase II with a silver 
backbone and an active site in ball and stick view. Colors; violet: zinc(II), blue: nitrogen, red: oxygen 
and yellow: sulfur.164, (Reproduced with permission from IUCr), (pdb: 4hba), (http://onlinelibrary.wiley.com/iucr/10.1107/S0907444913008743) 
Due to the various metabolic functions of carbonic anhydrases (e.g. respiration and pH regulation 
in the stomach) there are various isoenzymes, whose structures show only slight differences in 
contrast to their catalytic efficiency, which can differ greatly depending on the pH.118 The active 
site contains a tetrahedrally configured zinc(II) ion coordinated by three histidine residues (His94, 
His96, His119) and a water molecule. 
P H O S P H A T A S E  A C T I V I T Y  O F  H O M O -  A N D  H E T E R O D I N U C L E A R  T R A N S I T I O N  M E T A L  
C O M P L E X E S  O F  P A T E L L A M I D E S   | 68 
 
 
Figure 4.2: Scheme of the catalytic hydration of CO2.118,164,172 
The mechanism of carbonic anhydrase is briefly described, because the dinuclear copper(II) 
complexes of the patellamide derivatives, described in this thesis, have recently been shown to act 
as efficient carbonic anhydrase models.111 While exploring the zinc(II) chemistry of the 
patellamides the possibility of carbonic anhydrase activity was considered and will be discussed in 
Section 4.2.4 of this Chapter. For the mechanism of CO2 hydration by HCA II (Figure 4.2) there are 
two possible pathways; the Lipscomb-mechanism (internal proton transfer) and the Lindskog-
mechanism (pentacoordinated bidentate intermediate).118,172 Theoretical studies assume the 
Lindskog mechanism to be the naturally relevant mechanism.173,174.Carbonic anhydrases could 
generally work in two directions; clockwise from CO2 to bicarbonate (as displayed in Figure 4.2), 
relevant for the CO2 uptake in green plants chloroplasts and in the uptake of produced CO2 from 
human body cells to blood plasma; and anticlockwise, which takes places when bicarbonate from 
blood plasma goes into pulmonary alveoli as CO2. 
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The pKA value of the zinc(II) bound water molecule in carbonic anhydrase in the enzyme´s resting 
state is ≈ 7. Catalysis starts with the deprotonation of the coordinated water by histidine 64. Due 
to a later step, in which this proton is given back to the catalytic cycle, histidine 64 could be 
described as proton shuttle. 
Besides the broad range of mononuclear zinc(II) complexes, there is a smaller range of dinuclear 
zinc(II) complexes that catalytically hydrolyze CO2 via a nucleophilic attack of coordinated water or 
hydroxide have been described in the literature.149,175,176, 177-180 As well as some dinuclear 
copper(II) complexes are also known that hydrolyse CO2.181,182 But the most efficient copper(II) 
based model complexes known so far are those of the patellamides. 111 
 
4.1.2 Zinc(II) in the active site of hydrolases 
 
Nature appears to have selected zinc(II) in the majority of the hydrolyzing enzymes because of the 
capacity of the metal ion to promote the deprotonation of a coordinated water molecule in the 
physiological pH range. This ability is tunable by slight changes in the first coordination sphere of 
the metal ion as well as by the hydrogen bond network, provided from the second coordination 
sphere.183-187 Thus, zinc(II) acts as a Lewis acid and lowers the pKA value of the water molecule so 
that a nucleophilic OH- group is available at physiological pH.188 The relatively high ionization 
potential, displayed in its Lewis acidity, gives the zinc(II) ion the ability to polarize H2O, C-O and P-
O bonds easily.189 There are many examples biomimetic approaches to model the hydrolytic active 
zinc(II) sites in these zinc(II) hydrolases. The key factor is the acidity displayed in the pKA value of 
the zinc(II) bond water molecule. The pKA value, therefore, is known to depend on the number and 
on the nature of the zinc(II) coordinating ligands.190 
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Figure 4.3: Structures of [Zn([12]aneN3)H2O]2+ (a)191, [Zn([12]aneN4)H2O]2+ (b)160 and [Zn(cadip)H2O]2+ 
(c)192. 
The first model complex (based on a macrocyclic ligand) for carbonic anhydrase was reported in 
1975 by Woolley et al. (Figure 2.3 c).192,193 Kimura et al., whose research was focused on 
mononuclear zinc(II) complexes of macrocyclic tri- and tetramines, reported that while the 
coordination number of zinc(II) decreased from 5 to 4, the pKA value of the zinc(II) bound water 
molecule decreased from 8.0 to 7.3 (Figure 4.3 a and b).194, 195, 191 This feature could be explained 
by the decreasing charge on the zinc(II) ion with a decreasing coordination number, which 
consequently increases the zinc(II) ions capacity to polarize the coordinated water molecule.188 
Furthermore, while comparing [Zn([12]aneN4)H2O]2+ (Figure 4.3b) with [Zn(CR)H2O]2+ (Figure 4.3c) 
the influence of the ligand’s geometry was studied. The change from a cyclen platform (Figure4.3 
b) to the more rigid ligand cadip (Figure 4.3c) leads to a higher pKA of the zinc(II) bound water.196  
  
a) b) c) 
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Figure 4.4: Structures of [Zn(tpa)H2O]2+ (a), [Zn(bpg)H2O]2+ (b), [Zn(tapa)H2O]2+ (c) [Zn(tnpapa)H2O]2+ 
(d).184. 
The substitution of a neutral pyridine (Figure 4.4 a) by an anionic carboxylate (Figure 4.4b) also 
results in a higher pKA value.197 This can be explained with the decrease of the Lewis acidity of the 
zinc(II) ion by coordination to a carboxylate, which results in a lower ability to polarize/ionize the 
coordinated water molecule. The effect of hydrogen bonding donors was investigated by Mareque-
Rivas et al. (Figure 4.4 c). N-H hydrogen bonding donors can polarize the O-H bond of the zinc(II) 
coordinated water molecule, which results in a decrease of the pKA value with an increasing 
number of coordinating amino pyridyl residues (Figure 4.4 c).184 However, the ability of hydrogen-
bonding donors to decrease the pKA value of the zinc(II) coordinated water is limited. Due to the 
effect of greater stabilization of the zinc(II) bound hydroxide by the H-bond network, the pKA value 
of zinc(II) coordinated water starts to increase again when the number of coordinating 
aminopyridyl residues exceeds 2, or 3.184 
a) b) 
c) d) 
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Peptide zinc(II) complexes that functionally and structurally mimic the active site of zinc(II) 
hydrolases are rare.189 In order to model the biologically relevant zinc(II) coordination sphere by 
histidine side chains Ichikawa et al. and Ibrahim et al. investigated the benzyl imidazole containing 
pseudo-peptides L1 and L2 (Figure 4.5). With the use of benzyl imidazoles, they achieved an increase 
in the hydrophobicity of the zinc(II) center’s microenvironment. Additionally, the benzyl residues 
were expected to help aromatic hydrolysis substrates by 𝜋-stacking, which could be confirmed by 
high hydrolysis rates of model phosphoesters in the physiological relevant pH range.198 
 
Figure 4.5: Structures of [Zn(L1)H2O]2+ (a) and [Zn(L2)H2O]2+ (b):198,199, 200 
Coordinated imidazoles are more labile then amines.159 This leads to a decreasing pKA value of the 
coordinated water when comparing [Zn(L1)H2O]2+ (Figure 4.5 a) with [Zn(L2)H2O]2+ (Figure 4.5 b). 
The more flexible tripodal ligand L2 provides an optimum geometry for a tetrahedrally coordinated 
zinc(II) ion.198 
 
Figure 4.6: Structure of [Zn2(BBPAP)H2O]+.201 
a) b) 
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Model systems containing two metal centers were in general found to cleave various substrates 
faster than the corresponding mononuclear species. Bringing two zinc(II) centers in close distance 
leads to the possibility of cooperation; either by double Lewis acid activation of the substrate or by 
Lewis acid activation of the substrate coupled with the provision of a metal bound hydroxide 
nucleophile. Additionally, in the dinuclear case the pKA value of the Zn- OH2 moiety is the main 
influencing factor for the ability of zinc(II) complexes to hydrolyze specific substrates under defined 
conditions (see also section 4.1.3).202-206 Therefore, dinucleating ligand systems based on the 
skeleton of bis(bipyridylamino) isopropane (HBBPAP) (Figure 4.6) were developed.201 This ligand 
scaffold inspired further investigations towards the use of bridging phenols or imidazolates as 
linkers between bipyridylamines.207-210, 211-218 
 
4.1.3 Zinc(II) based Phosphatases 
 
The present thesis aims to identify and characterize zinc(II) and zinc(II)/copper(II) complexes of the 
model peptides H4pat1, H4pat2 and H4pat4 and to investigate their ability to hydrolyze the model 
phosphoester BDNPP. Therefore, the impact of phosphatases shall be discussed. Due to the fact 
that the literature described dinuclear copper(II) complexes of patellamides derivatives, which 
actias hydrolase models,107,111,112 the focus of this section is on dinuclear phosphatases. 
 
Phosphoesters are ubiquitous and have various key functions in biological chemistry for all forms 
of life.189 They are found in the linkage of nucleotides in deoxyribonucleic acid (DNA) and 
ribonucleic acid (RNA), phospholipids in cell membranes, secondary messengers and they are part 
of several organic cofactors (the most important being adenosine triphosphate (ATP), the universal 
biological energy carrier). Phosphoesters are highly stable as illustrated, for example, by DNA, 
which has a half-life of 30 million years.219 Thus one could imagine that nature has evolved various 
phosphoester cleaving strategies. The necessity to understand the chemistry of phosphatases has 
thus various reasons including understanding diseases, understanding ecosystems and 
development of artificial phosphatases for agricultural and pharmaceutical uses. 
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Alkaline phosphatases (AP) are also omnipresent and encompass a whole class of enzymes with 
various metabolic roles. The class of phosphomonoesterases described in the literature is quite 
substrate unspecific and has its highest catalysis rates at pH > 7.5. AP has a homodinuclear zinc(II) 
center in its active site.220 The active center of E. coli AP is schematically displayed in figure 4.7a.221 
In addition to the two different coordinated zinc(II) ions a magnesium(II) ion is bridged to one of 
the zinc(II) ions by an aspartate. The metal-metal distances within the trinuclear active site are 3.94 
Å, 4.88 Å, and 7.09 Å.220 The role of the magnesium ion is not completely understood. 
 
Figure 4.7: Schematic representation of the active sides of AP a) and PAP b) in their resting 
state.163,203,220,221 
Purple acid phosphatases (PAP) are also a ubiquitous class of enzymes with a dinuclear metal 
center. However, in contrast to AP, PAP has an acidic to neutral pH optimum and always contains 
iron(III) in its active site (Figure 4.7 b). The enzyme’s purple color derives from a CT band from 
tyrosine-Fe(III).183,222-225 PAP is involved in osteoporosis and therefore is a very interesting target 
for pharmaceutical industry.162,163,226,227 While iron(III) is always present in PAP the second divalent 
metal ion depends on the kind of organism204,228 While in mammalian PAP iron(II) is the second 
metal ion, in plant PAP zinc(II) or manganese(II) were found.185,229-232, Despite these differences the 
active site is structurally the same in all types of PAP (Figure 4.7b).185,233 
 
a) b) 
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Figure 4.8: Schematic representation of possible phosphoester activation routes/mehanisms by 
dinuclear zinc(II) complexes.159,203-206 
For dinuclear zinc(II) complexes there are three possible hydrolyzing scenarios of a phosphoester: 
first a bridging hydoxide could hydrolyze the substrate, secondly a terminal hydroxide bound at 
the second zinc(II) center could hydrolyze the substrate, and the third option occurs by hydrolysis 
of a coordinated substrate through a non-coordinated hydroxide activated by a coordinated 
hydroxide (Figure 4.8). The pKA values of the hydrolysis is dependent on the scenario.159,203-206 
Since the naturally occurring patellamides were isolated from ascidian cytoplasm, it is likely that 
their supposed transition metal complexes existing in a hydrophilic environment are acting as 
hydrolases. Indeed, the dinuclear copper(II) complexes of H4pat1 and H4pat2 have been shown to 
act as phosphatase models as well as carbonaic anhydrase . However, in nature the most common 
hydrolyzing transition metal in metallo-hydrolase centers is zinc(II). While keeping in mind that 
zinc(II) is also highly concentrated in the ascidians (see chapter 1.4)88 one aim of this thesis was to 
determine if dinuclear zinc(II) complexes of patellamide derivatives could act as artificial 
phosphatases. Furthermore, the question of whether this hydrolyzing scenario may play a 
biological role arises. Answering this question might help to identify the biological role of the 
patellamides.  
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4.2 Zinc(II) Coordination by Patellamide Derivatives 
 
4.2.1 Isothermal Calorimetric Titrations 
 
The thermodynamic stability of zinc(II) complexes of the ligands H4pat1 and H4pat2 was determined 
by isothermal calorimetric titrations (ITC) with zinc(II) triflate towards the ligands (Figure 4.9). ITC 
is a commonly used method that delivers thermodynamic data like enthalpy ΔH, entropy ΔS, 
reaction stoichiometry N and stability constant K.234,235 During the experiment one reactant 
(solvated metal) is titrated into a sample solution containing the other reactant (ligand). The 
temperature of the reaction vessel is kept constant by the calorimeter. Thus the heat which is 
released or absorbed which each titration step had to be compensated by the calorimeter, which 
measures the voltage needed and calculates the compensated energetic difference. 236,237 All 
experiments were performed with an experimental procedure according to a previous study in 
which copper(II) triflate was titrated towards the same ligands.106  
 
 
 
 
 
 
 
 
 
Figure 4.9: Isothermal titration calometry plots of a zinc(II) titration to the ligands H4pat1 (a) and  
H4pat2 (b).  
a) b) 
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Table 4.2. Zinc(II) and Copper(II) stability constants, entropies and enthalpies of complexation of the 
patellamide derivatives H4pat1 and H4pat2 (standard deviations in brackets), obtained from ITC.106 
 [H2pat1Cu2]2+ [H2pat1Zn2]2+ [H2pat2Cu2]2+ [H2pat2Zn2]2+ 
N a) 1.90 (0.09) 1.51 (0.16) 1.84 (0.08) 1.69 (0.78) 
K 1.71x106 (0.71) 1.03x105 (0.30) 4.03x104 (0.55) 3.34x104 (0.57) 
∆H [kJ/mol] 46.8 (4.6) -40.86 (0.77) 84.52 (7.7) -7.686 (3.644) 
∆S [J/(mol K)] 278.56 -41.04 371.53 60.67 
     
a)  computed ZnII/CuII : (H2patn) ratio238    
 
Interpretation of the resulting ITC data leads first to the conclusion that zinc(II) complexes with the 
naturally configured ligand H4pat1 and the 4S* configured ligand H4pat2 are less stabile than the 
formation of the corresponding copper(II) complexes. The trend between the ligands is for the 
zinc(II) coordination the same as for the copper(II) coordination; H4pat1 forms a more stable 
complex as H4pat2. Beyond that, the coordination of zinc(II) is, in contrast to the coordination of 
copper(II), directed by the enthalpy and not by the entropy. The low enthalpy while complexing 
zinc(II) displays a change in coordination sphere of the metal ion from tetrahedral to trigonal 
bipyramidal or even octahedral, which involves at least one solvent molecule more than with the 
ligand-“free” zinc(II), and thus leads to a higher degree of organization in the whole system. In 
consequence; the low stabilities of the zinc(II) complexes compared to the corresponding 
copper(II) complexes, is a result of the zinc(II) ions adaption of an uncommon coordination sphere. 
This effect was already described for the native peptides by Jaspars et al. 41,94 With both ligands, 
H4pat1 and H4pat2, the simulations of the ITC data lead only to one stability constant per ligand 
with a ligand to metal ratio of approximately 1:2, which supports a cooperative binding event. The 
cooperative effect was already described in the copper(II) chemistry of both ligands; the 
coordination of the first metal ion preorganizes the ligand for the coordination of the second metal 
ion.99  From crystal structures and NMR spectra of previous studies it is known that both ligands 
(as well as H4pat4)101 are exist in a saddle-shaped conformation. The angle between both binding 
sides in case of H4pat1 is more ideal for the coordination of two metal ions, which is displayed in 
the higher stability of [Cu2H2pat1]2+ compared to [Cu2H2pat2]2+. The naturally configured ligand 
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H4pat1 has to undergo less structural change while coordinating metal ions than H4pat2. The same 
effect explains the higher stability of [Zn2H2pat1]2+ compared to [Zn2H2pat2]2+. Interestingly, both 
ligand 1H NMR spectra show only very small changes when base is added, which indicates that the 
ligand conformation does nearly not change with increasing pH- value (Figure 4.10 b). Thus, it is 
obvious that every necessary structural change occurs while the coordination of metal ions, and 
not due to the addition of base, which can be explained with a metal assisted deprotonation. 
 
4.2.2 Nuclear Magnetic Resonance 
 
The coordination chemistry of zinc(II) with the patellamide derivatives was studied using by NMR-
spectroscopic titrations in combination with high resolution mass spectrometry. The d10 character 
of zinc(II) allows the observation of the complex formation via NMR spectroscopy.  
Titration of zinc(II) triflate to H4pat1 in the presence of base leads to the formation of a complex. A 
pure single existing species can be observed under water-free and highly basic conditions (Figure 
4.11a). High-resolution mass spectrometric experiments (see Section 4.2.3) show even at low 
zinc(II) concentrations and at low base concentrations the dinuclear zinc(II) complexes 
[Zn2(H2pat1)(OH)]+ and [Zn2(H2pat1)(OMe)]+. The species shown in Figure 4.11 a) was investigated 
by 2D-NMR (HMBC), which indicates that this species with the formula [Zn2(H2pat1)(OH)]+ (the 
most intense signal in mass spectrometry) is a C2-symmetric complex with two chemically different 
imidazoles (Figure 4.12). 1H-13C HBMC shows that upon zinc(II) coordination, the evolving signals 
in the 1H NMR are not resulting from a splitting, but they do belong to aromatic 13C resonances 
that have been developed during the coordination of zinc(II) and can thus be assigned as “new” 
imidazole signals. The existence of two chemically distinguishable imidazoles may be interpreted 
in two ways: First, both zinc(II) ions have a different coordination environment, i.e. means that one 
zinc(II) coordinates one solvent molecule more than the other. Second; if the hydroxide (or 
methoxide) is terminally coordinated to one of the zinc(II) ions both coordination sides (imidazoles) 
would have a different chemical shift in the NMR experiment. A third option is the coordination of 
both zinc(II) ions in an NamidNimidazoleNamid binding motif, but MM and DFT calculations indicate that 
this option is unlikely.117 Moreover, the direct formation of a dinuclear zinc(II) complex supports 
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the assumption of a cooperative effect while H4pat1 is coordinating zinc(II). Unfortunately, the 
existence of this species occurs only under absolutely water-free conditions, which makes it 
impossible for this species to act as a hydrolysis catalyst. 
 
Figure 4.10: 1H-NMR spectra of a) H4pat1, b) H4pat1+7.5 equivalents of NaOMe  
and c) [Zn2(H2pat1)(OH)]+ in CD3OD (10mM), ν = 600 MHz, 25°C. 
  
Figure 4.11: 13C-1H HMBC NMR spectra of a) H4pat1 and b) [Zn2(H2pat1)(OH)]+ in CD3OD (10mM) and         ν 
= 600 MHz, 25°C. 
2 3 1 
a 
b 
c 
2 3 
a 
b 
c 
a) 
b) 
ß 
α 
a) 
b) 
c) 
s 
P H O S P H A T A S E  A C T I V I T Y  O F  H O M O -  A N D  H E T E R O D I N U C L E A R  T R A N S I T I O N  M E T A L  
C O M P L E X E S  O F  P A T E L L A M I D E S   | 80 
The phenomenon, that the stability of zinc(II) complexes depends significantly on the presence or 
absence of water in solution is literature known.147 Recently, a mononuclear calixarene zinc(II) 
complex with three methyl imidazole donors was published, that coordinates zinc(II) under a 
massively increased ΔH and ΔS upon the addition of 0.1%Vol water to the in acetonitrile solvated 
complex.239 
When it comes to the 4S* configured ligand H4pat2, addition of zinc(II) (triflate or acetate) does not 
lead to the formation of spectroscopically detectable complexes. Addition of an excess of base 
leads to new signals in the 1H NMR spectrum. This can be assigned to the formation of new species. 
However, But the uncoordinated ligand is always the main component in solution and neither 
addition of an excess of zinc(II) nor of an excess of base, not even the absence of water in solution, 
leads to a single complex. This result reflects the relatively weak stability determined by ITC. H4pat2 
shows in the calculated ITC data a stability constant which is approximatively only one third of the 
stability with H4pat1. Since the thermodynamic stability of the zinc(II) complex of H4pat1 could only 
be described as moderate, the formation of stable zinc(II) complexes by H4pat2 is even more 
unlikely.  
A completely different result is obtainede by analyzing the 1H-NMR titration of zinc(II) triflate and 
sodium methanolate with the ligand H4pat4 (Figure 4.12). The 4S* configured ligand with C2 
symmetry (due to two benzyl residues at two opposite imidazoles) coordinates zinc(II) even 
without added base. Moreover, it starts to quantitatively form new species after the addition of 
small amounts of methanolate. There is no clean endpoint in this titration, neither with an excess 
of zinc(II) nor with an excess of base. Thus, there must be an equilibrium of various species. This 
coordination behavior was also observed when titrating copper(II) to the same ligand in EPR 
experiments (see Chapter 3, Section 3). Due to the fact that both, copper(II) and zinc(II) ions, show 
a similar behavior with H4pat4 and both deliver mass-spectrometrically the same stoichiometric 
composed species, it can be proposed that both metals form similar thermodynamically stable 
complexes with H4pat4. 
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Figure 4.12: 1H-NMR spectra of a) H4pat4, b) H4pat4 + 2eq ZnOTf2, c)  
H4pat4 + 2eq ZnOTf2 + 2eq OMe-, d) H4pat4 + 2eq ZnOTf2 + 4eq OMe-,  
e) H4pat4 + 2eq ZnOTf2 + 6eq OMe-, f) H4pat4 + 2eq ZnOTf2 + 8eq OMe-  
and g) H4pat4 + 2eq ZnOTf2 + 10eq OMe- in a CD3OD/CDCl3 mixture of 3:1 (10mM), ν = 600 MHz, 25°C. 
The described hydrolytcally active species (see Chapter 6) is already present at a ligand / zinc(II) / 
base ratio of 1:2:2 and its intensity grows with the addition of base. Due to the formation of solid 
zinc(II) hydroxide at a ligand / zinc(II) / base ratios larger than 1:2:4, it was not possible to 
distinguish or characterize a single species via NMR spectroscopy under these highly basic 
conditions. However, at a ligand / zinc(II) / base ratio of 1:2:4 it is possible to distinguish between 
the pure ligand and one main species (according to mass spectrometry [Zn2(H2pat4)(OH)]+, see next 
Section). Characterization of this main species was also done by 2D-NMR spectroscopy (15N-1H 
HMBC, Figure 4.13). The 15N-1H HMBC measurement of the ligand / zinc(II) / base-1:2:4-mixture 
produces a 2D-NMR spectrum of a mixture, in which it is difficult to distinguish between species 
(Figure 4.13b). The 15N-1H HMBC experiment was detected under the same conditions the pure 
ligand was measured (Figure 4.13a). A reduction of the number of scans leads to a 2D-NMR 
spectrum, that shows the pure ligand in addition to the main species (Figure 4.13c). This low 
resolution spectrum shows only the cross couplings of the outer imidazole nitrogens Nb and Nc 
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with the methyl groups 1,1` and 2 (Figure 4.13 right). Due to the fact that HR-ESI+ mass 
spectrometry of this component (Figure 4.14 and table 4.3) leads to a main species with the 
stoichiometry [Zn2H2pat4(OH)]+ it is concluded that the main species is a dinuclear zinc(II) complex, 
that has structurally two different types of imidazoles. Further, these cross couplings as well as the 
corresponding resonances in the 1H spectrum do not seem to split, which leads together with the 
fact that the ligand has also two chemically different types of imidazoles, to the conclusion that 
this complex has also C2 symmetry.  
 
 
Figure 4.13: 15N-1H HMBC NMR spectra of a) H4pat4, b) H4pat4 + 2eq ZnOTf2 and c) H4pat4 next to 
[Zn2(H2pat4)(OH)]+ (measured with a smaller number of scans) in a CD3OD/CDCL3 mixture of 3:1 (10mM), 
ν = 600 MHz, 25°C..  
a) 
b) 
c) 
α, 
α 
α` 
α` 
ß` 
ß` 
1 
1 
1´ 
1` 
ß 
2 
2 
3 
3 
a 
a 
b 
b 
c 
c 
d 
3 
1 
d 
a 
c 
α 
ß 
s s 
 
Z I N C ( I I )  C O O R D I N A T I O N  C H E M I S T R Y    
  | 83 
 
 
4.2.3 Mass Spectrometry 
 
In order to study the complex structure of the dinuclear zinc(II) complexes in solution, mass spectra 
(High-resolution electron-spray ionisation (HR-ESI+), fast atom bombardement (FAB) and matrix-
assisted laser-desorption/ ionization (HR-MALDI+) were measured. All the zinc(II) species described 
here are positively charged complex cations; negatively charged complexes were not detected. It 
was possible to identify, besides the signals belonging to the species listed in table 4.3, also a 
number of further species whose signals have a distinct pattern. In case of H4pat4, there was also 
a mononuclear zinc(II) species present. The interpreted spectra were obtained from 1mM 
methanolic solutions with varying macrocycle: zinc(II) (OTf): base (OMe-) ratios (see Table 4.3 and 
Appendix). Identified charged complexes of all three macrocycles are summarized in table 4.3. All 
mass peaks show the distinctive isotopic pattern of dinuclear zinc(II) complexes (Figure 4.14) 
except the mononuclear species of H4pat4.  
 
Figure 4.14: Recorded (top) and calculated (bottom) isotopic pattern for a) [Zn2(H2pat1)(OH)]+ b) 
[Zn2(H2pat4)(OH)(H2O)]+  c) [Zn(H3pat4)]+ in methanol and d) [Zn2(H2pat2)(CO2)(H2O)]+Na+ (odd mass). 
  
a) b) c) d) 
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Table 4.3: Detected Mass peaks in (HR-) ESI+ mass spectrometric measurements of various different 
ligand / zinc(II) / base mixtures of all three ligands. 
Ligand Complex 
detection ratio/ 
conditions  
peak found assigned to 
ligand / zinc(II) / OMe- [m/z] calc. [m/z] 
H4pat1 [Zn2(H2pat1)(OH)]+ all 1:2:OMe->>2 917,3284 917,3282 
 [Zn2(H2pat1)(OMe)]+  931,3442 931,3439 
 [Zn2(H3pat1)]+   835,4069 835,4068 
H4pat2 [Zn2(H2pat2)(OH)]+ 
all obtained with ecxess 
zinc(II) 
917,3 917,3 
 [Zn2(H2pat2)(CO2)(H2O)]+Na+ 
occurs only under OMe- 
ecxess  
985,3 985,3 
H4pat4 [Zn2(Hpat4)]+ in all samples  1051,4282 1051,3798 
 [Zn2(H2pat4)(OH)]+ 1:Zn>1:OMe->1 1083.4 1083.4 
 [Zn2(H2pat4)(OMe)]+ 1:Zn>1:OMe->1 1069.4 1069.4 
 [Zn(H3pat
4)]+ in all samples  987,4949 987,4649 
 
As expected, the detection of dinuclear zinc(II) complexes and the relative intensities of the m/z 
peaks depends strongly on the concentration of base, especially for H4pat1 and H4pat2. While 
H4pat1 exhibited NMR spectra of dinuclear zinc(II) complexes only under highly basic and dry 
conditions, the same ligand exhibits under mass spectroscopic conditions evidence for the 
formation of various dinuclear zinc(II) complexes. With an increasing concentration of base (>>4 
equivalents) the dinuclear complex [Zn2H2pat1(OH)]+ (917.3284 m/z) represented the most intense 
peak. Interestingly the 4S*configurated ligand H4pat2, which does not exhibit 1H NMR spectra 
identicative of complex formation, gave mass spectra with a few signals that are assignable to 
dinuclear zinc(II) species with a distinct pattern). Upon the addition of an excess of methanolate, 
it was possible to detect a species, which may assidned to a carbonato complex. In contrast the 
mass spectra of all zinc(II) / H4pat1 mixtures, those of H4pat2 do not show any doubly charged 
species. When it comes to H4pat4, the number of species in all experiments increases. Neither the 
existence nor the absence of some species does depend on the concentration of base. The 
mononuclear species [ZnH3pat4]+ could always be found in solution (with more or less intensity). 
As well as the dinuclear species [Zn2H3pat4]+. Therefore, all dinuclear zinc(II) species, which contain 
co-ligands (solvent and/or base) do only exist if zinc(II) and methanolate have larger concentrations 
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than the ligand, and relative intensities of their peaks increasing with zinc(II) and methanolate 
concentration. 
 
4.2.4 Complexation Equilibrium of the Patellamide Derivatives with Zinc(II) 
 
A general scheme for zinc(II) complexation equilibria (Figure 4.15) for all three peptides can be 
proposed, based on the results discussed in this chapter and supported by MM and DFT 
calculations. The calculations, which are not part of this thesis, confirmed the coordination of two 
zinc(II) ions in an NimidazoleNamideNimidazole binding motif and were performed by Annika Eisenschmidt. 
117  
Addition of zinc(II) to a solution of cyclic pseudo peptide leads to the formation of mononuclear 
and dinuclear zinc(II) complexes, which are spectroscopically detectable and could be 
characterized in the cases of H4pat1 and H4pat4. While H4pat4 forms an equilibrium with various 
complexes existing next to each other, H4pat1 forms a stable and solely existing dinuclear zinc(II) 
complex, which is assumed to be hydroxo bridged. This species exists only under dry and basic 
conditions (Figure 4.15red). Even if it was not possible to characterize any zinc(II) complexes of the 
unnatural 4S* configured ligand H4pat2 via NMR spectroscopy, mass spectrometry indicates the 
formation of carbonato and/or hydrogen carbonato dinuclear zinc(II) complexes (figure 4.15 
green). However, for all ligands investigated, there is a clear preference to form dinuclear zinc(II) 
complexes, which can be explained with the cooperative effect as it is already known from the 
copper(II) chemistry of the cyclic pseudo peptides85,99,101,106 and supported by ITC. With the ligand 
with the benzyl residues, H4pat4, it is possible to observe mononuclear zinc(II) complexes at low 
zinc(II) concentrations. While H4pat1 and H4pat2 show a zinc(II) coordination behavior which differs 
fundamentally from their copper(II) coordination behavior, H4pat4 shows a similar behavior for 
both metal ions. (see also Chapter 3.3). 
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Figure 4.15: Scheme of all complex described structures in pseudo octapeptide zinc(II) equilibrium. 
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Parts of the following chapter are to be published in a manuscript entitled: “Dinuclear Zinc(II) and 
Copper(II)/Zinc(II) complexes of artificial Patellamides as Phosphatase models”; Peter Comba, 
Annika Eisenschmidt, Lawrence R. Gahan, Graeme R. Hanson, Nina Mehrkens, Michael Westphal, 
manuscript in preparation, 2015
  
5 Heterodinuclear Complexes 
 
One major result of the studies described in Chapters 3 and 4, is that the 4 S* configured and two 
benzyl residues containing ligand H4pat4 forms stable dinuclear complexes with both copper(II) and 
zinc(II). Titration experiments with the two metal ions show the development of complexation 
equilibria. While H4pat1 and H4pat2 interact with zinc(II) only weakly or under special and 
unphysiological (hydrophobic and highly basic) conditions, H4pat4 forms with both metal ions 
structurally comparable complexes. Additionally, H4pat4 is the only ligand known from the 
patellamide-derivative-library (Chapter 1 Figure 1.17), which forms a single mononuclear species 
at low copper(II) and low base concentrations. Due to the fact, that H4pat4 shows with both metal 
ions (titrations with the corresponding salts) a similar complexation behavior, it seems likely that 
both copper(II) and zinc(II) have similar stability constants, which lead to the idea that this ligand 
may form heterodinuclear copper(II)-zinc(II) complexes. Descriptions in the literature of 
approaches to heterodinuclear copper(II)-zinc(II) complexes, in which the binding sites for both 
metal ions are chemically identical, are rare.240-242 The combination of the facts that H4pat4 forms 
a mononuclear copper(II) complex and that both metals seem to have a comparable 
thermodynamic stability could make sequential  coordination of both metal ions possible.  
A mixed strategy of EPR spectroscopy, UV/Vis-NIR spectroscopy and paramagnetic 1H NMR in 
combination with high resolution mass spectrometry was chosen in order to investigate this 
complexation. Paramagnetic NMR on one hand delivers the opportunity to have a closer look on 
the complexation equilibrium at room temperature and therefore makes it possible to compare 
the obtained results to those of the only-zinc(II) titration. EPR spectroscopy on the other hand gives 
information about changes in coordination sphere of the copper(II) ion which makes it possible to 
compare the copper(II)-zinc(II) titration to the only-copper(II) titration.  
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Additionally, same experiments were carried out with the 4S* configured ligand H4pat2. Even if 
H4pat2 does not form stable, spectroscopically detectable zinc(II) complexes (weak interaction), 
this ligand exhibits a cooperative effect in copper(II) coordination. Since H4pat2 forms less stable 
complexes with copper(II) than the naturally configured ligand H4pat1, there is the chance that due 
to the cooperative effect it may be possible with H4pat2 to obtain heterodinuclear copper(II)-zinc(II) 
complexes with an excess of zinc(II). 
The enzyme PAP (described in Chapter 4) isolated from kidney beans, has a heterodinuclear 
iron(III)/ zinc(II) center in its active side.243 The major reason for studying the formation of 
heterodinuclear copper(II)/ zinc(II) complexes is, that all in this thesis described complexes were 
tested phosphatase activity (chapter 6) and thus the formation of heterodinuclear complexes 
delivers a higher comparability to enzymes like PAP. 
 
5.1 CuII/ZnII Complexation by H4pat4 
 
5.1.1 Electron paramagnetic resonance 
 
Before commencing the formation of heterodinuclear copper(II)-zinc(II) complexes, it was 
important to investigate the exact concentration at which the formation of a homodinuclear 
copper(II) complex starts. As already mentioned in Chapter 3, at a ligand / copper(II) / base ratio 
of 1:0.5:0.5 a single mononuclear copper(II) species, [Cu(H3pat4)(OH)]+, was identified. The 
formation of dinuclear copper(II) complexes starts upon adding further 0.25 equivalents of each 
copper(II) and base. Thus the starting point chosen for the addition of zinc(II) was at a ligand / 
copper(II) / base / ratio of 1:0.5:0.5. A mixed copper(II)/ zinc(II) complex was obtained by addition 
of 0.5 equivalents of zinc(II). In figure 5.1 the EPR spectra of the mononuclear copper(II) complex 
(black, discussed in chapter 3.3) as well as of the copper(II) / zinc(II) complex (blue) are overlaied. 
Since zinc(II) is a d10 ion with nuclear spin of zero all changes in an EPR spectrum are due to 
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geometric changes and thus changes in the coordination sphere of the precoordinated copper(II) 
ion occurring by the coordination of the second metal ion into the same ligand. Indeed, the g values 
of the mononuclear copper(II) species and the heterodinuclear copper(II) / zinc(II) complexes are 
very similar, while the hyperfine splitting differs. 
 
Figure 5.1: EPR spectra of [Cu(H3pat4)(OH)] (black) and [CuZn(H3pat4)(OH]+ (blue). (X-Band, 140K, 1 mM 
in MeOH, ν = 9.446309 GHz) 
The well resolved spectrum delivers a superhyperfine coupling (Figure 5.2 b), which could be 
simulated (Table 5.1), involving two different types of nitrogen (NimidazoleNamideNimidazole). The 
superhyperfine coupling of the mononuclear copper(II) complex (Chapter 3, Table 3.2)  is smaller 
than that of the heterodinuclear copper(II)-zinc(II) species, it is enlarged with the addition of 
zinc(II). This enlargement can be explained by slight changes in distances and in angulars from the 
copper(II) ion to the ligand. The simulated spin Hamiltonian parameters gII > g and AII >> A are 
suggestive of a distorted square pyramidal coordination sphere of the copper(II) ion and in good 
agreement with the parameters obtained from previously investigated patellamide derivative 
copper(II) complexes.85,100,101 Another influencing factor for the ligandssphere, and thus, for the 
spectral differences, is the charge; [Cu(H3pat4)(OH)] has no charge, while[CuZn(H2pat4)(OH)]+ is +1 
charged.  
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Table 5.1. Simulated EPR parameter. 
 [CuIIZnII(H2pat4)(OH)]+ [CuII(H3pat4)(OH)] Superhyperfine [10-4cm-1]  
g
x
 2.046 2.048 A
x
(N
im
) 12.1 7.2 
g
y
 2.078 2.076 A
y
(N
im
) 7.0 11.6 
g
z
 2.280 2.269 A
z
(N
im
) 12.9 13.0 
A
x  [10-4cm-1] 13.4 6.3 Ax(Nam) 6.7 12.1 
A
y  [10-4cm-1] 11.5 6.8 Ay(Nam) 11.0 7.9 
A
z  [10-4cm-1] 155.0 159.0 Az(Nam) 13.2 13.1 
 
Figure 5.2: EPR spectra of [CuZn(H2pat4)(OH]+: a) first derivative and b) second derivative 
(detected:turquoise and simulated:black, X-Band, 140K, 1 mM in MeOH, ν = 9.446309 GHz). 
The coordination of copper(II) can also be followed via UV/Vis-NIR spectroscopy. In case of the 
ligand H4pat4 a complete complexation of both either solvated copper(II) as of solvated zinc(II) 
occurs with the addition of base, thus to a 1 mM methanolic solution of ligand plus one equivalent 
zinc(II) triflate, first a solution of copper(II) triflate was added stepwise (Figure 5.3 green), then 
base was added in 0.1 equivalent steps (Figure 5.3 blue). With the addition of base all solvated 
copper(II) is complexed (absorption > 800nm decreases) and the formation of two new d-d- bands 
is observable. In agreement with previous studies the absorption at approximatively 660 nm 
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belongs to a homodinuclear copper(II) species, while the absorption at 520 nm might belong to a 
new species, probably the expected copper(II)-zinc(II) species.  
 
Figure 5.3: UV/Vis titration of a) 0-0.5 eq. Cu(OTf)2 to H4pat4 1 eq. Zn(OTf)2 and b) 0-1.5 equivalents (n-
Bu)4OMe. 
To obtain further information about the complexation equilibrium, paramagnetic 1H NMR spectra 
were measured. The spectra were measured while zinc(II) triflate was titrated into a ligand / 
copper(II) solution (Figure 5.4). As expected 1H NMR spectroscopy shows a complexation 
equilibrium and the signals get broadened with the addition of zinc(II), indicating the cooperative 
coordination of copper(II) with increasing zinc(II) concentration. The expected shift or formation 
of new resonances in the low field region was first visible in spectrum d). The paramagnetic signal 
displayed in figure 5.4 f) belongs to Hα, the closest proton to the paramagnetic copper(II) ion. 
Surprisingly this grows with addition of zinc(II). This observation further indicates a cooperative 
effect. The addition of zinc(II) preorganizes the ligand for the coordination of a copper(II) ion.  
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Figure 5.4: Paramagnetic 1H NMR of H4pat4/ Cu(OTf)2/ OMe-/ Zn(OTf)2: a) pure Ligand, b) 1:0.5:0.5:0, 
c)1:0.5:1:0.5, d) 1:0.5:1.25:0.75, e) 1:0.5:2:1.5 and f) paramagnetic shifted signal of Hα in MeOD-d4 and 
CDCl3 3:1. 
High-resolution mass spectra of each solution were taken and a copper(II)/ zinc(II) species with an 
additional zinc(II) ion which gives both even and odd masses could be identified (Figure 5.5). 
The complexation equilibria that involve both metal ions, copper(II) and zinc(II), are proposed in 
Figure 5.6. From comparison with the copper(II)-only and the zinc(II)-only equilibria (see Chapters 
3 and 4) a mixture of both equilibria is evident. This indictates further, that both metals have a 
similar stability constant with H4pat4, as it was proposed at the beginning of this chapter. 
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Figure 5.5: Hr-ESI+ mass spectra of: a) [[CuZn(H2pat4)(OH)(OMe)]+Zn]+ (odd) and b) 
[CuZn(H2pat4)(OH)(OMe)]+Zn]2+ (even) 
 
a) b) 
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Figure 5.6: Proposed copper(II)/ zinc(II) complexation equilibrium of H4pat4. 
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5.2 CuII/ZnII Complexation by H4pat2 
 
For the formation ofheterodinuclear copper(II)-zinc(II) complexes with the 4 S* configured ligand 
H4pat2, which forms less stable dinuclear copper(II) complexes than the naturally configured ligand 
H4pat1 but exhibits also a high preorganization for the coordination of two metal ions, a different 
strategy had to be applied. With H4pat2 a single mononuclear species was not expected to be 
found85,100,101, and zinc(II) triflate was therefore titrated to a solution that already contained a 
mixture of mononuclear and dinuclear copper(II) complexes (Figure 5.7 blue). 
 
Figure 5.7: Overlay of selected EPR spectra at distinct ligand / CuI I/ ZnII / OMe- ratios: 1:1:0:1(blue, ν = 
9.447735 GHz) and 1:1:4:2 (black, ν = 9.446188 GHz) (X-Band, 140K, 1 mM in MeOH). 
The blue spectrum displayed in figure 5.7 shows according to previous studys a mixture of a 
dinuclear copper(II) species and a mononuclear copper(II) species.100,101 Upon addition of 4 
equivalents of zinc(II) and one more equivalent of base, the black spectrum displayed in Figure 5.7 
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was detected. The spectrum has the characteristical shape belonging to a mononuclear copper(II) 
complex, but due to the fact that it was obtained by the addition of an excess of zinc(II) to a solution 
with mono and dinuclear copper(II) complexes it can be assigned to a heterodinuclear copper(II)-
zinc(II) complex. Spin Hamiltonian parameter obtained by simulation with Xsophe differ 
significantly from the parameters obtained by simulation (table 5.2) for the mononuclear copper(II) 
complex (which was obtained by spectral substraction, parameter are purple in Table 5.2).100 
   
Figure 5.8: EPR spectra of [CuZn(H2pat2)(OH]+: a) first derivative and b) second derivative 
(detected:turquoise and simulated:black). 2:4 (ν = 9.446188 GHz, X-Band, 140K, 1 mM in MeOH). 
Table 5.2. Simulated EPR parameter. 
 [CuIIZnII(H2pat2)(OH)] [Cu(H3pat2)(OH)] Superhyperfine [10-4cm-1] 
g
x
 2.082 2.074 A
x
(N
im
) 11.8 
g
y
 2.045 2.051 A
y
(N
im
) 12.6 
g
z
 2.260 2.259 A
z
(N
im
) 10.8 
A
x  [10-4cm-1] 13.8 14.2 Ax(Nam) 11.3 
A
y  [10-4cm-1] 15.2 14.7 Ay(Nam) 7.2 
Az  [10-4cm-
1] 
168.6 150.0 Az(Nam) 15.4 
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The spectrum obtained also exhibits a well resolved superhyperfine coupling, which could be 
simulated involving two different types of nitrogen donors as already described for H4pat4. Due to 
the fact that the spectrum obtained has similar spin Hamiltonian parameters as obtained for the 
complexes of H4pat4 the constitutional formula [CuZn(H2pat2)(OH)]+ was tentatively proposed for 
this species. Comparison of the copper(II)/ zinc(II) species with the previously described 
mononuclear copper(II) species85,100,101 shows that the hyperfine splitting in Z- direction in this case 
is enlarged, while the g values are nearly the same.  
 
Figure 5.9: UV/Vis titration of a) 0-0.5 equivalents Cu(OTf)2 to H4pat2 1 equivalent Zn(OTf)2 and b) 0-1.5 
equivalents (n-Bu)4OMe. 
Performing the same UV/Vis-NIR titration experiment as in case of H4pat4, leads in case of H4pat2 
to a different result. The first steps of the stepwise addition of copper(II) to the zinc(II) containing 
ligand solution shows a d-d band at about 650 nm which might belong to a mixed species (Figure 
5.9 a). However, further addition of copper(II) leads to the formation of the known dinuclear 
copper(II) complexes.101 (Figure 5.9 b). 
A preliminary complexation equilibrium based on the EPR results could be proposed and is shown 
in figure 5.10. Addition of an excess of zinc(II) leads to the formation of a mononuclear looking EPR 
spectrum (Figure 5.10 black), which can be assigned to the formation of a heterodinuclear 
complex, because this ligand does not exhibit any point in the copper(II) complexation equilibrium 
were a single mononuclear copper(II) species exists. 
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Figure 5.10: Proposed copper(II)/ zinc(II) complexation equilibrium of H4pat2. 
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Parts of the following chapter are to be published in a manuscript entitled: “Dinuclear Zinc(II) and 
Copper(II)/Zinc(II) complexes of artificial Patellamides as Phosphatase models”; Peter Comba, 
Annika Eisenschmidt, Lawrence R. Gahan, Graeme R. Hanson, Nina Mehrkens, Michael Westphal, 
manuscript in preparation, 2015
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6 Hydrolysis of Phosphoesters 
 
Phosphoesters are omnipresent in nature, and thus, nature has evolved various strategies to cleave 
them. Many Artificial model catalysts that are capable of hydrolyzing CO2 often exhibit the ability 
to hydrolyze phosphoesters as well.112,202 For example, the dinuclear copper(II) complexes of the 
patellamide derivatives are very efficient carbonic anhydrase models107,111 and these complexes 
also act as phosphatase models112. It therefore seems likely that zinc(II) containing complexes of 
the patellamide analogues might act as even more efficient phosphatases. A well known 
phosphatase that has a dinuclear metal center and is active at neutral pH is the enzyme purple acid 
phosphatase (PAP). The active site of PAP has a dinuclear heterovalent metal center, which is in 
some cases also heterodinuclear (Chapter 4, Table 4). Enzymatic mimics for the hydrolysis of 
phosphoesters have the advantage that they have the ability to hydrolyze various substrates, which 
can be used in further applications. For example the hydrolytic degradation of organophosphate 
pesticides or nerve agents, both of which are often phosphotriesters and, due to their high stability, 
accumulated in nature.244,245 
The phosphoester hydrolyzing dinuclear copper(II) complexes of the patellamide derivatives 
function most efficiently at neutral pH and in a narrow pH range112, thus a mechanistic scenario 
similar to that of PAP is quite likely. In order to determine whether the dinuclear complexes 
described in chapters 3, 4 and 5 have the ability to hydrolyze phosphoesters catalytically, they were 
tested in a hydrolysis assay which is widely applied in PAP research.208 However, it is not the focus 
of this chapter to go deeply into the mechanistic scenario of the phosphodiester cleavage, but 
instead provide an overview about the hydrolytic abilities of homo- and heterodinuclear copper(II)-
zinc(II) complexes of patellamide derivatives.  
H Y D R O L Y S I S  O F  P H O S P H O E S T E R S  
  | 103 
 
Phosphoester cleavage was followed by monitoring the concentration of the hydrolysis product 
2,4-dinitrophenolate, which has a strong absorption at 400 nm (ɛ = 12,100 M-1cm-1) at 25°C via 
UV/Vis-NIR spectroscopy (Figure 6.1).208,209 The multicomponent buffer used for the pH 
dependence of the initial rate is described in detail in Chapter 8. The complexes tested were 
prepared in methanol for solubility reasons and for keeping the results comparable to the results 
from previous studies. The model substrate BDNPP was dissolved in acetonitrile. All measurements 
were performed in solutions with the final solvent ratio of H2O : MeCN : MeOH 50:45:5. The final 
catalyst concentration and the BDNPP concentration are described separately for each 
measurement in the respective section. To prevent inhibition by carbonate all solutions were 
carefully degassed and kept under argon. Autohydrolysis of BDNPP was determined in duplicate 
and subtracted from the observed catalyzed hydrolysis rates, these were determined in triplicate. 
 
Figure 6.1: Reaction scheme of the dinuclear metal(II)-patellamide catalyzed BDNPP hydrolysis. 
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The activity in hydrolyzing BDNPP was measured at constant BDNPP concentration at different pH 
values from pH = 4.5 to pH = 11. The data obtained were fitted with equation 6.1 to produce a pH 
profile. Equation 6.1, is based on a model for diprotic systems, with two active intermediates En 
and En-1, and gives equilibrium constants KAI and KAII for two deprotonation steps, which are 
tabulated as pKAI and pKAII. V0max, the maximum initial rate, is also defined in equation 6.1. The 
value γ indicates whether, En (the active catalyst) is more active (γ < 1) or En-1 (the protonated 
form)(γ > 1). 246 
 
𝑉0 = 𝑉0,𝑚𝑎𝑥 ∗
(1+
𝛾∗𝐾
𝐴𝐼𝐼
[𝐻+]
)
(1+
[𝐻+]
𝐾
𝐴𝐼
+
𝐾
𝐴𝐼𝐼
[𝐻+]
)
   (6.1) 
 
𝑉 =
𝑉𝑚𝑎𝑥∗[𝑆]0
𝐾𝑀+[𝑆]0
     (6.2) 
 
𝑘𝑐𝑎𝑡 =
𝑉𝑚𝑎𝑥
[𝐾]0
      (6.3) 
 
To obtain further kinetic information, substrate dependent measurements were performed at the 
pH value with the maximum rate. The data obtained were fitted according the Michaelis-Menten 
approach (equation 6 .2 and 6.3), where Vmax is the maximum rate at saturation conditions and KM 
the Michaelis-Menten constant. The catalytic efficiency kcat (equation 6.3) can be used to compare 
different catalysts. 
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6.1 Dinuclear Complexes of H4pat4 
 
The ligand H4pat4 is the only ligand of the set investigated which forms both a homodinuclear 
copper(II) and zinc(II) complexes and in addition also a heterodinuclear copper(II)-zinc(II) complex. 
The homodinuclear complexes of H4pat4 [MII2(H2pat4)OH]+ (M = Cu, Zn) were investigated in pH - 
dependent scans of the initial catalysis rate (Figure 6.2). 
 
Figure 6.2: pH profiles of the BDNPP hydrolysis with [Zn2(H3pat4)(OH)]+ (blue) and [Cu2(H3pat4)(OH)]+ 
(black); [BDNPP] 5mM and [cat.] 40µM, 25°C. 
 
The resulting pH profile Figure 6.2 is similar to those obtained in the previous study for 
[Cu2(H2pat1)OH]+ and [Cu2(H2pat2)OH]+.70,107,112 Both complexes hydrolyze BDNPP with a narrow 
pH profile. The dinuclear copper(II) complex has its maximum initial rate at pH 6.50, while the 
dinuclear zinc(II) complex has its maximum initial rate at pH 6.02, 0.5 pH units lower and has a 
broader pH activity range than the compared copper(II) complex. Both complexes function 
efficiently under neutral to slightly acidic conditions. The difference of 0.5 pH units between the 
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copper(II) and the zinc(II) complexes may be explained by the fact that macrocyclic N-donated 
coordinated zinc(II) is the better Lewis acid in comparison to corresponding copper(II) species and 
has the ability to deprotonate coordinated water at lower pH. (comparison of 
[Zn[12]aneN3(H2O)]2+: pKA = 7.3 (Figure 4.3a) and the corresponding [Cu[12]aneN3(H2O)]2+: pKA = 
8.4)159 
 
Figure 6.3: pH profiles of the BDNPP hydrolysis with [CuZn(H3pat4)(OH)]+ (green), [BDNPP] 8mM and 
[cat.] 15µM, 25°C. 
 
However, the mixed heterodinuclear copper(II)-zinc(II) complex was tested under slightly different 
conditions (Figure 6.3). The detected EPR spectrum of the mixed metal complex was detected at a 
ligand / copper(II) / zinc(II) / base ratio of 1:0.5:0.5:1 (Chapter 5). Therefore, this species is less 
concentrated by taking the same or a similar amount of stock solutions while in situ complex 
formation (compared to the homodinuclear complexes). The pH profile displayed in Figure 6.3 was 
obtained with a higher concentration of BDNPP. The pH value at which the catalyst exhibits its 
maximum rate is pH 6.41, as expected, between the pHmax values of the two homodinuclear 
complexes. Furthermore, there might be a second maximum in the pH profile at approximatively 
pH 8.5. There are various possible interpretations for this reproducible observation: (i) The active 
species could be a complex with three pKA values, which would consequently lead to a different 
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model and fitting equation (see ref.).247 (ii) The reaction solution might contain two different 
structural forms of the catalyst with different pH maxima. (iii), the active species at pH 6.5 could 
be the same as at pH 8.5 but hydrolysis of BDNPP at higher pH values might follow a different 
mechanism. An overview of the pH-dependend hydrolysis results obtain by fitting with equation 
6.1 is given in table 6.1. 
Table 6.1: Hydrolysis data of the dinuclear complexes of H4pat4 obtained by fitting with eq. 6.1. 
 
In order to investigate this, EPR spectra in methanol / buffer mixtures were detected (buffer / 
methanol = 1:3, 5mM complex). Figure 6.4 shows the EPR spectrum of a mononuclear copper(II) 
compound at pH = 6.5 b) and a different more complex spectrum at pH = 9.5 a). The spectrum 
detected at pH = 9.5 (Figure 6.4a) could not be satisfactorily simulated and might be the result of 
a mixture of various species. Comparison to literature known complexes1,101 tentatively indicates 
that there is probably a carbonato bridged species in solution. 
 pHmax 
V0,max 
[Ms-1] 
pKa(I) pKa(II) 
[Cu2(H2pat4)(OH)]+ 6.50 3.45x10-8 ±6.28x10-8 6.32 ± 0.57 6.58 ± 0.52 
[Zn2(H2pat4)(OH)]+ 6.02 1.78x10-8 ±2.24x10-9 5.32 ± 0.69 6.68 ± 0.71 
[CuZn(H2pat4)(OH)]+ 6.41 9.21x10-8 ±1.97x10-8 5.79 ± 0.12 6.59 ± 0.20 
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Figure 6.4: EPR spectra of 5 mM frozen solutions of H4pat4 + 0.5eq. of copper(II) triflate and 1.5eq. of 
zinc(II) triflate in methanol/ buffer mixtures; a) pH 6,5, ν = 9.444516 GHz and b) pH 9.5, ν = 9.445288 
GHz, (X-Band, 140 K, 5 mM in buffer / MeOH 1:3) 
 
Due to the fact that frozen buffer solutions are poor glasses, the spectra of the buffer solvent 
mixtures have poor resolution, no half field transitions and no superhyperfine coupling could be 
detected. The EPR spectrum at pH 6.5 shows a signal looking like a mononuclear copper(II) species, 
which is in table 6.2 compared to the spectrum obtained complex in pure methanol (Chapter 5, 
Figure 5.2). Spin Hamiltonian parameters obtained upon simulation are given in table 6.2. Mass 
spectrometry of the buffer solutions did not show any complexes. Thus spectral parameters are 
displayed without a proposed formula for the complexes. However, the g values and hyperfine 
splitting are in the expected range for patellamide derivative copper(II) complexes.85,100,101 
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Figure 6.5: EPR spectrum of H4pat4 + 0.5eq. of copper(II) triflate and 1.5eq. zinc(II) triflate at pH 6,5: a) 
measured and b) simulated (X-Band, 140 K, 5 mM in buffer / MeOH 1:3, ν = 9.444516 GHz). 
Table 6.2: EPR parameters obtained by simulation with Xsophe. 
 pH 6.5 [CuIIZnII(H2pat4)(OH)]+ 
gx 2.054 2.046 
gy 2.077 2.078 
gz 2.250 2.280 
Ax  [10-4cm-1] 4.7 13.4 
Ay  [10-4cm-1] 17.1 11.5 
Az  [10-4cm-1] 185.7 155.0 
 
The by simulation obtained spin Hamiltonian parameters of the spectrum obtained at pH = 6.5, are 
different form those, of the spectrum detected from a methanolic solution in chapter 5. Due to 
the different solvent environment, the copper(II) center might be coordinated by a different 
coligand, which would explain the shifted gz  and the enlarged A values (except Ay). The assumption 
that [CuZn(H2pat4)OH]+ is the active species at pH 6.5, could this way neither be confirmed nor be 
excluded. But this spectrum indicates that there is presumably no dinuclear copper(II) complex in 
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solution, which acts as hydrolysis catalyst. Thus, the fit (eq. 6.1) for a diprotic hydrolysis system 
was used, assuming [CuZn(H2pat4)OH]+ is the active species at pH 6.5. Following this assignment,  
all active species containing the ligand H4pat4 would have the same constitutional formula 
[MII2(H2pat4)OH]+. 
To compare the catalytic abilities of all dinuclear complexes of H4pat4, as efficiency and rate, a 
Michaelis Menten experiment was performed. The dependence of the initial rate on the substrate 
concentration was determined for each catalyst at its previously determined pH maximum 
([Cu2(H2pat4)OH]+ at pH = 6.51, [Zn2(H2pat4)OH]+ at pH = 6.00 and [CuZn(H2pat4)OH]+ at pH = 6.37). 
The substrate concentration was varied between 0.25 mM and 8 mM. Equation 6.2 and equation 
6.3 were used to obtain kinetic data, which are listed in table 6.3. It appears that the 
homodinuclear zinc(II) complex catalyzes the hydrolysis of BDNPP with a higher catalytic efficiency 
kcat as the corresponding homodinuclear copper(II) complex, and the highest catalytic efficiency is 
observed with the heterodinuclear copper(II)/ zinc(II) complex of H4pat4. Therefore, the same 
species has a small value of KM, which indicates that the catalyst-substrate intermediate of the 
heterodinuclear complex is less stable than thoses of the corresponding homodinuclear 
complexes. 
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Figure 6.6: Michaelis-Menten measurement fitted with equation 6.2; a) [Zn2(H3pat4)(OH)]+ (blue) and 
[Cu2(H3pat4)(OH)]+ (black). (both with [cat.] 40µM, 25°C) and b) [CuZn(H3pat4)(OH)]+ (green) ([cat.] 
15µM, 25°C). 
Table 6.3: Michaelis Menten parameter of the dinuclear complexes of H4pat4 obtained by fitting with 
eq. 6.2 and eq. 6.3. 
 
kcat 
[s-1] *10-3 
 
KM 
[mM] 
 
kcat/KM 
[M-1s-1] 
 
[Cu2(H2pat4)(OH)]+ 2.34 ± 0.07 16.56 ± 1.61 0.14 ± 0.04 
[Zn2(H2pat4)(OH)]+ 4.89 ± 0.00 16.98 ± 0.05 0.29 ± 0.02 
[CuZn(H2pat4)(OH)]+ 4.72 ± 0.04 13.93 ±0.17 0.34 ± 0.23 
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6.1 Dinuclear Complexes of H4pat1 and H4pat2 
 
With the ligands H4pat1 and H4pat2, the homodinuclear zinc(II) complexes are not expected to act 
as hydrolases due to the low complex stabilities in a wet environment (see chapter 4). They were 
tested anyway (Figure 6.7 and Appendix), but did not show any activity. The phosphatase activity 
of the proposed heterodinuclear complex (Chapter 5.2) was also examined. Figure 6.8 shows the 
pH profile obtained (blue trace). As there are reproducible two maxima, the pH profile is overlaid 
with the pH profile of [Cu2(H2pat2)(OH)]+ (black trace). A comparison of the spectra leads to the 
conclusion that there are two species present in solution, capable of hydrolyzing BDNPP; 
presumably [Cu2(H2pat2)(OH)]+ and [CuZn(H2pat2)(OH)]+. 
 
Figure 6.7: pH-profiles of the BDNPP hydrolysis with “[Zn2(H2pat2)(OH)]+”. 
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Figure 6.8: Overlaid pH profiles of the BDNPP hydrolysis with [Cu2(H2pat2)(OH)]+ (black, [BDNPP] 
6.25mM and [cat.] 40µM, 25°C.)70,107 and [CuZn(H2pat2)(OH]+ (blue,. [BDNPP] 5.25 mM and [cat.] 
30µM, 25°C). 
To obtain the desired hydrolysis data of the pH dependent hydrolysis by the proposed 
heterodinuclear complex [CuZn(H2pat2)(OH)]+ by fitting with equation 6.1 the detected initial rates 
from pH = 6.0 to pH = 6.5 had to be ignored, to avoid a obviously falsified result. The obtained data 
as well as those for [Cu2(H2pat2)(OH)]+ are displayed in table 6.4. Both complexes have narrow pH 
profiles and both do hydrolyse BDNPP with the maximum rate at pH values close to neutral. 
Interrestingly, the heterodinuclear complex of H4pat2 has a higher pHMax as the corresponding 
homodinuclear complex, which will be discussed in the next section. 
Table 6.4: Hydrolysis data of the dinuclear complexes of H4pat4 obtained by fitting with eq. 6.1. 
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pH
 pHmax 
V0,max 
[Ms-1] 
pKa(I) pKa(II) 
[Cu2(H2pat2)(OH)]+ 6.69 1.57x10-8 ±1.24x10-9 6.37 ± 0.40 7.25 ± 0.65 
[CuZn(H2pat2)(OH)]+ 7.31 2.89x10-8 ±1.55x10-8 7.58 ± 0.52 6.76 ± 0.14 
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6.3 Mechanistic Discussion 
 
To summarize, all obtained pH profiles show a bell-shaped maximum close to neutral pH. This leads 
together with the facts that the obtained pKA values are in all cases approximatively separated by 
one unit (narrow profile) to the proposal of a mechanism similar to that of PAP.112,218 The obtained 
pKA values were assigned to belong to two deprotonation steps that are possible when considering 
a dinuclear aqua species as catalyst (Figure 6.9). In water solvated copper(II) ions are stronger lewis 
acids as zinc(II) ions. ([Cu(H2O)6]2+: pKA = 8.0 and [Zn(H2O)6]2+: pKA = 9.0).248 But, upon coordination 
to macrocyclic N-donating ligands this effect turns back, and Zinc(II) becomes compared to 
copper(II) the better lewis acid ([Zn[12]aneN4(H2O)]2+: pKA = 7.9 (Figure 4.3b) and the 
corresponding [Cu[12]aneN4(H2O)]2+: pKA > 10).159 In PAP mechanism the substrate coordinates to 
one metal center and is attacked by the generated hydroxide from the other metal center.112,218 If 
this or a similar scenario, is the hydrolysis pathway (see Figure 4.8) used by the dinuclear 
patellamide derivative complexes, it is expected that the pKA values of water coordinated to a 
zinc(II) ion is lower in comparison to a water molecule coordinated by a copper(II) ion. 
The two pKA values of [Zn2(H2pat4)OH]+ obtained by fitting the data to equation 6.1 are pKAI = 5.32 
and pKAII = 6.68. Thus, pKAI of the dinuclear zinc(II) species is lower as that of the respective 
dinuclear copper(II) species (pKAI = 6.32), in contrast to the pKAII of the dinuclear zinc(II) species 
which higher compared to that of the respective copper(II) complex (pKAII = 6.58). This leads to a 
broadened pH-profile of hydrolysis catalyzed by the dinuclear zinc(II) complex (Figure 6.2). The 
broader pH profile can be explained by the zinc(II) ions slower exchange rates compared to 
copper(II) (Zn2+; ~ 6x108 and Cu2+; 4.4*109 s-1 (water exchange in water at 25°C)),249 and thus the 
active aqua species might be available over a broader pH range. 
The corresponding heterodinuclear complex [CuZn(H2pat4)OH]+ has a pH maximum between the 
pH maxima of both homodinuclear complexes. The by fitting with equation 6.1 obtained pKAII value 
pKAII = 6.59 is close to that of the homodinuclear copper(II) species, and might thus be assigned to 
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the deprotonation of a copper(II) coordinated water molecule. In consequence pKAI = 5.79 can be 
assigned to the deprotonation of an aqua coligand coordinated by the zinc(II) ion, which is in 
agrrement with the zinc(II) ions higher lewis acidity in macrocyclic azacrown ligands.159 
The proposed heterodinuclear copper(II)-zinc(II) complex of the 4S* configured ligand H4pat2 
(Chapter 5) is also shown to act as phosphatase. Interestingly, this complex seems to exist in 
solution along with the corresponding homodinuclear copper(II) complex. Surprisingly, in this case 
the pH maximum of the heterodinuclear species lies slightly higher than that of the respective 
homodinuclear copper(II) complex.  
  
Figure 6.9: Schematic representation of the pKA values in relation to the considered active species (blue). 
While comparing the results listed in table 6.2 it appears that the zinc(II) containing complexes of 
the benzyl residue containing ligand H4pat4 show the highest catalytic efficiency. In addition the 
heterodinuclear zinc containing complexes of the ligand H4pat4 exhibits a the smallest Michaelis-
Menten constant, meaning that this complex has the highest affinity towards the substrate BDNPP. 
The most efficient catalyst remains the homodinuclear zinc(II) complex of H4pat4. The question 
arises then: why is the unnatural 4S* configurated ligand H4pat4 the fastest? Eventually due to the 
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benzyl residues which may help the substrate to coordinate by π-stacking. Another reason may be 
that a more hydrophobic microenvironment surrounds the dinuclear metal center due to the large 
benzyl residues and thus stabilizes the zinc(II) complexes of H4pat4. In the case of the tripodal 
benzyl histidine ligands investigated by Ichikawa and Ibrahim,198 the effect of the benzyl groups is 
just described as that of a bulky substituent.198 
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Table 6.5. Kinetic Properties of [M2(H2paty)(OH]+ in BDNPP-hydrolysis. 
 
Catalyst pHmax 
V0,max 
pKa(I) pKa(II) 
kcat KM kcat/KM 
ref 
[Ms-1] [s-1] *10-3 [mM] [M-1s-1]  
[Cu2(H2pat1)(OH)]+ 7.21 1.58x10-7 ±3.00x10-9 6.91 ± 0.21 7.31 ± 0.20 3.95 ± 0.07 26.4 ± 2.20 0.15 ± 0.03 
70,107,112 
 
[Cu2(H2pat2)(OH)]+ 6.69 1.57x10-8 ±1.24x10-9 6.37 ± 0.40 7.25 ± 0.65 0.39 ± 0.03 5.5 ± 0.64 0.07 ± 0.05 
70,107 
 
[CuZn(H2pat2)(OH)]+ 7.31 2.89x10-8 ±1.55x10-8 7.58 ± 0.52 6.76 ± 0.14 0.34 ± 0.30 5.74 ± 1.74 0.06 ± 0.17  
[Cu2(H2pat4)(OH)]+ 6.50 3.45x10-8 ±6.28x10-8 6.32 ± 0.57 6.58 ± 0.52 2.34 ± 0.07 16.56 ± 1.61 0.14 ± 0.04  
[Zn2(H2pat4)(OH)]+ 6.02 1.78x10-8 ±2.24x10-9 5.32 ± 0.69 6.68 ± 0.71 4.89 ± 0.00 16.98 ± 0.05 0.29 ± 0.02  
[CuZn(H2pat4)(OH)]+ 6.41 9.21x10-8 ±1.97x10-8 5.79 ± 0.12 6.59 ± 0.20 4.72 ± 0.04 13.93 ±0.17 0.34 ± 0.23  
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7 Summary and Outlook 
 
The biological function of the naturally occurring cyclic peptides patellamide A-F and 
ascidiacyclamide, found in the ascidians of the Pacific and Indian oceans, is still unclear. Since 
the discovery of a carbonato-bridged dinuclear copper(II) complex of ascidiacyclamide,1 there 
has been a discussion about metal ions playing a key role in the chemistry these peptides.18 
Due to the the high concentration of copper(II) found in ascidians,88  the copper(II) coordination 
chemistry of the patellamides has been extensively investigated.70 A library of easily accessible 
patellamide derivatives has been designed to study their copper(II) chemistry.85 Recently, 
dinuclear copper(II) complexes of these artificial cyclic pseudo-peptides have been shown to 
act as extremely efficient hydrolases at neutral pH. The complex [Cu2(H2pat1)(OH]+ has, on one 
hand, been shown to hydrolyze very efficiently CO2111 and, on the other hand, this complex is 
also able to hydrolyze the model phosphodiester BDNPP.112 
The aim of this thesis was to explore the zinc(II) coordination chemistry of these cyclic pseudo-
octapeptides regarding biologically relevant hydrolysis chemistry. A further question was; 
whether the patellamide derivatives, known to preferably form dinuclear complexes, have the 
ability to form heterodinuclear copper(II) and zinc(II) complexes? Finally, this thesis aimed to 
test all explored complexes in a phosphoester hydrolysis assays. Besides this, the 
electrochemical properties of the patellamide derivative copper(II) complexes were 
investigated.  
The electrochemical results displays the equilibrium chemistry of the Patellamide derivative 
copper(II) complexes, and lead thus to the conclusion, that copper(I/II) based biological 
relevant redox chemistry is rather unlikely in neutral aqueous solution. Nevertheless, the 
complex [Cu2(H2pat1)(OH)]+ has been shown to take part in an oxygenation reaction under basic 
conditions. Kinetic properties were shortly discussed and oxygenation products have been 
identified via NMR spectroscopy and mass spectrometry.  
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The complexation equilibrium of the ligand H4pat4 was investigated by EPR spectroscopy in 
combination with high-resolution mass spectrometry. So far, H4pat4 is the only ligand of the of 
the patellamide derivative library that forms under specific conditions a pure mononuclear 
copper(II) complex. EPR simulations, cooperativity and the resulting copper(II) complexation 
equilibria have been discussed in Chapter 3. 
The zinc(II) chemistry of the patellamide derivatives is discussed in Chapter 4. Isothermal 
calorimetric titration (ITC) experiments show, that a homodinuclear zinc(II) complex of the 
naturally configured ligand H4pat1 has a higher thermodynamic stability than a homodinuclear 
zinc(II) complex of the 4S* configured ligand H4pat2. ITC experiments show that H4pat1 and 
H4pat2 prefer to coordinate two metal ions at once and exhibit a cooperative effect. In addition, 
the ITC experiment shows that zinc(II) coordination is rather enthalpy driven, in contrast to the 
corresponding copper(II) coordination. This is interpreted as a result of a change from a 
tetrahedral to a trigonal bipyramidal or octahedral coordination sphere, upon zinc(II) 
coordination by a patellamide derivative. This is believed to be one of the reasons for the lower 
stability of the zinc(II) complexes in comparison to the corresponding copper(II) complexes. 
The complexation behavior of zinc(II) by H4pat1 and H4pat4 was investigated by NMR 
spectroscopy, especially with the help of 2D methods i.e.  13C-1H HMBC and 15N-1H HMBC. The 
results, are interpreted in combination with HR mass spectrometry and lead to the proposal of 
a complexation equilibrium. 
Regarding the results of both, of copper(II) and of zinc(II) coordination by the ligand H4pat4, 
results of Chapters 3 and 4 indicate that H4pat4 forms similarly stable complexes with either 
metal ion. Under comparable conditions H4pat4 forms various species in equilibria with both 
metal ions. Thus, the formation of a heterodinuclear species was investigated in Chapter 5. 
Specifically, the 4S* configured ligand H4pat2 was examined in the formation of a 
heterodinuclear copper(II)-zinc(II) complex. Even if for both ligands, H4pat2 and H4pat4, 
heterodinuclear complexes were found, different strategies have been applied. Both ligands 
heterodinuclear complexes deliver EPR spectra that have been simulated and analyzed in 
combination with UV/Vis spectroscopy and mass spectrometry. 
In Chapter 6, all complexes were tested in a phosphoester hydrolysis assay. The kinetics were 
measured as function of pH and of as function of the substrate concentration. Results were 
analyzed considering a model for dinuclear hydrolyzing enzymes and considering Michaelis 
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Menten kinetics. All three dinuclear complexes of H4pat4 (Cu2II, Zn2II, CuIIZnII) were shown to act 
as phosphatases. The in chapter 5 proposed heterodinuclear copper(II)-zinc(II) complex of 
H4Pat2 has been shown to act as phosphatase as well. The pH profiles and Michaelis Menten 
plots are discussed with respect to their biological relevance. It could be shown, that all zinc(II) 
containing complexes are slightly more active than the corresponding copper(II) complexes. 
Having the biological relevance of these results in mind, a first conclusion is that, if possibly 
existing dinuclear copper(II) complexes of patellamides fulfill a metabolic function in the 
ascidian cytoplasm, it is likely that this is a hydrolytic reaction rather than any role involving a 
copper(I) state. The results of the zinc(II) chemistry, especially that of H4pat2 and H4pat1, lead 
to the conclusion that, if a metal ion has biological relevance for the patellamides, it is more 
likely that copper(II) is the relevant metal ion. However, regarding the zinc(II) chemistry of 
H4pat4 , these results deliver an interesting insight into the solution chemistry of the 
patellamide derivatives complexes from a diamagnetic point of view. The zinc(II) complexes of 
H4pat4 are efficient phosphoester hydrolysis catalysts, working in a neutral pH range. And in 
addition the zinc(II) chemistry showed, that the cooperativity i.e. the preferential formation of 
dinuclear complexes seems to be more important than metal selectivity.  
The exact mechanistic description of phosphoester hydrolysis, catalyzed by dinuclear 
complexes of the patellamide derivatives is in the focus of computational studies.117 The 
hydrolysis ability towards further substrates as ß-lactams and glycosides are aims of ongoing 
investigations as well.117 
The most challenging question is, whether copper(II)-patellamide derivative hydrolysis 
chemistry in vivo is possible. Therefore, a suitable imaging strategy is required, which is in the 
focus of an ongoing study.117 
The biological role of the patellamides and ascidiacyclamide remains thus a mystery, but this 
open question can be regarded from various perspectives and creates great scientific ideas. 
This way, I hope that this question remains still unsolved for a while. 
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8 Experimental Section 
 
8.1 Materials, Methods and Instruments 
 
8.1.1 Materials 
 
All solvents and reagents (absolute, p.a. grade and purum grade) were purchased and used 
without further purification. Dry solvents were kept over molecular sieves. MilliQ water (R > 
18MΩ) was used for the kinetic assays. Phosphoryl chloride was distilled and 2,4-dinitrophenol 
was three times recrystallized from ethanol before use. The cyclic peptides H4pat3 and H4LAscA 
were obtained from Dr. Michael Westphal. The peptide H3L1 was provided by Dr. Nina Dovalil. 
Both were used without further purification. 
 
8.1.2 Chromatography 
 
Thin layer chromatography (TLC) on silica gel 60 F254 plates (POLYGRAM® SIL G/UV, Macherey-
Nagel) was conducted in order to monitor reactions. Detection was accomplished with a UV-
lamp (λ=254 nm). Flash chromatography was performed using silica gel 60 (230-400 mesh) 
purchased from Macherey-Nagel. 
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8.1.3 Microanalyses 
 
Quantitative microanalysis was performed at the microanalytical laboratory of the University 
of Heidelberg with a Vario EL and a Vario MICRO cube instrument (Elementar). 
 
8.1.4 Mass Spectrometry 
 
Electrospray ionization mass spectra (ESI) were measured on a Finnigan LCQ spectrometer at 
the institute of Organic Chemistry of the University of Heidelberg. High-resolution electrospray 
ionization mass spectra (ESI-HR MS) were measured on a Bruker Apex-Qe hybrid 9.4 T FT-ICR 
instrument with an Apollo II MTP ion source in the positive-ion and negative-ion mode, 
respectively, at the Institute of Organic Chemistry of the University of Heidelberg. External mass 
calibration was performed on [argininen+H]+ cluster ions prior to analysis. A mass accuracy of 
1ppm was achieved. The instrument was controlled by the Bruker ApexControl 2.0.0 beta 
software. At the School of Chemistry and Molecular Biosciences of the University of 
Queensland, high-resolution mass spectra were measured on a Bruker microTOF ESI-MS 
spectrometer. High-resolution fast atom bombardement (FAB) mass spectrometric 
measurements were performed on a Finnigan TSQ 700 instrument at the institute of Organic 
Chemistry of the University of Heidelberg. The matrix used was nitrobenzylalcohol. High-
resolution direct-analysis-in-real-time (HR-DART) mass spectra were measured on a Bruker 
Apex-Qe hybrid 9.4 T FT-ICR instrument in the positive-ion mode, at the Institute of Organic 
Chemistry at the University of Heidelberg. 
Data analysis was performed with the Bruker Compass Data Analysis 3.4 software. 
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8.1.5 NMR Spectroscopy 
 
1H, 13C, 15N and 31P nuclear magnetic resonance (NMR) measurements as well as; two 
dimensional correlation spectroscopy (COSY), heterodinuclear single quantum correlation 
(HSQC), heterodinuclear multiple bound correlation (HMBC) and nuclear Overhauser-effect 
spectroscopy NOESY) were performed with a Bruker 200 MHz DRX, a Bruker 400 MHz Advance-
II, a Bruker 600 MHz Advance-II or a Bruker 900 MHz Advance-III spectrometer, respectively. 
Chemical shifts (δ) in ppm are calculated relative to TMS. For 1H and 13C NMR spectra the 
deuterated solvent peaks are indicated in brackets in the analytical data. For 31P NMR spectra 
85% H3PO4 (0 ppm) was used as reference for the chemical shifts δ. All reported coupling 
constants are 1H-1H couplings. Signal multiplicities are described by the following abbreviations: 
s = singlet, d = doublet, t = triplet, q = quartet, quin = quintet, dd = doublet of doublets, dt = 
doublet of triplets, tt = triplet of triplets, o = octet, m = multiplet and b = broad. In peptides the 
H-atom next to the N-amide is assigned with Hα and the second H-atom is assigned with Hß.The 
Bruker software package TopSpinTM was used to analyze the recorded data. All measurements 
were performed at 25°C, unless a different temperature is designated at the respective points, 
and the solutions for complex titrations were kept under Argon, unless carbonato-complexes 
were desired. 
 
8.1.6 EPR Spectroscopy 
 
X-Band continuous wave (CW) EPR spectra were recorded with a Bruker Biospin Elexsys E500 
at the University of Heidelberg or with an Elexis E580 spectrometer at the University of 
Queensland, fitted with either a super high Q cavity or an ER 4118X resonator. The microwave 
frequency and the magnetic field were calibrated with a Bruker ER 036TM Teslameter and a 
Bruker microwave frequency counter, respectively. Temperatures of 110 - 140 K at the sample 
position were achieved by a flow-through cryostat in conjunction with a Eurotherm B-VT-2000 
variable temperature controller. The Bruker Xepr software (version 2.4b.12) was used for 
Spectrometer tuning, signal averaging and visualization. Simulations of the mononuclear 
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copper(II) complexes and of the copper(II)-zinc(II) complexes were carried out with the Xsophe 
software from Bruker.145 The simulation of the dinuclear copper(II) complex spectrum was 
obtained using the Bruker software Molecular Sophe.146. All measurements were performed at 
140 K, unless a different temperature is designated at the respective points, and the solutions 
kept under Argon unless carbonato-complexes were desired. 
 
8.1.7 Spectrophotometric Titrations 
 
Spectrophotometric titrations were carried out with 1 mM cyclic peptide solutions in MeOH. 
Metal and base solutions (CuII(CF3SO3)2, CuII(CH3COO)2, ZnII(CF3SO3)2, ZnII(OMe)2, 
(nBu)4N(OMe), NaOMe)) in methanol (25 mM or 10 mM) were added in 0.1 equivalent steps 
and NIR-UV/vis-NIR and CD spectra were recorded. The spectra obtained were corrected with 
respect to the dilution factor. All measurements were performed at 25°C and the solutions kept 
under Argon unless carbonato-complexes were desired. 
 
8.1.8 NIR-UV/Vis-NIR and CD-Spectroscopy  
 
A Jasco V-570 spectrophotometer equipped with a JASCO ETC-505T cryostat, a TIDAS II 
spectrophotometer or a Varian Cary 50 Bio UV/Vis-NIR spectrometer with a peltier 
temperature controller were used to record UV/Vis-NIR spectra in the range of 200-900 nm, as 
well as time-course measurements at fixed wavelengths. All measurements were performed at 
25°C and the solutions kept under Argon unless carbonato-complexes were desired. 
 
8.1.9 CD-Spectroscopy  
 
Circular Dichroism (CD) spectra were measured with a JASCO J-170 spectropolarimeter 
equipped with a JASCO ETC-505T cryostat. A Jasco CD spectrometer with a peltier temperature 
controller were used to record CD spectra in the range of 200-900 nm. All measurements were 
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performed at 25°C and the solutions kept under Argon unless carbonato-complexes were 
desired. 
 
8.1.10 IR Spectroscopy 
 
A Perkin Elmer 16C FTIR spectrometer was used to record infrared (IR) spectra of solid samples 
in KBr pellets as well as of liquid samples in an irtran4 (CaF2) cuvette. Liquid samples were 
prepared from methanolic or deutero methanolic stock solutions. IR spectroscopic titrations 
were performed by stepwise addition of 0.5 equivalents of metal ion or base solution. IR spectra 
in solution were recorded between 450 and 4000 cm–1 at 25°C, and the solutions kept under 
Argon unless carbonato-complexes were desired. 
 
8.1.11 Electrochemistry 
 
Electrochemical properties were studied by cyclic voltammetry (CV) and square wave 
voltammetry (SQW) in methanol using (nBu)4N(PF6) as supporting electrolyte. All 
measurements were performed with a CH Instruments CHI660D electrochemical workstation, 
equipped with a CH Instruments Picoamp booster and Faraday cage, with a three-electrode 
setup consisting of a glassy-carbon working electrode, a Pt wire as auxiliary electrode and a 
Ag/AgNO3 reference electrode (0.01 M Ag+, 0.1 M (Bu4N)(BF4) in methanol). The solutions were 
thoroughly degassed and measured with a slight argon-flow was above the solution during the 
measurement. A scan rate of 100 mVs-1 was applied. 
The Copper(II) complex solutions were prepared in situ according to the spectrophotometric 
titrarions as follows: First a 25 mM CuII(CF3SO3)2 methanolic solution was added in 0.1 
equivalent steps to 0.1 mM ligand solution into the electrochemical cell (7ml). Afterwards, a 10 
mM (nBu)4N(OMe) methanolic solution was added in 0.1 equivalent steps to the 
electrochemical cell. In a final step a slight stream of CO2 was set above the solution for 10 
minutes, to generate carbonato complexes. After each step a CV and a SQW scan were 
recorded. 
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8.1.12 Isothermal Titration Calometry (ITC) 
 
ITC measurements were performed with a MicroCal ITC 200 instrument at the School of 
Chemistry and Molecular Biosciences of the University of Queensland. All experiments were 
done in methanolic solutions containing 0.1 M (nBu)4N(ClO4) for control of the ionic strength 
during each measurement. Initially, the reaction vessel contained 200 µL of a 1mM ligand 
solution in methanol. A 20 mM Zinc(II) triflate solution in methanol was added either in 38 steps 
of 1 µL or in 76 steps of 0.5 µL by an injection syringe to the ligand solution. The spectra 
obtained were analyzed by the program Origin 7® with the plugin Microcal LLC – VPViewer 2000 
ITC®. 
 
8.1.13 pH Measurements 
 
A Metrohm 713 pH-meter equipped with a KCl electrode was used to adjust pH values at 25°C. 
The pH meter was calibrated with pH standard solutions at pH 4, pH 7 and pH 9. Reported pH 
values of buffer/ solvent mixtures refer to the aqueous component. The pH value of a 1:1 
mixture of buffer and acetonitrile was the same as the corresponding buffer solution itself. 
250,251 
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8.1.14 Preparation of Buffers 
 
A multicomponent buffer was used to measure the pH-dependent and Michaelis-Menten 
kinetics. The aqueous buffers consisted of :  
 CAPS, N-cyclohexyl-3-aminopropanesulfonic acid, pKA = 10.40 
 CHES, 2-(N-cyclohexylamino)ethanesulfonic acid, pKA = 9.30 
 HEPES, 4-(2-hydroxyethyl)-1-piperazinylethanesulfonic acid, pKA = 7.55 
 MES, 2-(N-morpholino)ethanesulfonic acid, pKA = 6.15 
Each component was dissolved in Milli-Q water. The final concentration of each buffer was 50 
mM. The ionic strength was adjusted with LiClO4 (250mM) to µ = 0.45. Afterwards the 
multicomponent buffer solution was separated in 40 ml aliquots and their pH values were 
adjusted with 2 M NaOH. Metal ions were removed by stirring the adjusted buffers with Chelex 
100 overnight, and filtration through 45 µm syringe filters.  
 
8.1.15 Phosphoester Hydrolysis Assay 
 
The phosphatase-like activity was determined by measuring the hydrolysis of the model 
substrate bis(2,4-dinitrophenyl)phosphate (BDNPP). Phosphoester cleavage of BDNPP 
produces 2,4-dinitrophenolate, which can be detected by monitoring the increase of a strong 
absorbance at 400 nm (ε = 12100M-1cm-1) via UV/Vis spectroscopy at 25°C (settings see section 
8.1.8). Initial rates were obtained by the initial rate method, which leads to an assay-design 
where the initial linear portion of data can be reproducibly used for analysis. The reported rates 
are averages with standard deviations from triplicates. Each assay was corrected for 
autohydrolysis, which was also determined in triplicates. The substrate BDNPP was dissolved in 
acetonitrile. The catalysts [MII(H2patn)(OH)]+ ( MII = CuII, ZnII) were prepared in situ from stock 
solutions (ligand 1mM, MIIOTf2 25mM, (nBu)4N(OMe) 25mM) in methanol (for solubility 
reasons). The aqueous multi component buffer described in section 8.1.14 was used for pH-
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dependent kinetics. All assays were carried out in a mixture as follows: H2O/MeCN/MeOH = 
50:45.5; [MII(H2patn)(OH)]+ = 40µM, [buffer] = 25mM. To prevent the formation of CO32- (and 
consequently the formation of inhibiting carbonato-species), it was necessary to use freshly 
degassed solutions. The pH-dependence of the hydrolysis rate was measured in the range of 
pH 4.5 - 11.5. While measuring the substrate concentration dependence at a distinct pH the 
BDNPP concentration was varied between 0.25 - 10 mM. The resulting data were plotted with 
the program Origin (OriginLab) and fitted to Equation 7.1 (chapter 7.2).246 Reported pH values 
refer to the aqueous component. The pH value of a 1:1 mixture of buffer and acetonitrile was 
the same as the corresponding buffer solution itself.250,251 
 
8.1.16 Oxygenation Assay 
 
The oxygenation properties of [Cu2(H2pat1)OH]+ were studied according to a literature known 
procedure, which was performed as follows: 236.7 mg (1.149 mmol) of 3,5-ditertbutylphenol 
(DTBPH) were dissolved in 10 mL dry and degassed methanol. After the addition of one 
equivalent of base ((nBu)4NOMe, 1.92 mL of a 20% methanolic solution) under argon, 600 µL 
of the catalyst solution (1 mM in methanol under Ar) were added. Subsequently, a first UV/Vis 
spectrum was recorded. A slight flow of pressed air was conducted through the reaction 
solution while stirring, UV/Vis spectra were recorded as a function of time. The formation of 
the oxygenation product 3,5-ditertbutylquinone DTBQ was monitored at the increasing 
absorption at 407 nm (1830L mol-1 cm-1). After each spectrum taken, the measured solution 
was returned to the reaction mixture. Before each measurement the volume of the reaction 
mixture was corrected to the initial volume with dry and degassed methanol, to keep initial 
concentrations constant.   
E X P E R I M E N T A L  S E C T I O N  
  | 133 
 
8.2 General Procedures 
 
Cyclic Peptides and their precursors were prepared according to known literature procedures 
with slight modifications. All moisture or air sensitive reactions were performed applying 
Schlenk-techniques. 
 
8.2.1 General Procedure for Methyl Ester Cleavage (GP1):113 
 
The methyl-protected amino acid (1eq) or methyl–protected peptide was dissolved in a 
MeOH/dioxane mixture = 10:7 (resulting in a 0.1 M solution) and cooled to 0°C. Then, a 2M 
NaOH solution (10 eq) was slowly added. The reaction mixture was allowed to warm up to rt. 
While stirring for at least one day, the reaction progress was monitored by TLC. After the 
consumption of all starting material, brine and 1 M HCl solution were added until a neutral pH 
value was reached. The reaction solution was extracted with DCM. The combined organic 
phases were dried over Na2SO4 and concentrated in vacuo to yield the desired acidic product. 
 
8.2.2 General Procedure for Boc Group Cleavage (GP2):113 
 
The respective of the Boc-protected Amine (1eq) was dissolved in DCM (resulting in a 0.1 M 
solution), and cooled to 0°C. At this temperature concentrated TFA (3ml/1mmol) was added 
slowly. After stirring for further 30 min at 0°C, the ice bath was removed, and the reaction 
mixture was stirred at rt while monitoring the reaction progress by TLC. After complete 
conversion, solvent and TFA were removed in vacuo. The remaining TFA was removed through 
repetitive stripping with EtOAc. Finally the deprotected amine was dried to yield a colorless 
foam. 
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8.2.3 General Procedure for Peptide Coupling with COMU (GP3):113,252 
 
The methyl deprotected acidic building block (1mM) was dissolved under Ar atmosphere in dry 
MeCN (100ml/ 10mmol). After addition of EDIPA (10eq) the reaction mixture was cooled to 0°C 
and the coupling reagent COMU (0.95eq) was added. After further stirring for 30 min the amine 
building block was added. The reaction mixture was permitted to warm slowly until rt was 
reached. The reaction mixture was stirred at rt until a TCL showed consumption of all starting 
materials. Solvent and base were removed in vacuo, and the resulting residue was dissolved in 
EtOAc and then extracted with H2O, 1M HCl solution and brine (each at least twice). The 
combined organic layers were concentrated in vacuo and then purified by flash 
chromatography with silica gel. 
 
8.2.4 General Procedure for Cyclic Peptide Coupling with COMU (GP4): 113,252 
 
The respective deprotected dimeric building block (1eq) was dissolved in dry MeCN (0.1 M) 
mixed with EDIPA (10 eq) and cooled to 0°C while stirring under Ar atmosphere. Then COMU 
(1.95 eq) was added before the reaction mixture was allowed to slowly warm to rt. The reaction 
progress was monitored by TLC until all starting material was consumed. Solvent and base were 
removed in vacuo. The resulting residue was dissolved in EtOAc and then extracted with H2O, 
1M HCl solution and brine (each at least three times). The combined organic layers were 
concentrated in vacuo and purificated by column chromatography with silica gel.  
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8.2.5 General Procedure for the preparation of dinuclear transition metal complexes of the 
Peptides (GP5): 
 
Complexes for all experiments were prepared in situ from stock solutions in dry and degassed 
MeOH, which has been stored under an Ar atmosphere. The concentration of the ligand 
solutions was 1 mM. For deprotonation, a methoxide base was used, either sodium 
methanolate or tetra butyl-ammonium methoxide salt ((nBu)4NOMe) was added.  
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8.3 Synthesis of H4pat1 
 
8.3.1 (E)-methyl-2-(hydroximo)-3-oxobutanoate (1): 
 
       Molecular formula: C5H7NO4 
       Molecular weight: 145.11 g/mol 
1 
Following known literature procedures,113,253 methyl acetoacetate (103.13 g, 936.57 mmol) 
was dissolved in glacial acetic acid (140 ml) and cooled to -5°C. While stirring at a temperature 
ranging from -5 to -10°C, 200 ml of aqueous sodium nitrite solution (148.55 g, 2152.09 mmol) 
were added slowly. The reaction mixture was stirred for 3 h at -5 °C and afterwards for 1.5h at 
rt. The reaction mixture was poured on 800 g ice. After extraction with diethyl ether (3x) the 
combined organic phases were washed with saturated NaHCO3 solution until CO2 production 
ended, dried over Na2SO4, and concentrated in vacuo to yield 1 (95.67 g, 659.28 mmol, 70.39%) 
as a white solid. 
 
1H NMR: (200 MHz, CDCl3): δ = 2.35 (s, 3H, COCH3); 3.85 (s, 3H, CO2CH3); 10.80 (bs, 1H, NOH) 
ppm. 
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8.3.2 1-Methoxy-1,3-dioxobutan-2-ammonium chloride (2): 
 
       Molecular formula: C5H10ClNO3 
       Molecular weight: 167.59 g/mol 
     2 
Compound 2 was prepared according to known literature procedures.113,253 The oxime 1 (50.43 
g, 347.53 mmol) was dissolved in EtOH (800 ml). Palladium on charcoal was suspended (10 %, 
25g) before 348 ml 3 M methanolic HCl (1040 mmol, 3eq) were slowly added. The reaction 
mixture was stirred for 3 days under a H2-atmosphere. Afterwards the mixture was filtered 
twice over Celite and the solvent was removed in vacuo. The crude product was dissolved in 
EtOAc, recrystallized at -20°C from EtOAc, filtered and washed with ice cold DCM. The 
ammonium chloride salt 2 (46.43 g, 277.05 mmol, 79.72%) was isolated as a white crystalline 
solid. 
Microanalysis: C5H10ClNO3: calc. (%): C 35.41, H 7.13, N 8.26; found (%): C 34.08, H 7.03, N 7.89 
(Report No. 33726) 
1H NMR: (200 MHz, DMSO - d6): δ = 2.38 (s, 3H, COCH3); 3.81 (s, 3H, CO2CH3); 5.30 (s, 1H, 
CHNH3), 8.91 (bs, 3H, NH3) ppm. 
13C NMR: (50 MHz, DMSO - d6): δ = 28.34 (COCH3); 53.92 (OCH3); 61.52 (CHNH3), 164.61 
(COCH3), 197.15 (CO2CH) ppm. 
HR-FAB+ MS: m/z calc. for C5H10NO3+ 132.062, found 132.066. 
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8.3.3 Methyl 2-((S)-2-(tert-butoxycarbonylamino)-3-methylbutanamido)-3-oxobutanoate (3): 
 
       Molecular formula: C15H26N2O6 
       Molecular weight: 330.38 g/mol 
  3 
Following known literature procedures,66,113 (S)-Boc-valine (18.31 g, 84.27 mmol) and NMM 
(8.59 g, 84.27 mmol, 1 eq) were dissolved in anhydrous THF (450 ml) and cooled to -25°C. Then, 
isobutyl chloroformate (11.68 g, 84.27 mmol, 1 eq) was added carefully. After stirring the 
reaction mixture for 1h at -25°C, the ammonium chloride salt 2 (28.23 g, 168.54 mmol, 2 eq) 
was added. Subsequently, the reaction mixture was treated with NMM (8.59 g, 84.27 mmol, 
1eq) and the the cooling bath was  removed (over 2h) slowly. The reaction mixture was stirred 
for another day at rt before the solvent was removed in vacuo. The crude product was dissolved 
in EtOAc and extracted with brine, dried over Na2SO4, and concentrated in vacuo to a colorless 
oil. After addition of n-hexane, colorless crystals were obrtained on standing overnight at -20°C. 
Filtration yielded 3 (23.69 g, 71.78 mmol, 85.17%) as a white crystalline solid. 
Microanalysis: C15H26N2O6: calc. (%): C 54.53, H 7.93, N 8.48; found (%): C 54.67, H 7.57, N 8.80 
(Report No. 33435) 
1H NMR: (200 MHz, CDCl3): δ = 0.89 (d, 3H, CH(CH3)2, 3JH-H  = 6.7 Hz); 0.96 (d, 3H, CH(CH3)2,      3JH-
H  = 6.8Hz); 1.43 (s, 9H, C(CH3)3), 2.15 – 2.25 (m, 1H, CH(CH3)2), 2.37 (s, 3H, COCH3), 3.79 (s, 3H, 
CO2CH3), 4.09 (m, 1H, NHCHCO), 4.95-4.99 (m, 1H, CO2NH), 5.21 (d, 1H, BocNHCHCO), 7.01-
7.12, (m, 1H, NH) ppm. 
HR-DART+ MS: m/z calc. for [M+H]+: 331.182, [M+NH4]+ = 348.213, [2M+H]+ = 661.365, 
[2M+NH4]+ = 678.392; found: 331.186, 348.213, 661.365, 678.392.  
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8.3.4 Methyl 2-((R)-2-(tert-butoxycarbonylamino)-3-methylbutanamido)-3-oxobutanoate (4): 
 
       Molecular formula: C15H26N2O6 
      4     Molecular weight: 330.38 g/mol 
Following known literature procedures,66,113 (R)-Boc-valine (5.00 g, 22.90 mmol) and NMM 
(2.33g, 22.90 mmol, 1 eq) were dissolved in anhydrous THF (300 ml) and cooled to -25°C. Then, 
isobutyl chloroformate (3.18 g, 22.90 mmol, 1eq) was added slowly. After stirring the reaction 
mixture for 1h at -25°C, the ammonium chloride salt 2 (7.67 g, 45.80 mmol, 2 eq) was added. 
Subsequently NMM (2.33 g, 22.90 mmol. 1eq) was added to the reaction mixture and the 
cooling bath was removed (over 2h) slowly. The reaction mixture was stirred for another day 
at rt before the solvent was removed in vacuo. The crude product was dissolved in EtOAc and 
extracted with H2O and brine, dried over Na2SO4, and concentrated in vacuo to a colorless oil. 
After addition of n-hexane, colorless crystals formed on standing overnight at -20°C. Filtration 
and subsequent washing with ice- cold n-Hexane yielded 4 (4.81 g, 14.81 mmol, 63.61%) as a 
white crystalline solid. 
Microanalysis: C15H26N2O6: calc. (%): C 54.53, H 7.93, N 8.48; found (%): C 54.55, H 7.89, N 8.72 
(Report No. 33436) 
1H NMR: (200 MHz, CDCl3): δ = 0.89 (d, 3H, CH(CH3)2, 3JH-H  = 7.1 Hz); 0.95 (d, 3H, CH(CH3)2,      3JH-
H  = 6.7Hz); 1.42 (s, 9H, C(CH3)3), 2.09 – 2.28 (m, 1H, CH(CH3)2), 2.36 (s, 3H, COCH3), 3.78 (s, 3H, 
CO2CH3), 4.04 (m, 1H, NHCHCO), 4.93-5.04 (m, 1H, CO2NH), 5.21 (d, 1H, BocNHCHCO), 7.02-
7.14, (m, 1H, NH) ppm. 
13C NMR: (200 MHz, CDCl3): δ = 17.47 (CH(CH3)2); 19.23(CH(CH3)2); 28.01 (COCH3); 28.29 
(C(CH3)3), 30.88 (CH(CH3)2), 53.29 (CO2CH3), 62.95 (NHCHCO2), 80.23 (C(CH3)3), 166.34 
(NHCOC(CH3)3), 171.44 (CO2CH3), 180.25(NHCO), 197.98 (COCH3) ppm. 
HR-DART+ MS: m/z calc. for [M+H]+: 331.182, [M+NH4]+ = 348.213, [2M+H]+ = 661.365, 
[2M+NH4]+ = 678.392; found: 331.188, 348.213, 661.371, 678.400.  
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8.3.5 Methyl 2-((S)-2-(tert-butoxycarbonylamino)-2-methylpropyl)-1,5-dimethyl-imidazole-4-
carboxylate (5): 
 
       Molecular formula: C16H27N3O4 
       Molecular weight: 325.40 g/mol 
          5 
Following known literature procedures,66,113 the amide 3 (23.69 g, 71.78 mmol) was dissolved 
in xylene (450 ml) and glacial acetic acid (28.6 ml) and MeNH2 (25.6 ml) were added to the 
solution. The reaction mixture was refluxed for 3 h at 155°C. Then, further 19.7 ml glacial acetic 
acid and 9.85 ml MeNH2 were added, and the reaction mixture was refluxed for another 5 h. 
After cooling to rt the solvent, MeNH2 and acetic acid were removed in vacuo. The crude 
product was purified by flash chromatography with silica gel (5 x 30 cm, EtOAc/PE= 4:1) to yield 
5 (20.21 g, 62.19 mmol, 86.63%) as a white solid. 
Microanalysis: C16H27N3O4: calc. (%): C 59.06, H 8.36, N 12.91; found (%): C 58.97, H 7.94, N 
13.04 (Report No. 33487) 
1H NMR: (200 MHz, CDCl3): δ = 0.78 (d, 3H, CH(CH3)2, 3JH-H  = 6.6 Hz); 1.02 (d, 3H, CH(CH3)2, 3JH-
H  = 6.5 Hz); 1.38 (s, 9H, C(CH3)3), 2.08 – 2.46 (m, 1H, CH(CH3)2), 2.53 (s, 3H, imiCH3), 3.54 (s, 3H, 
CO2CH3), 3.85 (s, 3H, NCH3), 4.53 (t, 1H, NHCH, 3JH-H  = 9.4Hz), 5.35 (bs, 1H, NH) ppm. 
HR-DART+ MS: m/z calc. for [M+H]+: 326.207, [2M+H]+ = 651.407, found: 326.208, 651.409. 
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8.3.6 Methyl 2-((R)-2-(tert-butoxycarbonylamino)-2-methylpropyl)-1,5-dimethyl-imidazole-4-
carboxylate (6): 
 
       Molecular formula: C16H27N3O4 
       Molecular weight: 325.40 g/mol 
         6 
Following a known literature procedures,66,113 the amide 3 (4.81 g, 14.58 mmol) was dissolved 
in xylene (92 ml). Glacial acetic acid (5.8 ml) and MeNH2 (5.2 ml) were added, before the 
reaction mixture was refluxed for 3 h at 155°C. Then, additional 2 ml glacial acetic acid and 4 
ml MeNH2 were added, and the reaction mixture was refluxed for another 5 h. After cooling 
the mixture to rt, the solvent, MeNH2 and acetic acid were removed in vacuo. The crude 
product was purified by flash chromatography with silica gel (3 x 25 cm, EtOAc/PE 3:1) to yield 
6 (3.02 g, 9.28 mmol, 63.65%) as a white solid. 
Microanalysis: C16H27N3O4: calc. (%): C 59.06, H 8.36, N 12.91; found (%): C 58.86, H 8.46, N 
12.74 (Report No. 33486) 
1H NMR: (200 MHz, CDCl3): δ = 0.80 (d, 3H, CH(CH3)2, 3JH-H  = 6.5 Hz); 0.99 (d, 3H, CH(CH3)2, 3JH-
H  = 6.8Hz); 1.38 (s, 9H, C(CH3)3), 2.11 – 2.30 (m, 1H, CH(CH3)2), 2.51 (s, 3H, imiCH3), 3.54 (s, 3H, 
CO2CH3), 3.85 (s, 3H, NCH3), 4.50 (t, 1H, NHCH, 3JH-H  = 9.1Hz), 5.35 (d, 1H, NH, 3JH-H  = 9.4Hz) 
ppm. 
HR-DART+ MS: m/z calc. for [M+H]+: 326.207, [2M+H]+ = 651.407, found: 326.208, 651.408. 
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8.3.7 (S)-1-(4-(methoxycarbonyl)-1,5-dimethyl-imidazole-2-yl)-2-methylpropan-1-ammonium 
trifluoro acetat (7): 
       Molecular formula: C13H20F3N3O4 
       Molecular weight: 339.31 g/mol 
 
     7 
The imidazole building block 5 (4.50 g, 13.83 mmol) was converted into 7 (4.71 g, 13.88 mmol) 
according to general procedure GP2 using TFA (27.5 ml) and DCM (210 ml). In this way, 7 was 
obtained quantitatively as a white solid foam. 
1H NMR: (200 MHz, CDCl3): δ = 0.80 (d, 3H, CH(CH3)2, 3JH-H  = 6.4 Hz); 0.98 (d, 3H, CH8CH3)2, 3JH-
H  = 6.7 Hz); 2.08 – 2.46 (m, 1H, CH(CH3)2), 2.50 (s, 3H, imiCH3), 3.54 (s, 3H, CO2CH3), 3.85 (s, 1H, 
NCH3), 4.50 (t, 1H, NHCH, 3JH-H  = 9.1Hz), 5.35 (d, 1H, NH, , 3JH-H  = 9.6 Hz) ppm. 
13C NMR: (200 MHz, CDCl3): δ = 10.57 (imiCH3), 18.66 (CH(CH3)2); 18.96(CH(CH3)2), 31.21 
(CH(CH3)2),33.63 (NCH3), 51.92 (CO2CH3), 53.48 (NH3+CH), 125.93 (CimiCO2), 139.17 (CimiNCH3), 
144.04 (CimiCH3), 169.85 (CO2CH3), 180.25(NHCO) ppm. 
HR-DART+ MS: m/z calc. for [2Mamine+H]+ = 451.303, [3Mamine+H]+ = 676.450, found: 
451.303, 676.452.  
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8.3.8 (R)-2-(1-(tert-butoxycarbonylamino)-2-methylpropyl)-1, 5-dimethyl-imidazole-4-carbox 
ylic acid (8): 
 
       Molecular formula: C15H25N3O4 
       Molecular weight: 311.38 g/mol 
         8 
According to general procedure GP1, the imidazole building block 6 (4.95 g, 15.20 mmol) was 
converted into 8 (3.77 g, 12.11 mmol, 79.65%) as a white solid. Using 2M NaOH (77 ml) and 
174 ml of a dioxane/MeOH mixture. 
1H NMR: (200 MHz, CDCl3): δ = 0.81 (d, 3H, CH(CH3)2, 3JH-H  = 6.3 Hz); 1.17 (d, 3H, CH(CH3)2, 3JH-
H  = 6.4 Hz); 1.37 (s, 9H, C(CH3)3), 2.70 – 2.88 (m, 1H, CH(CH3)2), 2.63 (s, 3H, imiCH3), 3.85 (s, 3H, 
NCH3), 4.62 (t, 1H, NHCH, 3JH-H  = 9.5Hz), 5.27 (s, 1H, NH) ppm. 
HR-DART+ MS: m/z calc. for [M+H]+: 312.192, [2M+H]+ = 623.376, found: 312.193, 623.381.  
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8.3.9 Methyl 2-((S)-1-(2-((R)-1-(tert-butoxycarbonylamino)-2-methylpropyl)-1, 5-dimethyl-
imidazole-4-carboxamido)-2-methylpropyl)-1.5-dimethyl-imidazole-4-carboxylate (9): 
 
       Molecular formula: C26H42N6O5 
       Molecular weight: 518.64 g/mol 
 
    9 
Following general procedure GP3, the methyl deprotected building block 8 (3.11 g, 9.99 mmol) 
was coupled with the boc deprotected building block 7 (4.06 g, 11.97 mmol) to yield 9 (5.18 g, 
9.99 mmol). After purification by flash chromatography with silica gel (3 x 30 cm, 
EtOAc/DCM/MeOH 70:29:1) 9 was obtained as a lightly yellow powder. Coupling was done 
using 100 ml MeCN, 8.56 g (20.00 mmol) COMU, and 3.84 ml EDIPA (2.85 g, 22.04 mmol). 
1H NMR: (200 MHz, CDCl3): δ = 0.73 (d, 3H, CH(CH3)2, 3JH-H  = 6.6 Hz); 0.83 (d, 3H, CH(CH3)2, 3JH-
H  = 7.1 Hz); 0.88 (d, 3H, CHCH3, 3JH-H  = 6.7 Hz); 1.01 (d, 3H, CHCH3, 3JH-H  = 7.03 Hz); 1.40 (s, 9H, 
C(CH3)3), 2.01 – 2.27 (m, 1H, CH(CH3)2), 2.48 (s, 3H, imiCH3), 2.50 (s, 3H, imiCH3), 3.06 – 3.20 
(m, 1H, CH(CH3)2), 3.46 (s, 3H, NCH3), 3.56 (s, 3H, NCH3), 3.85 (s, 3H, CO2CH3),4.58 (t, 1H, NHCH, 
3JH-H  = 9.4Hz), 4.94 (d, 1H, NHCH, 3JH-H  = 9.2Hz), 5.50 (d, 1H, NHBoc), 8.10 (bs, 1H, NH) ppm. 
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8.3.10 2-((S)-1-(2-((R)-1-(tert-butoxycarbonylamino)-2-methylpropyl)-1,5-dimethyl-imidazole-4-
carboxamido)-2-methylpropyl)-1.5-dimethyl-imidazole-4-carboxylic acid (10): 
 
       Molecular formula: C25H40N6O5 
       Molecular weight: 504.62 g/mol 
 
    10 
According to general procedure GP1, the dimeric building block 9 (5.18 g, 9.99 mmol) was 
converted into 10 (4.83 g, 9.57 mmol, 95.81%) as a yellowish solid. 2M NaOH (80.6 ml) and 180 
ml of a dioxan/MeOH mixture were used. 
1H NMR: (200 MHz, CDCl3): δ = 0.74 (d, 3H, CH(CH3)2, 3JH-H  = 7.3 Hz); 0.88 (d, 3H, CH(CH3)2, 3JH-
H  = 6.7 Hz); 0.96 (d, 3H, CHCH3, 3JH-H  = 6.7 Hz); 1.09 (d, 3H, CHCH3, 3JH-H  = 7.1 Hz); 1.40 (s, 9H, 
C(CH3)3), 2.06 – 2.22 (m, 1H, CH(CH3)2), 2.30 – 2.53 (m, 1H, CH(CH3)2), 2.60 (s, 3H, imiCH3), 2.63 
(s, 3H, imiCH3), 3.22 (bs, 3H, NCH3), 3.66 (s, 3H, NCH3), 4.49- 4.82 (m, 2H, NHCßH), 5.24- 5.46 
(m, 1H, NHBoc), 6.8 (bs, 1H, NH), 9.92 (bs, 1H, COOH) ppm. 
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8.3.11 (R)-1-(4-(((S)-1-(4-carboxy-1,5-dimethyl-imidazol-2-yl)-2-methylpropyl)carbamoyl)-1,5-
dimethyl-imidazol-2-yl)-2-methylpropan-1-ammonium trifluoroacetat (11): 
 
       Molecular formula: C22H33N6O5F3 
       Molecular weight: 518.53 g/mol 
 
   11 
The methyl deprotected dimeric building block 10 (4.83 g, 9.57 mmol) was converted into the 
twice deprotected dimeric building block 11 (4.92 g, 9.49 mmol) following general procedure 
GP2. Compound 11 is isolated as a yellowish foam. TFA (18.33 ml) and DCM (80 ml) were used. 
The crude product was used without further purification. 
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8.3.12 H4pat1 (12): 
 
       Molecular formula: C40H60N12O4 
       Molecular weight: 772.98 g/mol 
 
 
 
 
12 
The cyclic pseudo octapeptide H4pat1 was prepared according to general procedure GP3. The 
deprotected peptidic building block 11 (4.67g, 9.00 mmol) was converted into 12 (1.17 g, 
1.51mmol, 16.80%) and obtained as a white solid. After purification by repetitive 
recrystallization from a MeOH / diethyl ether mixture and flash chromatography with silica gel 
(3 x 20 cm, EtOAc/DCM/MeOH 70:29:1) the product was obtained as a white powder. Coupling 
was performed, using 90 ml MeCN, 7.72 g (18 mmol) COMU, and 11.63 ml EDIPA (90 mmol). 
1H NMR: (600 MHz, MeOD-d4): δ = 0.86 (d, 12H, CH(CH3)2, 3JH-H  = 6.8 Hz); 0.91 (d, 12H, CH(CH3)2, 
3JH-H  = 6.8 Hz); 2.27 (o, 4H, CH(CH3)2), 2.57 (s, 12H, imiCH3), 3.65 (s, 12H, NCH3), 5.11 (bd, 4H, 
CH, 3JH-H  = 7.1 Hz), 8.68 (d, 0.9 H, NH, 3JH-H  = 9.0 Hz) ppm. 
13C NMR: (150 MHz, MeOD-d4): δ = 10.14 (CHetCH3); 19.10, 19.98 (CH(CH3)2); 31.67 (NCH3), 
35.07 (Cß), 51.47 (Cα), 130.46 (CHet-CO), 135.04 (CHet-NCH3), 148.57 (C=N), 165.76 (CO) ppm. 
15N NMR: (60 MHz, MeOD-d4): δ = 115.6 (NH); 166.0 (NCH3), 246.0 (C=N) ppm. 
HR-ESI+ MS: m/z calc. for [M+H]+: 773.493, [M+Na]+ = 795.475; found: 773.49, 795.476.  
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8.4 Synthesis of H4pat2 
 
8.4.1 (S)-2-(1-(tert-butoxycarbonylamino)-2-methylpropyl)-1,5-dimethyl-imidazole-4-carbox-ylic 
acid (13): 
 
       Molecular formula: C15H25N3O4 
       Molecular weight: 311.38 g/mol 
         13 
According to general procedure GP1, the imidazole building block 5 (3.10 g, 9.57 mmol) was 
converted into 13 (2.90 g, 9.31 mmol, 97.28%) as a white solid. 46.7 ml 2M NaOH and 112.5ml 
of the dioxan/MeOH mixture were used. 
1H NMR: (200 MHz, CDCl3): δ = 0.78 (d, 3H, CH(CH3)2, 3JH-H  = 6.3 Hz); 1.11 (d, 3H, CH(CH3)2, 3JH-
H  = 6.4 Hz); 1.37 (s, 9H, C(CH3)3), 2.39 – 2.55 (m, 1H, CH(CH3)2), 2.58 (s, 3H, imiCH3), 3.68 (s, 3H, 
NCH3), 4.55 (t, 1H, NHCH, 3JH-H  = 9.5Hz), 6.81 (bs, 1H, NH) ppm. 
HR-DART+ MS: m/z calc. for [M+H]+: 312.192, [2M+H]+ = 623.376, found: 312.193, 623.381.  
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8.4.2 Methyl 2-((R)-1-(2-((R)-1-(tert-butoxycarbonylamino)-2-methylpropyl)-1,5-dimethyl-
imidazole-4-carboxamido)-2-methylpropyl)-1.5-dimethyl-imidazole-4-carboxylate (14): 
 
       Molecular formula: C26H42N6O5 
       Molecular weight: 518.64 g/mol 
 
   14 
Following general procedure GP3, the methyl deprotected building block 13 (2.96 g, 9.51 mmol) 
was coupled with the boc deprotected building block 7 (3.78 g, 11.14 mmol) to yield 14 (4.04 
g, 7.79 mmol, 81.90%), after purification by flash chromatography with silica gel (3 x 30 cm, 
EtOAc/DCM/MeOH 75:25:1) as a light yellow powder. Coupling was done, using 130 ml MeCN, 
8.57 g (20.01 mmol) COMU, and 3.84 ml EDIPA (3.88 g, 30.02 mmol). 
1H NMR: (200 MHz, CDCl3): δ = 0.73 (d, 3H, CH(CH3)2, 3JH-H  = 7.3 Hz); 0.81 (d, 3H, CH(CH3)2, 3JH-
H  = 6.8 Hz); 0.91 (d, 3H, CHCH3, 3JH-H  = 7.2 Hz); 0.99 (d, 3H, CHCH3, 3JH-H  = 7.5 Hz); 1.38(s, 9H, 
C(CH3)3), 2.00 – 2.31 (m, 1H, CH(CH3)2), 2.44 (s, 3H, imiCH3), 2.45 (s, 3H, imiCH3), 3.08 – 3.21 
(m, 1H, CH(CH3)2), 3.42 (s, 3H, NCH3), 3.56 (s, 3H, NCH3), 3.81 (s, 3H, CO2CH3),4.32- 4.55 (m, 2H, 
NHCH ), 5.20 (d, 1H, NHBoc, 3JH-H  = 9.0Hz ), 7.62 (d, 1H, NH, 3JH-H  = 9.5Hz) ppm. 
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8.4.3 2-((S)-1-(2-((S)-1-(tert-butoxycarbonylamino)-2-methylpropyl)-1,5-dimethyl-imidazole-4-
carboxamido)-2-methylpropyl)-1.5-dimethyl-imidazole-4-carboxylic acid (15): 
 
       Molecular formula: C25H40N6O5 
       Molecular weight: 504.62 g/mol 
 
    15 
According to general procedure GP1, the dimeric building block 14 (4.04 g, 7.79 mmol) was 
converted into 15 (1.11 g, 2.20 mmol, 28.80%), which was obtained as a yellowish solid. 63 ml 
2M NaOH and 138 ml of the described dioxan/MeOH mixture were used. 
1H NMR: (200 MHz, CDCl3): δ = 0.80 (d, 3H, CH(CH3)2, 3JH-H  = 7.2 Hz); 0.82 (d, 3H, CH(CH3)2, 3JH-
H  = 7.1 Hz); 0.90 (d, 3H, CHCH3, 3JH-H  = 6.7 Hz); 1.03 (d, 3H, CHCH3, 3JH-H  = 7.0 Hz); 1.39 (s, 9H, 
C(CH3)3), 2.10 – 2.41 (m, 1H, CH(CH3)2), 2.54 (bs, 6H, imiCH3), 3.21 (bs, 3H, NCH3), 3.62 (s, 3H, 
NCH3), 3.87- 4.39 (bm, 1H, CH(CH3)2), 4.55 (q, 1H, NHCßH, 3JH-H  = 8.7 Hz), 5.08 (t, 1H, 1H, NHCßH, 
3JH-H  = 10.0 Hz), 6.59 (d, 1H, NHBoc, 3JH-H  = 8.3 Hz), 8.65 (bs, 1H, NH) ppm. 
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8.4.4 (S)-1-(4-(((S)-1-(4-carboxy-1,5-dimethyl-imidazol-2-yl)-2-methylpropyl)carbamoyl)-1,5-
dimethyl-imidazol-2-yl)-2-methylpropan-1-ammonium trifluoroacetat (16): 
 
       Molecular formula: C22H33N6O5F3 
       Molecular weight: 518.53 g/mol 
 
   16 
According to general procedure GP2, the methyl deprotected dimeric building block 15 (1.55 
g, 3.07 mmol) was converted into 16 (1.58 g, 3.04 mmol) as a yellowish foam. Using 5.9 ml TFA 
and 25 ml DCM, a quantitative yield was reached and the product was used without further 
purification.  
1H NMR: (200 MHz, DMSO d6): δ = 0.80 (d, 3H, CH(CH3)2, 3JH-H  = 5.9 Hz); 0.86 (d, 3H, CH(CH3)2, 
3JH-H  = 7.0 Hz); 0.95 (d, 3H, CHCH3, 3JH-H  = 6.8 Hz); 1.01 (d, 3H, CHCH3, 3JH-H  = 6.7 Hz); 2.10 – 
2.39 (m, 1H, CH(CH3)2), 2.44 (s, 3H, imiCH3), 2.47 (s, 3H, imiCH3), 3.50 (bs, 3H, NCH3), 3.09- 3.20 
(bm, 1H, CH(CH3)2), 3.53 (bs, 3H, NCH3), 4.02 (q, 1H, NHCßH, 3JH-H  = 7.2 Hz), 4.42 (bs, 1H, NH2), 
5.07 (t, 1H, 1H, NHCßH, 3JH-H  = 9.9 Hz), 8.02 (bs, 1H, NH, 3JH-H  = 9.9 Hz), 8.43 (bs, 1H, COOH) 
ppm. 
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8.4.5 H4pat2 (17): 
 
       Molecular formula: C40H60N12O4 
       Molecular weight: 772.98 g/mol 
 
 
 
 
17 
The cyclic pseudo octapeptide H4pat1 was prepared according to general procedure GP3. The 
twice deprotected peptidic building block 16 (1.68 g, 3.32 mmol) was converted into 17 (0.22 
g, 0.28 mmol, 8.79%) as a white solid. After purification by repetitive recrystallization from a 
methanol / diethyl ether mixture and flash chromatography with silica gel (3 x 20 cm, 
EtOAc/DCM/MeOH 70:29:1) the product yielded as a white powder. Coupling was done, using 
35 ml MeCN, 2.78 g (6.48 mmol) COMU, and 5.6 ml EDIPA (32.4 mmol). 
1H NMR: (600 MHz, MeOD-d4): δ = 0.88 (d, 12H, CH(CH3)2, 3JH-H  = 6.7 Hz); 1.10 (d, 12H, CH(CH3)2, 
3JH-H  = 6.7 Hz); 2.36- 2.45 (m, 4H, Hß), 2.49 (s, 12H, imiCH3), 3.66 (s, 12H, NCH3), 4.92 (d, 4H, Hα, 
3JH-H  = 7.1 Hz), 7.89 (d, 0.1 H, NH, 3JH-H  = 9.0 Hz) ppm. 
13C NMR: (150 MHz, MeOD-d4): δ = 10.20 (CHetCH3); 19.83, 20.08 (CH(CH3)2); 30.98 (NCH3), 
34.24 (Cα), 51.63 (CH(CH3)2), 130.08 (CHet-CO), 135.05 (CHet-NCH3), 149.01 (C=N), 165.69 (CO) 
ppm. 
15N NMR: (60 MHz, MeOD-d4): δ = 114.1 (NH); 165.5 (NCH3), 241.5 (C=N) ppm. 
HR-ESI+ MS: m/z calc. for [M+H]+: 773.493, [M+Na]+ = 795.475; found: 773.493, 795.477. 
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8.5 Synthesis of H4pat4 
 
8.5.1 Methyl 2-((S)-2-(benzyloxycarbonylamino)-3-methylbutanamido)-3-oxobutanoat (18): 
 
       Molecular formula: C18H24N2O6 
       Molecular weight: 364.39 g/mol 
       18 
According to literature known procedures, 66,113 (S)-Cbz-valine (10.00 g, 39.79 mmol) and NMM 
(4.05 g, 39.79 mmol, 1eq) were dissolved in 520 ml dry THF and cooled to -25°C. Then, 1 eq. of 
isobutyl chloroformate (5.53 g, 39.79 mmol) was added carefully. After stirring the reaction 
mixture for 1h at -25°C, the ammonium chloride salt 2 (6.66 g, 39.79 mmol, 1eq) was added. 
The reaction mixture was treated subsequently with NMM (4.05 g, 39.79 mmol, 1eq). 
Afterwards, the cooling bath was removed slowly (over 2h), and the reaction mixture was 
stirred for another day at rt, before the solvent was removed in vacuo. The crude product was 
dissolved in EtOAc and extracted with H2O and brine, dried over Na2SO4, and concentrated in 
vacuo to a colorless oil. Colorless crystals were obtained on standing overnight at -20°C. 
Filtration and subsequent washing with ice-cold n-hexane yielded 18 (9.50 g, 26.07 mmol, 
65.52%) as a white crystalline solid. 
Microanalysis: C18H24N2O6: calc. (%): C 59.33, H 6.64, N 7.69; found (%): C 59.61, H 7.22, N 6.68 
(Report No. 33724) 
1H NMR: (200 MHz, CDCl3): δ = 0.85 – 1.07 (m, 6H, CH(CH3)2); 1.88- 2.29 (m, 1H, CH(CH3)2), 2.36 
(s, 3H, COCH3), 3.79 (s, 3H, CO2CH3), 4.05 (d, 1H, NHCαH, 3JH-H  = 6.6 Hz), 5.09 (s, 2H, CH2-Ar), 
5.19 (d, 1H, NHCHCOOMe, 3JH-H  = 6.6 Hz), 5.25- 5.35 (m, 1H, NHCHCOOMe), 6.99 (bt, 1H, NH, 
3JH-H  = 6.6 Hz), 7.26- 7.38 (m, 5H, Harom) ppm. 
ESI+ MS: m/z calc. for [M+H]+: 365.0, [M+Na]+ = 387.1; found: 365.0, 387.1 
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8.5.2 Methyl 2-((S)-1-(benzyloxycarbonylamino)-2-methylpropyl)-5-methyl-1H-imidazole-4-
carboxylate (19): 
 
       Molecular formula: C18H23N3O4 
       Molecular weight: 345.39 g/mol 
        19 
Compound 19 was prepared following known literature procedures.67 The twice protected oxo- 
peptide 18 (4.40 g, 12.07 mmol) was suspended in 200 ml xylene, before 1.85 ml TFA (2 eq, 
24.15 mmol, 2.75 g) and 0.53 ml ammonia in methanol (2 eq, 24.15 mmol, 0.41 g) were added. 
The reaction mixture was refluxed for 6h, with azeotropic removal of water. Then a further 2 
ml of TFA and 1 ml of ammonia were added, and the reaction mixture was refluxed for another 
6 h. After cooling to rt, solvent, ammonia and TFA were removed in vacuo. The crude product 
was purified by flash chromatography with silica gel (5 x 30 cm, EtOAc/PE 1:1) to yield 19 (1.60 
g, 4.63 mmol, 38.36%) as a white foam. 
1H NMR: (200 MHz, CDCl3): δ = 0.90 – 1.01 (m, 6H, CH(CH3)2); 2.08- 2.25 (m, 1H, CH(CH3)2), 2.15 
(s, 3H, COOCH3), 3.59 (s, 3H, imiCH3), 3.93- 4.13 (m, 1H, NHCαH), 5.09 (s, 2H, CH2-Ar), 5.25- 5.50 
(m, 1H, NH), 7.34 (m, 5H, Harom) ppm. 
HR-ESI+ MS: m/z calc. for [M+H]+: 346.176, [M+Na]+ = 368.158; found: 346.177, 368.158 
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8.5.3 Methyl 2-((S)-1-( tert-butoxycarbonylamino)-2-methylpropyl)-5-methyl-1H-imidazole-4-
carboxylate (20): 
 
       Molecular formula: C15H25N3O4 
       Molecular weight: 311.18 g/mol 
       20 
According to known literature procedures,67 9 the cbz- protected imidazole building block 19 
(4.03 g, 11.68 mmol) was dissolved in THF (200 ml). Then palladium hydroxide (45g) and Boc2O 
(1 eq, 2.55 g, 11.70 mmol) were suspended. The reaction mixture was stirred for 1 day under a 
H2-atmosphere before the mixture was filtered over celite. The solution was concentrated in 
vacuo. The crude product was dissolved in EtOAc, purified by flash chromatography with silica 
gel (5 x 25 cm, PE/EtOAc 2:3) and yielded the boc- protected imidazole 20 as a white foam (4.03 
g, 12.95 mmol,). 
1H NMR: (600 MHz, CDCl3): δ = 0.78 (d, 3H, CH(CH3)2, 3JH-H  = 5.5 Hz), 0.99 (d, 3H, CH(CH3)2,      3JH-
H  = 5.5 Hz), 1.41 (s, 9H, C(CH3)3), 2.40 – 2.53 (m, 1H, CH(CH3)2), 2.49 (s, 3H, imiCH3), 3.81 (s, 3H, 
CO2CH3),  4.29 (bs, 1H, CαH) ppm. 
HR-DART+ MS: m/z calc. for [M+H]+: 312.192, [2M+H]+ = 623.376, found: 312.193, 623.381. 
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8.5.4 Methyl-1-benzyl-2-((S)-1-(tert- butoxycarbonylamino)-2-methylpropyl)-5-methyl-
imidazole-4-carboxylate (21): 
 
       Molecular formula: C22H31N3O4 
       Molecular weight: 401.50 g/mol 
 
       21 
Following known literature procedures,67 the boc- protected imidazole building block 20 (4.03 
g, 12.95 mmol) was dissolved in dry DMF (400 ml) and cooled down to 0°C. At this temperature 
NaH (60% dispersion in mineral oil: 1.5eq, 777g, 19.42 mmol) was suspended. Subsequently 
1.5 eq. of benzyl bromide (3.33 g , 19.429 mmol) was added to the reaction mixture. Afterwards 
the mixture was stirred for 3h at 0°C, before it was allowed to warm up to rt. At rt the reaction 
mixture was stirred overnight. The next day the reaction mixture was slowly poured on Ice 
(1000 g). After allowing the mixture to warm up to rt the resulting solid was filtered off. The 
crude product was dissolved in DCM and extracted with H2O and brine, dried over Na2SO4, and 
concentrated in vacuo to yield as a yellowish solid 21 (4.16 g, 10.37 mmol, 80.07%). 
1H NMR: (600 MHz, CDCl3): δ = 0.64 (d, 3H, CH(CH3)2, 3JH-H  = 6.8 Hz), 0.96 (d, 3H, CH(CH3)2,      3JH-
H  = 6.8 Hz), 1.38 (s, 9H, C(CH3)3), 2.15 – 2.25 (m, 1H, CH(CH3)2), 2.45 (s, 3H, imiCH3), 3.89 (s, 3H, 
CO2CH3),  4.47 (d, 1H, CαH, 3JH-H  = 9.6Hz), 5.38 (d, 1H, CαH2-Ph, 3JH-H  = 5.0Hz), 7.06-7.37 (m, 
5H, CArH) ppm. 
HR-DART+ MS: m/z calc. for [M+H]+: 402.239, [2M+H]+ = 804.470, found: 402.239, 804.476. 
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8.5.5 Methyl 2-((S)-1-(tert- butoxycarbonylamino)-2-methylpropyl)-5-methyl-imidazole-4-
carboxylic acid (22): 
 
       Molecular formula: C21H29N3O4 
       Molecular weight: 387.47 g/mol 
 
  22 
Methyl deprotected building block 22 was prepared according to general procedure GP1 from 
the imidazole building block 21 (4.16 g, 10.37 mmol). Compound 22 (4.87 g, 12.57 mmol, 
quantitative) yielded as a white solid foam. 53 ml 2M NaOH and 126 ml of the dioxane/MeOH 
mixture were used. 
1H NMR: (600 MHz, CDCl3): δ = 0.42 (d, 3H, CH(CH3)2, 3JH-H  = 6.8 Hz), 0.68 (d, 3H, CH(CH3)2,      3JH-
H  = 7.1 Hz), 1.10 (s, 9H, C(CH3)3), 2.04 – 2.10 (m, 1H, CH(CH3)2), 2.31 (s, 3H, imiCH3), 4.14 (t, 1H, 
CαH, 3JH-H  = 9.2Hz), 5.10 (s, 1H, CH2-Ph), 6.80-7.19 (m, 5H, CArH) ppm. 
HR-DART+ MS: m/z calc. for [M+H]+: 388.223, found: 388.222. 
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8.5.6 Methyl 2-((S)-1-(1-benzyl-2-((S)-1- (tert-butoxycarbonylamino)-2-methylpropyl)-5-methyl-
imidazole-4-carboxamido)-2-methylpropyl)-1.5-dimethyl-imidazole-4-carboxylate (23): 
 
       Molecular formula: C32H46N6O5 
       Molecular weight: 594.75 g/mol 
 
23 
According to general procedure GP3, the methyl deprotected building block 21 (4.87 g, 12.57 
mmol) was coupled with the boc deprotected building block 5 (3.58 g, 10.61 mmol) to yield 23 
(5.04 g, 8.90 mmol, 85.57%) as a yellowish foam, which was recrystallized a few times in a 
CHCl3/MeOH mixture. Coupling was performed, using 80 ml MeCN, 4.22 g (9.85 mmol) COMU, 
and 40 ml EDIPA. 
1H NMR: (600 MHz, CDCl3): δ = 0.50-0.61 (m, 3H, CH(CH3)2); 0.81-0.87 (m, 6H, CH(CH3)2); 0.91-
0.97 (m, 3H, CH(CH3)2); 1.33 (s, 3H, C(CH3)3); 2.20 – 2.31 (m, 1H, imiBn-CH(CH3)2), 2.44 (s, 3H, 
imiBn-CH3), 2.53 (s, 3H, imi-CH3), 2.62- 2.78 (s, 1H, CH(CH3)2), 3.73 (s, 3H, NCH3), 3.89 (s, 3H, 
CO2CH3), 4.47 (t, 1H, imiBn-CßH, 3JH-H  = 9.1 Hz), 4.96 (t, 1H, imi-CßH, 3JH-H  = 9.6 Hz), 5.10-5.43 
(m, 2H, CH2-Ph) 6.98-7.36 (m, 5H, CArH) ppm. 
HR-DART+ MS: m/z calc. for [M+H]+: 595.360, [2M+H]+ = 1189.713, found: 595.358, 1189.704. 
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8.5.7 Methyl 2-((S)-1-(1-benzyl-2-((S)-1- (tert-butoxycarbonylamino)-2-methylpropyl)-5-methyl-
imidazole-4-carboxamido)-2-methylpropyl)-1.5-dimethyl-imidazole-4--carboxylic acid (24): 
 
       Molecular formula: C31H44N6O5 
       Molecular weight: 580.72 g/mol 
 
24 
Following to general procedure GP1, the dimeric building block 23 (8.00 g, 14.11 mmol) was 
converted into the yellowish solid 24 (4.76 g, 8.20 mmol, 58.04%). 2M NaOH (70 ml) and 220 
ml of a dioxin/MeOH mixture were used. The crude product 25 was used without further 
purification. 
HR-DART+ MS: m/z calc. for [M+H]+: 581.344, found: 581.344. 
 
8.5.8 (S)-1-(4-(((S)-1-(4-carboxy-1,5-dimethyl-imidazol-2-yl)-2-methylpropyl)carbamoyl)-1- 
benzyl-5-methyl-imidazol-2-yl)-2-methylpropan-1-ammonium trifluoroacetat (25): 
 
       Molecular formula: C28H37N6O4F3 
       Molecular weight: 578.63 g/mol 
 
             25 
According to general procedure GP2, the methyl deprotected dimeric building block 24 (4.76 
g, 8.19 mmol) was converted into 25 (4.90 g, 8.20 mmol), which is isolated as a yellowish resin. 
16.36 ml TFA and 160 ml DCM were used. The crude product 25 was used without further 
purification.  
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8.5.9 H4pat4 (26): 
 
       Molecular formula: C52H68N12O4 
       Molecular weight: 924.17 g/mol 
 
 
 
         26 
The cyclic pseudo octapeptide H4pat1 26 (900 mg, 0.93 mmol, 11.86%) was prepared from the 
deprotected building block 25 (4.90 g, 8.20 mmol), following general procedure GP3. After 
purification 26 was obtained as a white solid. Purification was done by repetitive 
recrystallization from a methanol/diethyl ether mixture and flash chromatography with silica 
gel (3 x 30 cm, EtOAc/DCM 65:35). Coupling was performed, using MeCN (30 ml), COMU (7.02 
g, 16.40 mmol), and EDIPA (20 ml). 
1H NMR: (600 MHz, MeOD-d4/CDCl3 3:1): δ = 0.72 (d, 6H, CH(CH3)2, 3JH-H  = 6.58 Hz); 0.87 (d, 6H, 
CH(CH3)2, 3JH-H  = 6.71 Hz); 1.01 (d, 6H, CH(CH3)2, 3JH-H  = 6.73 Hz); 1.12 (d, 6H, CH(CH3)2, 3JH-H  = 
6.62 Hz); 2.28 (m, 2H, Bn-imi-Hß); 2.41 (s, 6H, BnN-CHetCH3); 2.42 (s, 6H, CH3N-CHetCH3); 2.48- 
2.56 (m, 2H, CH3-imi-Hß); 3.66 (s, 6H, NCH3); 4.89 (d, 4H, Hα, 3JH-H  = 9.90 Hz); 5.37 (dd, 4H, CH2-
Ph, 2JH-H  = 16.98 Hz, 1JC-H  = 154.65 Hz); 6.90- 6.93 (m, 4H, HPh); 7.14- 7.20 (m, 6H, HPh) ppm. 
13C NMR: (150 MHz, MeOD-d4/CDCl3 3:1): δ = 10.32 (CH3N-CHetCH3); 10.35 (BnN-CHetCH3); 19.80, 
19,84; 19.86; 20.71 (CH(CH3)2); 30.99 (NCH3); 32.95 (CH3-imi-Cß); 34.47 (Bn-imi-Cß); 47.60 (CH2-
Ph); 51.02, 51.93 (Cα); 127.18 (CPh); 128.73 (CPh); 129.94 (CPh); 130.50 (CH3N-CHetCH3); 134.70 
(CH3-imiCHet-CO); 134.89 (Bn-imiCHet-CO); 137.78 (BnN-CHetCH3); 148.83 (CH3-imiC=N); 149.14 
(Bn-imiC=N); 165.04 (CH3-imi-CO); 165.57 (CH3-imi-CO) ppm. 
15N NMR: (60 MHz, MeOD-d4/CDCl3 3:1):δ = 119 (NH); 167 (NBn), 177 (NCH3), 248 (C=N) ppm. 
HR-ESI+ MS: m/z calc. for [M+H]+: 926.181, [M+Na]+: 947.537; found: 926.182, 947.538.  
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8.6 Synthesis of H4pat5 (27): 
8.6.1 H4pat5 (27): 
 
       Molecular formula: C64H76N12O4 
       Molecular weight: 1077.366 g/mol 
 
 
 
 
27 
According to general procedure GP2, the methyl deprotected peptidic building block 22 
(387.47mg, 1.04mmol) was boc-deprotected using TFA (6.5 ml) and DCM (70 ml) a quantitative 
Yield was expected, and the crude product was subsequently coupled to a tetramer as 
described in GP3. After purification by repetitive recrystallization from a methanol / Chloroform 
/ diethyl ether mixture and flash chromatography with silica gel (3 x 30 cm, EtOAc/DCM 20:80) 
the product 27 was isolated 164.80mg (149.25µmol, 14.35%) as a white powder. Coupling was 
done, using MeCN (100 ml), FDPP (1.12 g, 2.93 mmol), and EDIPA (0.8 ml, 4.39 mmol). 
1H NMR: (600 MHz, MeOD/CDCl3 3:1): δ = 0.59 (d, 12H, CH(CH3)2, 3JH-H  = 6.7 Hz); 1.01 (d, 12H, 
CH(CH3)2, 3JH-H  = 6.7 Hz); 2.28- 2.38 (m, 4H, CH(CH3)2), 2.43 (s, 12H,imiCH3), 4.86 (d, 4H, CßH, 
3JH-H  = 9.70 Hz), 5.43 (dd, 4H, CH2-Ph, 2JH-H  = 16.92 Hz, 1JC-H  = 184.06 Hz), 7.05-7.30 (m, 20H, 
Ph) ppm. 
13C NMR: (150 MHz,MeOD/CDCl3 3:1): δ = 9.18 (CHetCH3); 18.30, 19.01 (CH(CH3)2); 32.08 (Cα), 
46.58 (CH2-Ph); 49.98 (Cα); 126.178 (CPh); 127.56 (CPh); 128.57 (CPh); 133.33 (Bn-imiCHet-CO); 
136.28 (BnN-CHetCH3); 147.77 (Bn-imiC=N); 163.60 (CO) ppm. 
15N NMR: (60 MHz, MeOD/CDCl3 3:1): δ = 118.4 (NH); 177.6 (NBn), 246.9 (C=N) ppm. 
HR-ESI+ MS: m/z calc. for [M+H]+: 1077.619, [M+Na]+ = 1100.608; found: 1077.620, 1100.609.  
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8.7 Synthesis of Phosphatase model substrate 
8.7.1 Pyridinium Bis-(2,4-dinitrophhenyl) phosphate (27): 254 
 
       Molecular formula: C17H12N5O12P 
       Molecular weight: 509.28 g/mol 
27 
2,4-Dinitrophenol (9.80 g, 53.2 mmol, 3 eq) was  dissolved in anhydrous MeCN (100 ml) under 
an Ar-atmosphere. After addition of anhydrous pyridine (8.6 ml, 106 mmol, 6 eq), the solution 
was cooled to 0°C and phosphoryl chloride (1.63 ml, 17.7 mmol, 1 eq) was added carefully. The 
reaction mixture was stirred for 30 minutes at 0°C before it was poured onto 100 g of ice and 
kept in the fridge over night. The resulting precipitate was filtered off and washed with a small 
amount of ice cold water. Afterwards, the crude product was recrystallized from acetone to 
yield BDNPP pyridinium salt 27 (7.62 g, 14.27 mmol, 80.62%) as a white crystalline solid. 
Microanalysis: C5H10ClNO3: calc. (%): C 40.09, H 2.37, N 13.73; found (%): C 40.03, H 2.56, N 
13.74 (Report No. 36464) 
1H NMR: (400 MHz, Acetone - d6): δ = 3.04 (bs, 1H, NH+); 8.11 (d, 2H, CArHortho, 3JH-H  = 9.2 Hz); 
8.23 (dd, 2H, CPyHMeta, 3JH-H  = 7.5 Hz, 3JH-H  = 6.6 Hz); 8.51 (dd, 2H, CArHMeta, 3JH-H  = 9.2 Hz, 4JH-H  
= 2.8 Hz); 8.71 (d, 2H, NO2C-CH-CNO2, 3JH-H  = 2.8 Hz); 8.76 (dd, 1H, CPyHPara, 3JH-H  = 7.9 Hz, 4JH-H  
= 1.5 Hz); 9.01 (d, 2H, CPyHOrtho, 3JH-H  = 5.4 Hz) ppm. 
13C NMR: (100 MHz, Acetone - d6): δ = 121.73 (NO2Cortho-CArH); 124.37 (CArHortho); 124.40 
(CArHMeta); 128.45 (CPyHMeta); 129.29 (COrthoNO2); 143.26 (CParaNO2); 143.30 (CPyHOrtho); 147.33 
(CPyHPara); 152.15 (POC) ppm. 
31P NMR: (162 MHz, Acetone - d6): δ = -14.13 ppm. 
HR-ESI- MS: m/z calc. for C12H6N4O12P- 428.975, found 428.972. 
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10 Appendix 
 
Figure A.1: CV traces for selected copper(II) complexation-steps of H4pat4 (0.1mM in methanol with 
0.1M (tBu)4NPF6 and vs. Fc/Fc+ at 25°C). 
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Figure A.2: CV of a selected copper(II) complexation-step of H4pat1 (1mM in methanol with 0.1M 
(tBu)4NPF6 and vs. Fc/Fc+ , 100 mV/s, Ag/AgNO3 0.01M,at 25°C). 
 
Figure A.3: CV of selected copper(II) complexation-steps of H4pat1 (0.1mM in methanol with 0.1M 
(tBu)4NPF6 and vs. Fc/Fc+ , 100 mV/s, Ag/AgNO3 0.01M,at 25°C). 
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Figure A 4: SQW overlays for selected copper(II) complexation-steps of H4pat1 (0.1mM in methanol 
with 0.1M (tBu)4NPF6 and vs. Fc/Fc+, 100 mV/s, Ag/AgNO3 0.01M,at 25°C). 
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Figure A.5: CV of selected copper(II) complexation-steps of H4pat2 (0.1mM in methanol with 0.1M 
(tBu)4NPF6 and vs. Fc/Fc+ , 100 mV/s, Ag/AgNO3 0.01M,at 25°C).  
 
Figure A.6: CV/ SQW overlay of a selected copper(II) complexation-steps of H4pat2 (0.1mM in 
methanol with 0.1M (tBu)4NPF6 and vs. Fc/Fc+ , 100 mV/s, Ag/AgNO3 0.01M,at 25°C).
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Figure A.7: SQW of selected copper(II) complexation-steps of H4pat2 (0.1mM in methanol with 0.1M 
(tBu)4NPF6 and vs. Fc/Fc+ , 100 mV/s, Ag/AgNO3 0.01M,at 25°C).  
 
Figure A.8: CV of selected copper(II) complexation-steps of H4pat3 (1mM in methanol with 0.1M 
(tBu)4NPF6 and vs. Fc/Fc+ , 100 mV/s, Ag/AgNO3 0.01M,at 25°C).  
1000 0 -1000 -2000
E[mV]
 H
4
pat
2
+2eq Cu
II
 +4eq OMe
-
 +CO2
 H
4
pat
2
+2eq Cu
II
 +4eq OMe
-
 
 H
4
pat
2
+2eq Cu
II
 +3eq OMe
-
 H
4
pat
2
+2eq Cu
II
 +2eq OMe
-
 H
4
pat
2
+2eq Cu
II
5µA
1000 0 -1000 -2000
10µA
E[mV]
 H
4
Pat
3
+2eq Cu
II
 +4eq OMe
-
 + CO2
 H
4
Pat
3
+2eq Cu
II
 +4eq OMe
-
 H
4
Pat
3
+2eq Cu
II
 +3eq OMe
-
 H
4
Pat
3
+2eq Cu
II
 +2eq OMe
-
 H
4
Pat
3
+2eq Cu
II
 +1eq OMe
-
 H
4
Pat
3
+2eq Cu
II
P H O S P H A T A S E  A C T I V I T Y  O F  H O M O -  A N D  H E T E R O D I N U C L E A R  T R A N S I T I O N  M E T A L  
C O M P L E X E S  O F  P A T E L L A M I D E S     | 184 
 
Figure A.9: SQW of selected copper(II) complexation-steps of H4pat3 (0.1mM in methanol with 0.1M 
(tBu)4NPF6 and vs. Fc/Fc+ , 100 mV/s, Ag/AgNO3 0.01M,at 25°C).  
 
Figure A.10: CV of selected copper(II) complexation-steps of H4pat5 (0.1mM in methanol with 0.1M 
(tBu)4NPF6 and vs. Fc/Fc+ , 100 mV/s, Ag/AgNO3 0.01M,at 25°C).  
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Figure A.11: SQW of selected copper(II) complexation-steps of H4pat5 (0.1mM in methanol with 
0.1M (tBu)4NPF6 and vs. Fc/Fc+ , 100 mV/s, Ag/AgNO3 0.01M,at 25°C).  
 
 
 
Figure A.12: HR-+ESI MS of oxygenation solution.  
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Figure A.13: X-Band EPR spectra of CuOTf2 1 mM in MeOH (black) and 5 mM in MeOH / Bufffer 3:1 
at pH = 6.5, both detected at 140K and 9.44 GHz.  
 
 
Figure A. 14: Recorded 13C NMR spectra in methanol with and without an in situ prepared H4pat2 
and zinc(II) triflate and sodium methanolate mixture, MeOD 1mM, 25°C, 400 mHz. 
1.6 1.8 2.0 2.2 2.4 2.6 2.8
g-factor
 MeOH
 buffer-MeOH
Cu(OTf)
2
   | 187 
 
 
Figure A 15: Michaelis-Menten measurement fitted with equation 6.2; [CuZn(H3pat2)(OH)]+ ([cat.] 
30µM, 25°C). 
 
Figure A 16: pH-profiles of the BDNPP hydrolysis with “[Zn2(H2pat1)(OH)]+”. 
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